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Abstract 
 Protein fucosylation regulates a diverse set of physiological functions such as 
memory and learning, development, and disease pathogenesis. However, our current 
understanding of these processes is far behind that of other post-translational modifications, 
such as phosphorylation. This is, in part, due to the lack of tools available for the study of 
this important protein modification. To address this need, I have developed novel 
chemoenzymatic methods that enable the labeling and detection of unique forms of 
fucosylation, specifically fucose-α(1-2)-galactose (Fucα(1-2)Gal) and core fucose. 
Additionally, novel glycosyltransferase assays were developed in-house to aid in the future 
development of both new and existing chemoenzymatic approaches.  
 I have demonstrated that the approach to detect Fucα(1-2)Gal is highly selective for 
this disaccharide motif, detects a variety of complex glycans and glycoproteins, and can be 
used to profile the relative abundance of this motif on live cells, discriminating malignant 
from normal cells. I have also shown that the chemoenzymatic detection of core fucose 
exhibits superior specificity towards this glycan on a variety of complex N-glycans and 
when compared to current fucose-specific lectins.  Further, the approach is amenable to 
detection of core fucosylated glycans from multiple biological settings, can be exploited as 
an antibody-conjugation method, and can be integrated into a diagnostic platform for the 
profiling of protein specific core fucosylation levels. These approaches represent new 
potential strategies for biomarker identification and expand the technologies available for 
understanding the role of these important fucosylated glycans in physiology and disease. 
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Introduction:  
Chemical Approaches for the Detection of Fucose and  
the Biological Significance of Fucose-α(1-2)-Galactose and Core Fucose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 2 
INTRODUCTION  
 Protein glycosylation is an abundant post-translational modification found in all 
forms of life.1 However, our understanding of this important protein modification is 
decades behind that of other post-translational modifications, such as phosphorylation, due 
to the vast complexity of glycan structure, biosynthesis, and the lack of tools available to 
effectively study specific types of glycosylation. Protein fucosylation is a specific form of 
glycosylation that has been show to regulate a variety of physiological functions such as 
memory and learning, development, and disease pathogenesis.1 Multiple forms of 
fucosylation exist, further complicating our understanding of their individual functions.  
 
CHEMICAL APPROACHES USED FOR THE DETECTION OF FUCOSE 
Lectins 
 Currently, the work directed at characterizing protein fucosylation relies heavily on 
fucose-specific antibodies or lectins. However, these reagents generally suffer from poor 
specificity and weak binding affinities. These issues cause lectins and antibodies to display 
cross-reactivity with multiple different glycan structures.2-4 For example, the lectin Ulex 
Europaeus Agglutinin I  (UEA1) claims specificity towards the Fucose-α(1-2)-Galactose 
disaccharide; however it was shown to detect multiple forms of fucosylation, and free 
fucose itself.3 The recent development and application of glycan microarrays have enabled 
researchers to carefully characterize the specificity of carbohydrate-specific antibodies and 
lectins in a high throughput fashion.5  
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Metabolic Labeling 
 An alternative method for glycan detection, metabolic labeling, provides a powerful 
approach for the study of glycans.6-10 This method requires the uptake of non-natural 
monosaccharide analogues, bearing bioorthogonal chemical functionality such as an azide 
or alkyne. This non-natural monosaccharide makes its way though the biosynthetic 
pathway and ultimately gets incorporated into the cellular glycans that normally contain 
this monosaccharide (Figure 1.1A). Next, bioorthogonal chemistry is performed on the 
sample to install a visualization tag (Figure 1.1A). While this method has provided 
numerous publications and is invaluable to the study of glycans, it suffers from specificity 
and sensitivity issues as well. First, specific disaccharides or trisaccharides of specific 
linkage and composition, such as Fucose-α(1-2)-Galactose, cannot be identified. For 
example, metabolic labeling of cells with a fucose analogue will not enable researchers to 
distinguish Fucose-α(1-2)-Galactose from O-linked fucose or core fucose. Additionally, 
non-natural sugar analogues will be competing with the endogenous, naturally occurring, 
monosaccharides. This competition will cause sensitivity issues, as the non-natural 
analogue will be incorporated in sub-stoichiometric levels.   
 Unfortunately, these sensitivity and specificity issues are not the only potential 
problems when utilizing the metabolic labeling approach. The path a non-natural sugar 
analogue takes from uptake to incorporation into the glycoconjugates is not simple. The 
non-natural monosaccharides need to be converted into the nucleotide diphosphate-non-
natural sugar (NDP-non-natural sugar), pass through transporters from the cytosol into the 
golgi and/or ER, and be recognized by glycosyltransferases. Any one of these points can 
create a bottleneck. However, the most pressing issue with this process is that of 
 4 
glycosyltransferase preference.  Since one NDP-sugar donor substrate can be utilized by 
multiple glycosyltransferases, it is reasonable to assume that some glycosyltransferases 
utilize particular non-natural substrates better than others. In the case of fucose, over 13 
fucosyltransferase are established in mammalian systems; however, they do not utilize 6-
alkyne-fucose with the same effeicnety.11 It was determined that protein O-
fucosyltransferase 1 (POFUT1) and protein O-fucosyltransferase 2 (POFUT2) utilize this 
non-natural substrate much better than fucosyltransferase 8 (FUT8). The issue here is that 
in most systems, the metabolic labeling approach will yield biased incorporation 
stoichiometries among different glycoconjugates of similar monosaccharide composition 
and this type of information is not currently characterized.  
 Another potential issue is that large amounts of sugar are being introduced to the 
cells, potentially perturbing the endogenous cellular metabolism. To date, studies have not 
been conducted that determine the physiological or metabolic effects of these non-natural 
sugar analogues. Finally, because this approach requires that the cells or organism be 
incubated with the non-natural sugar, biological material from human samples cannot be 
interrogated using this approach. This metabolic approach has been invaluable to the 
scientific community and has advanced our understanding of glycan function over the 
recent decade; however, this approach suffers from sensitivity and selectivity issues, among 
other limitations.  
 
Chemoenzymatic Labeling 
 Most recently, the chemoenzymatic approach has been utilized to detect specific 
glycan structures with superior sensitivity and selectivity over the preceding methods. This 
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approach involves incubating cells or proteins, from any biological source, with an 
exogenous glycosyltransferase and a non-natural donor substrate (Figure 1.1B). Then, as 
with the metabolic labeling approach discussed above, bioorthogonal chemistry is 
performed to install detection tags specifically onto the glycan structure of interest (Figure 
1.1B). This approach provides several advantages over the metabolic labeling approach. 
First, the specificity is dictated by the glycosyltransferase, which installs the non-natural 
sugar onto very specific glycan structures of defined connectivity and composition. 
Additionally, because the reaction proceeds in quantitative yield, the sensitivity of 
detection is much greater than that of the metabolic labeling or lectin based approaches. 
Because this approach covalently installs detection tags onto the specific glycan structures, 
it is amenable to direct glycoproteomic profiling and site mapping studies of these unique 
glycoproteins. Finally, because any biological sample can be interrogated using this 
approach, the chemoenzymatic labeling strategy is an excellent resource for identification 
of carbohydrate-based disease biomarkers.  
 To date, only a handful of these methods exist, with two of them described in this 
thesis. Developed over a decade ago by the Hsieh-Wilson group, the first chemoenzymatic 
approach was used to selectively detected O-linked-β-N-acetylglucosamine (O-GlcNAc).12 
This approached exploited the β-1,4 galactosyltransferase, GalT, which was engineered to 
accept galactose analogs with non-natural functionality installed at the C-2 position. In this 
initial publication of the method, a ketone-galactose analogue was used with aminooxy-
derivatized detection reagents. Years later this approach was updated to include the use of 
an azido-galactose analogue, GalNAz, and the copper catalyzed azide-alkyne cycloaddition 
(CuAAC), commonly referred to as “click chemistry”.13 Recently, this approach was 
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modified to determine the stoichiometry of glycosylation on specific proteins.14 In this 
approach, the enzymatic labeling step was unchanged; however, instead of installing a 
detection tag, a 2- or 5- kilodalton mass tag was installed onto the labeled O-GlcNAc 
glycoproteins. The samples were then subjected to SDS-PAGE and resolved by western 
blot analysis for specific proteins of interest. This enabled visualization of the different 
glycoforms of a particular glycoprotein and informed the protein specific dynamics of this 
modification. A tremendous amount of information has been learned with this single 
chemoenzymatic approach, demonstrating the value of this method.  
 More recently, Wu and co-workers developed a chemoenzymatic approach for the 
detection of N-acetyllactosamine (LacNAc), a disaccharide of defined compositing and 
connectivity.15 This was the first study to utilize the chemoenzymatic approach for the 
visualization of specific glycan motifs on whole organisms, C. elegans, and utilizing a flow 
cytometry readout, highlighting the versatility of the chemoenzyamtic approach.  
 It was during this time that I was finalizing the second chemoenzymatic approach 
from the Hsieh-Wilson lab. This approach enabled the detection of the Fucose-α(1-2)-
Galactose motif, and with this approach I was able to profile the cell surface expression 
levels of this disaccharide across various cancer cell lines.16 Further, I was able to 
distinguish prostate cancer cells from healthy prostate epithelial cells, demonstrating the 
diagnostic capacity of the chemoenzymatic approach. This method is described in detail in 
chapter 2.  
 Finally, I have recently completed the development of a chemoenzymatic approach 
for the detection of core fucosylated glycoproteins (in preparation). I was able to integrate 
this approach into a diagnostic ELISA platform (Chapter 3), develop a biomarker 
 7 
identification proteomic workflow (Chapter 3), and exploit this approach as an antibody-
conjugation method (Chapter 4).  
 
Figure 1.1 Comparison of metabolic labeling to in situ chemoenzymatic labeling of glycans. In 
metabolic labeling, a non-natural sugar (red) containing a bioorthogonal functional group is taken 
up by the cell and incorporated via the cell’s biosynthetic machinery into glycoconjugates. In 
chemoenzymatic labeling, an exogenous glycosyltransferase enzyme and non-natural nucleotide 
sugar analog (green) are used to transfer a non-natural sugar containing a bioorthogonal group onto 
specific glycan structures. Once a bioorthogonal group is installed, both methods use bioorthogonal 
ligation chemistry to install a detectable probe (yellow) to track the labeled glycans.  
 
 
Metabolic Labeling 
Chemoenzymatic Labeling B 
A 
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BIOLOGICAL SIGNIFICANCE OF FUCOSE-α(1-2)-GALACTOSE AND CORE 
FUCOSE 
Fucose-α(1-2)-Galactose 
 The Fucose-α(1-2)-Galactose (Fucα(1-2)Gal) disaccharide is produced by the α(1-
2) addition of fucose (red) to galactose, catalyzed by either FUT1 or FUT2, which are 
differentially expressed in a tissue dependent fashion (Figure 1.2). Fucα(1-2)Gal is found 
on the non-reducing terminus of a many important glycans, including blood group H1 and 
H2, Globo H, Fuc-GM1, Lewis B, and Lewis Y. These glycans play important roles in 
processes such as learning and memory and contribute to asthma, inflammation, and 
tumorigenesis.17-26  
 
Figure 1.2 The Fucose-α(1-2)-Galactose disaccharide is produced by the α(1-2) addition of fucose 
(red) to galactose, catalyzed by either FUT1 or FUT2. R can be either protein or lipid and this 
disaccharide is generally a terminal motif of longer glycan chains.  
 
 Interestingly, task-specific learning and long-term potentiation (LTP) induce this 
glycan in hippocampal neurons.18 Additionally, the injection of 2-deoxy-galactose (2-D-
Gal), an inhibitor of Fucα(1-2)Gal synthesis, causes reversible amnesia in rats and 
interferes with the maintenance of LTP.27 The Fucα(1-2)Gal glycan also regulates the 
stability and turnover of synapsin I, a protein important for synapse formation and 
neurotransmitter release.28  
 This glycan has also been implicated as a cancer biomarker.29-33 Specifically, the 
Globo H antigen, a hexasaccharide glycosphingolipid with a terminal Fucα(1-2)Gal 
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epitope, is overexpressed on a variety of epithelial cell tumors (Figure 1.3).21,29,31 Fucα(1-
2)Gal glycan expression was also elevated in prostate cancer tissue and on the tumorigenic 
prostate-specific antigen (PSA) protein, when compared to normal epithelial tissue or 
PSA.32 
 
Figure 1.3 The Globo H antigen is a hexasaccharide glycosphingolipid, terminating with the 
Fucose-α(1-2)-Galactose disaccharide, and is overexpressed on a variety of epithelial cell tumors. 
 
  More recently, it has been determined that this glycan is induced in the small 
intestine of mice upon bacterial infection and modulates microbe-host interactions.33,34 
Systemic infection led to increased expression of the Fut2 gene and subsequent cell surface 
and secreted Fucα(1-2)Gal glycoproteins. Fucose was cleaved from this disaccharide by 
bacterial fucosidases and utilized by the microbes in an unknown manner. This process led 
to a suppression of pathogen virulence, providing a protective role towards the host. This 
glycan clearly plays roles in many facets of healthy and disease physiology. 
 
Core Fucose 
 Core fucose is a FUT8 catalyzed α-1,6-fucose attached to the reducing end N-
Acetylglucosamine (GlcNAc) of N-glycans (Figure 1.4).1 This modification is the most 
abundant post-translational fucosylation and regulates a variety of important biological 
processes such as cell signaling,35,36 cell adhesion,37,38 long-term potentiation,39 and 
antibody-dependent cellular cytotoxicity40 and is upregulated in various cancers.41-50 The 
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recent development of fut8 kock-out mice has led to numerous discoveries, demonstrating 
that misregulation of core fucose has broad consequences and implicating this protein 
modification in physiological, developmental, and immunological disorders.51  
 
Figure 1.4 Core fucose (red) is an alpha-1,6 fucose attached to the core GlcNAc of N-linked 
glycans and catalyzed by fucosyltransferase 8 (FUT8). The N-Glycan is directed attached to 
asparagine residues (blue).  
 
 The fut8 knock-out mice have been used to show that the loss of core fucose on the 
TGF-β1 receptor led to deregulation of this signaling pathway, presenting a emphysema-
like phenotype.52 Also, loss of core fucose on the EGF-receptor attenuated the EGF 
signaling pathway35 and downregulated integrin α4β1-mediated cell adhesion.37 
Additionally, loss of VCAM-1 core fucosylation led to decreased pre-B cell binding to 
stromal cells, leading to misregulated B cell development and function.38 Finally, with the 
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recent use of therapeutic antibodies, work has demonstrated that loss of core fucose on 
human IgG1 antibodies leads to ~ 100 fold increase in antibody-dependent cellular 
cytotoxicity (ADCC).40  
 Core fucose has also been implicated in both cancer pathogenesis and as a 
diagnostic marker.41-47 Specifically, increased core fucosylation of serum glycoproteins has 
been discovered in breast,41 prostate,42 and pancreatic cancers,43 but perhaps best studied in 
the case of Hepatocellular Carcinoma (HCC) where increased core fucosylation of α-
fetoprotein (AFP), among other proteins, has been shown to directly correlate with HCC 
pathogenesis.44-50 AFP levels are currently used to monitor HCC progression and used as a 
prognostic marker.48 However, AFP levels are also elevated during other liver disorders 
such as chronic hepatitis (in both HepB and HepC) and cirrhosis.49,50 The core fucosylation 
levels on AFP, regardless of the total AFP levels, have been shown to be the strongest 
correlate with HCC prognosis. Taken together, these observations clearly demonstrate 
multiple physiological roles for core fucose, likely influencing protein structure and 
dynamics, and this glycan can be used in a protein-specific fashion for cancer diagnostics. 
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ABSTRACT  
 The disaccharide motif fucose-α(1-2)-galactose (Fucα(1-2)Gal) is involved in 
many important physiological processes, such as learning and memory, inflammation, 
asthma, and tumorigenesis. However, the size and structural complexity of Fucα(1-2)Gal-
containing glycans have posed a significant challenge to their detection and study.  In this 
chapter, I report a new chemoenzymatic strategy for the rapid, sensitive detection of 
Fucα(1-2)Gal glycans.  I have demonstrated that the approach is highly selective for the 
Fucα(1-2)Gal motif, detects a variety of complex glycans and glycoproteins, and can be 
used to profile the relative abundance of the motif on live cells, discriminating malignant 
from normal cells. This approach represents a new potential strategy for biomarker 
detection and expands the technologies available for understanding the roles of this 
important class of carbohydrates in physiology and disease. 
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INTRODUCTION 
 Defects in glycosylation are a hallmark of many human diseases, including 
autoimmune disorders, neurodegenerative diseases, and cancer.1-3 As part of a general 
interest in understanding the role of protein glycosylation in disease, I investigated the 
glycan motif fucose-α(1,2)-galactose (Fucα(1-2)Gal). Fucα(1-2)Gal is found on the non-
reducing terminus of a large family of important glycans, including blood group H1 and 
H2, Globo H, Fuc-GM1, Lewis B, and Lewis Y.  These glycans play important roles in 
processes such as learning and memory and contribute to asthma, inflammation, and 
tumorigenesis.4-13 However, the size and structural complexity of Fucα(1-2)Gal glycans, 
which range from simple linear to large branched structures, has posed a significant 
challenge to their detection and study. 
 Antibodies or lectins are typically used to detect glycans, but these methods often 
suffer from weak binding affinity and limited specificity, displaying cross-reactivity 
toward multiple glycan epitopes.14-16 An alternative method, metabolic labeling, provides 
a powerful and versatile approach to the detection of glycans.17-21 However, as stated in 
chapter one, metabolic labeling requires the uptake of non-natural monosaccharide 
analogs into biosynthetic pathways, which allows for their incorporation into numerous 
glycans.  As a consequence, disaccharide or trisaccharide motifs of specific sugar 
composition and glycosidic linkage, such as Fucα(1-2)Gal, cannot be uniquely detected.  
Furthermore, the non-natural sugar must compete with natural sugars and thus is often 
incorporated sub-stoichiometrically into glycoconjugates, thereby reducing detection 
sensitivity.  Given the diversity of carbohydrate structures at the cell surface, there is an 
urgent need to develop new technologies for the specific detection of complex glycans.   
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 In this chapter, I report the first strategy for the rapid, sensitive, and selective 
detection of Fucα(1-2)Gal glycans.  The approach capitalizes on the substrate tolerance of 
a bacterial glycosyltransferase to covalently tag specific glycans of interest with a non-
natural sugar analog (Figure 2.1).  As the reaction proceeds in quantitative yield, 
stoichiometric addition of the non-natural sugar can be achieved, affording higher 
detection sensitivity relative to antibodies, lectins, and metabolic labeling. Although 
chemoenzymatic approaches have been reported for two saccharides, O-linked-β-N-
acetylglucosamine (O-GlcNAc)22,23 and N-acetyllactosamine (LacNAc),24 this study 
demonstrates the first direct detection of complex oligosaccharides, opening up the 
potential to track a broad range of physiologically important glycans. 
 
Figure 2.1 The chemoenzymatic labeling approach for the detection of Fucα(1-2)Gal 
glycoconjugates.   
 
RESULTS AND DISCUSSION 
 To develop this approach, I exploited the bacterial homologue of the human blood 
group A antigen glycosyltransferase (BgtA), which has been shown to transfer N-
acetylgalactosamine (GalNAc) from UDP-GalNAc onto the C-3 position of Gal in 
Fucα(1-2)Gal structures.25  I suspected that BgtA might tolerate substitution at the C-2 
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position of GalNAc, which would allow for the selective tagging of Fucα(1-2)Gal with an 
azido or ketone functionality (Figure 2.2).   
 
Figure 2.2 (A) Chemoenzymatic strategy for the detection of Fucα(1-2)Gal glycans. (B) Alkyne 
or aminooxy probes used for detection of glycans.  
 
 To test the approach, Fucα(1-2)Gal substrate 1 was synthesized via reductive 
amination of 2’-fucosyllactose with p-nitrobenzylamine and sodium cyanoborohydride 
(Figure 2.3). Additionally, BgtA was expressed and purified as described (Figure 2.4).25  
Indeed, treatment of 1 with BgtA and either UDP-2-deoxy-2-(acetonyl)-β-D-
galactopyranoside (UDP-ketoGal, 2) or UDP-N-azidoacetylgalactosamine (UDP-
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GalNAz, 3) led to complete conversion to the desired products 4 and 5, respectively, after 
12 h at 4 °C, as determined by liquid chromatography-mass spectrometry (LC-MS; 
Figures 2.5 and 2.6). Subsequent reaction with the aminooxy-biotin derivative 7 (Figure 
2.2) or with an aza-dibenzo-cyclooctyne-biotin derivative (ADIBO-biotin, 6; Figure 2.2), 
using copper-free click chemistry (3 h, rt), afforded the biotinylated products 8 and 9, 
respectively, in quantitative yield (Figures 2.5 and 2.6). 
 
Figure 2.3 Synthesis of Fucα(1-2)Gal substrate 1.   
 
 
Figure 2.4 Purified BgtA visualized with SDS-PAGE and coomassie stain. Bovine serum 
albumin (BSA) is also run on the gel as a standard.  
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Figure 2.5 (A) Chemoenzymatic labeling of substrate 1 with UDP-ketoGal 2. HPLC-MS analysis 
of the reaction progress at time 0 (top), 12 h after the addition of BgtA and 2 (middle), and 24 h 
after the addition of aminooxy-biotin derivative 7 (bottom). HPLC chromatogram is shown.  
 Given the repertoire of probes that can react with azides, as well as the high 
background labeling witnessed using aminooxy probes in protein lysates (data not 
shown), it was decided that UDP-GalNAz (3) would be used moving forward. To more 
rigorously characterize the products generated after treating 1 with BgtA and UDP-
GalNAz (3), followed by ADIBO-biotin (6), MS/MS spectra were collected and 
fragmentation ions were characterized (Figure 2.7).  The fragmentation of compounds 1, 
5, and 9 produced b, c, y, and z ions, consistent with the fact that GalNAz is directly 
modifying the galactose of 1 (Figure 2.7B). Additionally, the MS/MS analysis of 9 
demonstrates that ADIBO-biotin (6) does not produce non-specific reactions with 1 and 
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is specific for the azide of GalNAz (Figure 2.7C).  These findings provide evidence that 
BgtA adds GalNAz directly onto the galactose of Fucα(1-2)Gal molecules.  
Figure 2.6 Labeling of substrate 1. LC-MS traces monitoring the reaction progress at time 0 
(top), 12 h after the addition of BgtA and 3 (middle), and 3 h after the addition of ADIBO-biotin 
6 (bottom). Total ion chromatogram is shown.  
 
Kinetic analysis revealed an apparent kcat/Km value of 5.7 nM-1min-1 for UDP-
GalNAz, approximately 7-fold lower than the value of 40.4 nM-1min-1 obtained for the 
natural UDP-GalNAc substrate (Figure 2.8).25  Additionally, the apparent Km values were 
determined to be 127 ± 36 µM (UDP-GalNAc) and 168 ± 55 µM (UDP-GalNAz).  
RT: 1.50 - 7.00 SM: 11G
1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Re
lati
ve 
Ab
und
anc
e
NL:
3.85E4
Base Peak 
 MS 
050811_3_
noE
RT: 1.50 - 7.00 SM: 11G
1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Re
lati
ve 
Ab
und
anc
e
NL:
7.30E4
Base Peak 
 MS 
051011_0
min
RT: 1.50 - 7.00 SM: 11G
1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Re
lati
ve 
Ab
und
anc
e
NL:
2.20E4
Base Peak 
 MS 
051011_on
_neg_2
R
el
at
iv
e 
in
te
ns
ity
 
Time (min) 
2" 3" 4" 5" 6"
100"
80"
60"
40"
20"
100"
80"
60"
40"
20"
100"
80"
60"
40"
20"
[M + H]+  
625.17  
[MGalNAz + H]+ 
869.15 
[MGalNAz-Biotin]-  
1520.24 
1 
O
O
HO
HO
OH
O
HOOH
OH NH
OH
HO
O
HO OH
NO2
O
O
OH OH
O
HOOH
OH NH
OH
HO
O
HO OH
NO2
O
O
HO OH
HO
NH
O
N3
O
O
OH OH
O
HOOH
OH NH
OH
HO
O
HO OH
NO2
N
O
O
HO OH
HO
NHO
NN
N
O
H
N
O
SO3-H
NS
HN NH
O
H
H
O
5 
9 
	   24 
 
Figure 2.7 LC-MS/MS analysis of 1, 5, and 9 during the chemoenzymatic labeling process. (A) 
Compound 1 at time 0. (B) Compound 5, 12 h after the addition of BgtA and UDP-GalNAz 3. (C) 
Biotinylated glycan 9, 3 h after reaction with ADIBO-biotin 6.  The MS spectrum for each 
compound is shown on top; the MS/MS spectrum for the most abundant ion is shown on the 
bottom. The m/z of peaks found in each MS/MS analysis are shown as either b and y or c and z 
ions. The corresponding fragmentation products and probable cleavage sites are denoted in the 
respective structures.  1 and 5 were detected in positive scanning mode; 9 was detected in 
negative scanning mode. 
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Finally, the apparent Vmax value for UDP-GalNAc (0.100 ± 0.010 nmolmin-1) is 
approximately 5-fold higher than that of UDP-GalNAz (0.020 ± 0.002 nmolmin-1; 
Figure 2.8). These parameters suggest that UDP-GalNAc is a preferred substrate for 
BgtA; however, UDP-GalNAz still exhibits sufficient kinetic parameters to enable 
efficient chemoenzymatic labeling.  
 
Figure 2.8 Kinetic comparison of the BgtA-catalyzed reaction of 1 with UDP-GalNAc (black) 
and UDP-GalNAz (blue, 3). Reactions were performed in duplicate using 100 µM of acceptor 1 
and varying concentrations of the donor. Initial rates as a function of substrate concentration were 
plotted and revealed apparent kcat/Km values of 5.7 nM-1min-1 and 40.4 nM-1min-1, respectively, 
and apparent Km values of 127 ± 36 µM and 168 ± 55 µM, respectively. The apparent Vmax value 
for UDP-GalNAc (0.100 ± 0.010 nmolmin-1) is approximately 5-fold higher than that of UDP-
GalNAz (0.020 ± 0.002 nmolmin-1). 
 
Having demonstrated that BgtA accepts non-natural donor substrates, I next 
determined the acceptor substrate profile for BgtA using carbohydrate microarrays from 
the Consortium for Functional Glycomics.26-27 These carbohydrate microarrays contain 
611 different glycan structures, enabling the characterization of glycans modified by 
BgtA in a controlled environment. Glycosylation reactions with BgtA and UDP-GalNAz 
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were performed on the array with 3 different time points (0.5, 2, and 12 h) followed by 
subsequent reaction with ADIBO-biotin (Figure 2.9). The biotinylated glycans were 
finally detected using Cy5-conjugated streptavidin.   
 
Figure 2.9  Characterization of the the acceptor substrate profile of BgtA. (A) Scheme of the 
work flow using the glycan array. After treating the slide with BgtA and UDP-GalNAz (3), 
ADIBO-biotin (6) was used to install a biotin reporter onto the BgtA modified glycans. Slides 
were then incubated with a streptavidin conjugated AlexaFluor-488 and slides were scanned with 
a fluorescent slide reader. (B) Representative data showing the BgtA dependent labeling of 
different glycan structures.  
 
Strong fluorescence labeling of Fucα(1-2)Gal structures was observed within 0.5 
h and the top 26 glycans labeled contained terminal Fucα(1-2)Gal structures, highlighting 
the specificity of the chemoenzymatic approach (Figure 2.10).  Moreover, ~91% of the 
terminal Fucα(1-2)Gal containing a free C-3 hydroxyl group on Gal were labeled on the 
array, including the H1 (68, 69) and H2 antigens (76, 77), the ganglioside Fuc-GM1 (65), 
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and the Globo H antigen (60), a hexasaccharide overexpressed on breast, lung, and 
prostate tumors and associated with poor prognosis (Figures 2.10 and 2.11).8-12 A wide 
variety of linear (e.g., 501, 75, and 60) and branched structures (e.g., 450, 362, and 457) 
containing the Fucα(1-2)Gal motif were efficiently labeled (Figures 2.10 and 2.12).  
Modifications of the core disaccharide, such as replacing Gal with GlcNAc, or changing 
the α(1-2) linkage to an α(1-3), α(1-4) or β(1-3) linkage eliminated the enzymatic 
labeling by BgtA (e.g., 80, 81, and 82; Figure 2.12A). 
 
Figure 2.10 Time course analysis using a glycan microarray. Representative structures from the 
top 26 glycans with the highest relative fluorescence intensity after 0.5 h are plotted, all of which 
represent terminal Fucα(1-2)Gal structures. UDP-GalNAz (3) was omitted from some of the 
reactions as a control (12 h, -UDP-GalNAz).  
 
Consistent with a previous report,25 BgtA exhibited more relaxed specificity 
toward structures appended to the reducing end of the Gal residue.  Specifically, glycans 
containing a β(1-3)GalNAc, β(1-3)GlcNAc, β(1-4)GlcNAc, or β(1-4)Glc in this position 
were efficiently labeled (e.g., 62, 66, 74, and 78, respectively; Figure 2.12A).   
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Figure 2.11 Additional Fucα(1-2)Gal structures on the microarray and their ability to be labeled 
by BgtA (see also Figure 2 A). Relative fluorescence intensities are plotted as a function of time 
and represent the mean of 4 values. Error bars represent the standard deviation of the mean. 
Glycans were considered labeled if they showed a time-dependent increase in fluorescence 
labeling and their signal at 12 h after subtraction of the background in the absence of UDP-
GalNAz (12 h, -UDP-GalNAz) was >1000 relative fluorescence units. The red asterisks indicate 
structures that were not considered to be labeled. W indicates very weak labeling.  
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Figure 2.12 The chemoenzymatic approach labels a variety of linear (A) and branched (B) 
Fucα(1-2)Gal structures.  (A) The third sugar toward the reducing end of the glycan does not 
significantly affect the labeling reaction (eg., 62, 66, 74, and 78).  Acceptor substrate structures 
that have a GlcNAc, instead of Gal, and change the linkage from α(1-2) to α(1-3), α(1-4), or β(1-
3) are not modified by BgtA (eg., 80, 81, and 82). Representative structures from the microarray 
are shown for comparison.  Relative fluorescence intensities are plotted as a function of time to 
show how subtle changes in the structure affect the kinetics of labeling. Error bars represent the 
standard deviation of the mean of 4 values after removing the high and low values from n = 6 
replicates of each glycan printed on the array. 
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Figure 2.13 The chemoenzymatic approach labels a variety of Fucα(1-2)Gal structures. (A) 
Branching at the third position GlcNAc via α(1-3) or α(1-4) fucosylation severely hindered the 
labeling efficiency. (B) Weak labeling of Galβ (1-4)GlcNAc structures was also observed.  This 
labeling was accompanied by high background, as indicated by the 12 h time point in the absence 
of UDP-GalNAz.  No labeling of these structures was observed in solution, suggesting that the 
labeling was likely due to non-covalent interactions with the microarray.  Representative 
structures are shown for comparison.  Relative fluorescence intensities are plotted as a function of 
time to show how changes in glycan structure affect the labeling reaction. Error bars represent the 
standard deviation of the mean of 4 values after removing the high and low values from n = 6 
replicates of each glycan printed on the array. 
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Lewis B (61) and Lewis Y (72, 73) antigens, or no appreciable labeling (e.g., 71, and 
363; Figures 2.11 and 2.13A).  Interestingly, we also observed weak labeling of Galβ(1-
4)GlcNAc structures on the glycan array (Figure 2.13B).  However, these structures also 
exhibited high background signal even in the absence of UDP-GalNAz, and BgtA failed 
to label p-nitrophenyl 2-acetamido-2-deoxy-4-O-(β-D-galactopyranosyl)-β-D-
glucopyranoside (Galβ(1-4)GlcNAc-pNP) in solution (2 h, 25 °C; data not shown), 
suggesting that Galβ(1-4)GlcNAc structures are not covalently labeled by BgtA.  
Together, these studies demonstrate the strong specificity of BgtA for Fucα(1-2)Gal 
structures and the power of glycan microarrays to rapidly profile the specificities of 
glycosyltransferases for the development of chemoenzymatic detection strategies.  
 
Figure 2.14 Chemoenzymatic labeling of Fucα(1,2)Gal glycoproteins from cells.  (A) In-gel 
fluorescence detection of Fucα(1,2)Gal glycoproteins from olfactory bulb lysates.  Low 
background fluorescence was observed in the absence of BgtA, UDP-GalNAz 3, or TAMRA-
alkyne 10.  The strong band at approximately 35 kDa is likely autoglycosylated BgtA.  (B) 
Specific chemoenzymatic labeling of endogenous Fucα(1,2)Gal glycoproteins from olfactory 
bulb lysates.  Glycosylated NCAM, synapsin I, and munc18-1 were detected after 
chemoenzymatic labeling with alkyne-biotin, streptavidin pull-down, and immunoblotting for 
each protein of interest. (C) Specific chemoenzymatic labeling of Flag-tagged synapsin I 
overexpressed in HeLa cells.  Glycosylated synapsin I was detected after chemoenzymatic 
labeling with alkyne-TAMRA, synapsin pull-down with an anti-Flag antibody, and 
immunoblotting with an anti-TAMRA antibody. B and C were performed with Chithra 
Krishnamurthy.  
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To determine whether the approach could be used to track Fucα(1-2)Gal 
glycoproteins in complex cell lysates, I labeled proteins from rat brain extracts with BgtA 
and UDP-GalNAz, followed by Cu(I)-catalyzed reaction with the alkyne-functionalized 
tetramethyl-6-carboxy-rhodamine dye 10 (alkyne-TAMRA; Figure 2.2B). Strong 
fluorescence labeling of Fucα(1-2)Gal glycoproteins was observed, with minimal non-
specific labeling in the absence of BgtA, UDP-GalNAz, or alkyne-TAMRA (Figure 
2.14A).  
Interestingly, a strong band is witnessed at an apparent molecular weight (MW) of 
37kDa, the MW of BgtA itself (Figure 2.14A). Considering the fact that the bacterial 
species that endogenously expresses BgtA contain the Fucα(1-2)Gal disaccharide, I 
suspect that BgtA is a glycoprotein itself and modifies itself to a high degree during the 
chemoenzymatic labeling. This hypothesis is further supported given that the total 
concentration of BgtA, relative to other Fucα(1-2)Gal proteins, in the labeling reaction is 
so high that one would expect it would be the brightest band detected. No further studies 
were conducted to validate this hypothesis; however, no amount of washing the protein 
pellet could remove this intense band witnessed in every lysate labeling reaction 
performed.  
To confirm further the specificity of the reaction, we labeled the lysates with the 
alkyne-biotin derivative 11 (Figure 2.2B), captured the biotinylated proteins using 
streptavidin resin, and immunoblotted for the presence of known Fucα(1-2)Gal 
glycoproteins.28.29  Neural cell adhesion molecule (NCAM), synapsin I, and munc18-1 
were all chemoenzymatically labeled and detected in the presence, but not in the absence, 
of BgtA (Figure 2.14B).  In contrast, p44 mitogen-associated protein kinase (p44 
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MAPK), a protein that has not been shown to be fucosylated, was not detected.  
Glycosylated synapsin I was also readily observed following overexpression of Flag-
tagged synapsin I in HeLa cells, chemoenzymatic labeling of the lysates with alkyne-
TAMRA, synapsin immunoprecipitation, and visualization using an anti-TAMRA 
antibody (Figure 2.14C).   
 
Figure 2.15 Comparison of UEAI lectin affinity chromatography to the chemoenzymatic 
strategy.  Glycosylated synapsin I from olfactory bulb lysate (500 µg) was subjected to lectin 
affinity chromatography or chemoenzymatic labeling followed by streptavidin capture.  Western 
blotting for synapsin I indicated that UEAI failed to capture and detect glycosylated synapsin I, 
whereas the chemoenzymatic strategy allowed for ready detection. Performed by Chithra 
Krishnamurthy. 
 
Importantly, UEAI lectin affinity chromatography failed to pull-down and detect 
glycosylated synapsin I when performed on the same scale (Figure 2.15).  Moreover, 
previous studies have reported that the Fucα(1-2)Gal-specific antibody A46-B/B10 does 
not immunoprecipitate glycosylated synapsin I from the same neuronal lysates.28  Thus, 
our chemoenzymatic approach enables the highly sensitive detection of glycoproteins and 
provides a variety of different enrichment strategies and readouts for the Fucα(1-2)Gal 
motif.   
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Next, we investigated whether the chemoenzymatic strategy could be used to 
image Fucα(1-2)Gal glycans in cells.  HeLa cells overexpressing Flag-tagged synapsin I 
were fixed, permeabilized, and chemoenzymatically labeled on coverslip with BgtA and 
UDP-GalNAz.  Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) chemistry was then 
performed using an alkyne-functionalized Alexa Fluor 488 dye (12; Figure 2.2) to install 
a fluorescent reporter onto the Fucα(1-2)Gal glycans.  Strong fluorescence labeling was 
observed in cells transfected with synapsin I, and the labeling showed excellent co-
localization with intracellular synapsin I expression (Figure 2.16).  No labeling of cells 
was observed in the absence of BgtA, and only weak labeling of endogenous Fucα(1-
2)Gal glycoproteins was seen in the absence of synapsin I overexpression (Figure 2.16), 
confirming the specificity of the in situ chemoenzymatic reaction. 
 
Figure 2.16 Fluorescence detection of Fucα(1,2)Gal glycans (green) in HeLa cells shows 
significant co-localization (yellow, overlay) with Flag-tagged synapsin I (red). Low levels of 
fluorescence labeling of endogenous Fucα(1-2)Gal glycoproteins is witnessed in mock-
transfected HeLa cells, suggesting low expression levels of endogenous Fucα(1-2)Gal 
glycoproteins (bottom row). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; 
blue). Performed by Chithra Krishnamurthy. 
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As the Fucα(1-2)Gal epitope has been reported to be a useful biomarker for 
cancer progression and prognosis,11,12 the ability to detect Fucα(1-2)Gal glycan levels on 
the surface of cancer cells would facilitate investigations into Fucα(1-2)Gal as a 
diagnostic or prognostic marker and a therapeutic target for cancer vaccines.  However, 
antibodies and lectins that bind Fucα(1-2)Gal have been shown to cross-react with other 
sugar epitopes14,15 such as β-linked Fuc,14 or recognize an incomplete subset of Fucα(1-
2)Gal glycans,16 indicating the need for more selective, yet comprehensive, high-affinity 
detection methods.  Therefore we applied the chemoenzymatic approach to the detection 
of Fucα(1-2)Gal glycans on live cancer cells.  Cells from the human breast 
adenocarcinoma cell line MCF-7 were chemoenzymatically labeled with BgtA and UDP-
GalNAz for 1 h at 37 °C.  After reaction with ADIBO-biotin (1 h, rt), Fucα(1-2)Gal 
glycans were detected using streptavidin conjugated to Alexa Fluor 488 dye.  Membrane-
associated fluorescence was observed for cells treated with both BgtA and UDP-GalNAz, 
whereas no labeling was detected for control cells labeled in the absence of BgtA (Figure 
2.17).  
 
Figure 2.17 Fluorescence detection of Fucα(1,2)Gal glycans (green) on live MCF-7 cells. Nuclei 
were stained with Hoechst 342 (blue). Performed by Chithra Krishnamurthy. 
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Figure 2.18 (A) Flow cytometry analysis of the relative expression levels of Fucα(1,2)Gal 
glycans across various cancer cell lines, with comparison to non-cancerous PrEC cells. Cells were 
untreated (red) or chemoenzymatically labeled in the presence (blue) or absence (green) of BgtA. 
(B) Quantification of the mean fluorescence intensity (MFI) relative to cells labeled in the 
absence of. Error bars represent data from duplicate (MCF-7, MDA-mb-231, H1299) or triplicate 
(LnCAP, PrEC) experiments. Performed by Chithra Krishnamurthy. 
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with BgtA and UDP-GalNAz (2 h, 37 °C), reacted with ADIBO-biotin (1 h, rt), and 
stained with the streptavidin-Alexa Fluor 488 conjugate (20 min, 4 °C). As shown by 
flow cytometry analysis, LnCaP, MCF-7, and MDA-mb-231 cells displayed the highest 
levels of fluorescence (Figure 2.18), consistent with reports of high Globo H expression 
on mammary and prostate tumors.8-10 H1299 cells, a model for non-small cell lung 
carcinoma and also reported to express Globo H,13 showed lower Fucα(1-2)Gal 
expression.  Importantly, flow cytometry analysis revealed a 53% increase in Fucα(1-
2)Gal expression on the surface of LnCAP cells compared to non-cancerous PrEC cells.  
These results demonstrate that this chemoenzymatic labeling approach can readily 
discriminate cancerous cells from normal cells, providing a new potential strategy for 
rapid biomarker detection.  The method could be particularly useful for the detection of 
prostate cancer from tissue biopsies, as the current standard of PSA detection to diagnose 
prostate cancer has a significant false-positive rate, leading to overtreatment.30 In addition 
to histological detection, this chemoenzymatic approach could potentially provide a new 
strategy to distinguish normal PSA from tumorigenic PSA, which is reported to have 
higher levels of Fucα(1-2)Gal glycosylation.31   
 
CONCLUSION 
In this chapter I have described a newly developed chemoenzymatic strategy that 
detects Fucα(1-2)Gal glycans with improved efficiency and selectivity over existing 
methods.  This strategy detects a variety of complex Fucα(1-2)Gal glycans and 
glycoproteins and permits living cells or complex tissue extracts to be rapidly 
interrogated.  I anticipate that the strategy will accelerate both the discovery of new 
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Fucα(1-2)Gal glycoproteins and advance an understanding of the biological roles of this 
important sugar in neurobiology and cancer.  Moreover, this study represents a proof-of-
concept that chemoenzymatic labeling strategies can be extended to more complex 
oligosaccharides.  Future studies will expand chemoenzymatic detection approaches to a 
broad range of glycans to provide a powerful new set of tools for glycomics research. 
 
EXPERIMENTAL METHODS  
General Methods for Chemical Synthesis.  Unless otherwise stated, all starting 
materials and reagents were purchased from Sigma-Aldrich and used without further 
purification.  All 1H and 13C NMR spectra were recorded on a Varian Innova 600 
spectrometer and referenced to solvent peaks.  Data for 1H NMR spectra are reported as 
follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet), coupling constant in Hz, and integration.  Low-resolution mass 
spectra were recorded on an 1100 Agilent Liquid Chromatograph Mass Spectrometer 
with an Agilent SB-C18 reverse-phase column (3.5 µm, 4.6 x 250 mm) with monitoring 
at 280 and 310 nm.  High-resolution mass spectra (HRMS) were obtained using an 
Agilent 6200 Series Time of Flight Mass Spectrometer with an Agilent G1978A 
Multimode source using mixed electrospray ionization/atmospheric pressure chemical 
ionization (MultiMode ESI/APCI). 
 
Synthesis of 1-p-Nitrobenzyl-(2-fucosyl)-lactose (1).  A 0.35 M solution of p-
nitrobenzylamine in 7:3 (v/v) DMSO/AcOH (50 µL, 18 µmol) was added slowly to 2’-
fucosyllactose (1.0 mg, 2.0 µmol) at rt. NaCNBH3 (50 µL of a 1 M solution in 7:3 (v/v) 
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DMSO/AcOH, 50 µmol) was then added slowly at rt, and the solution was stirred at 65 
°C for 4 h.  The reaction was quenched by adding 10 volumes of MeCN and incubated at 
-20 °C for 2 h.  The precipitated mixture was then centrifuged at 10,000 x g for 5 min at 4 
°C, and the supernatant was discarded.  Ten additional volumes of MeCN were added to 
the pellet, and the vortexed mixture was incubated at -20 °C for 2 h and centrifuged as 
above. This step was repeated two more times to remove the excess p-nitrobenzylamine.  
The pellet was then resuspended in 5% MeCN and the product purified by semi-
preparative HPLC (Agilent 1100) using two preparative reverse-phase columns (Agilent 
Eclipse XDB-C18; 5 µm, 9.4 x 250 mm) connected in series and a gradient of 5-20% B 
over 20 min at 4 mL/min (A, 0.5% aqueous AcOH; B, 100% MeCN).  The product eluted 
at approximately 9.5 min.  Lyophilization afforded a fluffy white solid (0.72 mg; 56% 
yield): 1H NMR (600 MHz, D2O) δ 8.33 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.7 Hz, 2H), 
5.31 (s, 1H), 4.60 (d, J = 7.8 Hz, 1H), 4.33 (q, J = 13.7 Hz, 2H), 4.23 (t, J = 6.3 Hz, 2H), 
3.93 (d, J = 3.4 Hz, 1H), 3.91–3.86 (m, 4H), 3.83 (t, J = 4.4 Hz, 4H), 3.79–3.71 (m, 4H), 
3.67 (dd, J = 9.5, 7.9 Hz, 1H), 3.32 (d, J = 11.7 Hz, 1H), 3.10 (t, J = 11.1 Hz, 1H), 1.23 
(d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, D2O) δ 147.86, 130.43, 124.09, 109.99, 
107.14, 100.42, 99.65, 76.94, 76.65, 75.19, 73.42, 71.69, 70.48, 70.19, 69.45, 68.97, 
68.51, 68.21, 67.18, 61.93, 60.90, 50.51, 49.52, 23.19, 15.29. HRMS: [M+H]+ calculated 
for C25H40N2O16 625.5996, found 625.2451.  
 
Expression and Purification of BgtA.  E. coli BL21 (DE3) harboring the recombinant 
plasmid vector pET28a-BtgA-His was kindly provided by Dr. Peng George Wang (Ohio 
State University).  The protein was expressed and purified as described.25 Briefly, the 
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cells were grown in LB medium (1L) at 37 °C.  Isopropyl-1-thio-β-D-galactospyranoside 
(IPTG, 0.8 mM final concentration; Sigma) was added when the cells reached an OD600 
of 0.8, and the cells were incubated for an additional 18 h at 16 °C.  The pelleted cells 
were lysed in Cell Lytic B Lysis Reagent (Sigma-Aldrich) supplemented with EDTA-free 
Complete™ protease inhibitors (Roche), 0.5 M NaCl, and 20 mM imidazole (Sigma-
Aldrich) by rotating end-over-end for 20 min at rt.  After centrifugation, the clarified 
lysate was added to prewashed Ni-NTA beads and incubated at 4 °C for 1 h, washed in 
20 mM Tris•HCl pH 7.5, 0.5 M NaCl and 50 mM imidazole, and eluted in a step gradient 
with the elution buffer (20 mM Tris•HCl pH 7.5, 0.5 M NaCl, and 100, 200, or 500 mM 
imidazole).  After SDS–PAGE analysis, the purified protein was concentrated with 
10,000 Da molecular weight cut-off (MWCO) spin filters (Millipore) and dialyzed into 
20 mM Tris•HCl pH 7.5 containing 10% glycerol and stored at 4 °C.  
 
BgtA Activity Assay and Monitoring of Chemoenzymatic Labeling Reactions by 
LC-MS/MS.  The Fucα(1-2)Gal substrate 1 (10 µM) was dissolved in 20 mM Tris•HCl 
pH 7.5, 50 mM NaCl, and 5 mM MnCl2.  BgtA enzyme and UDP-ketoGal 222 or UDP-
GalNAz 3 (Invitrogen) were added to final concentrations of 0.16 mg/mL and 50 µM, 
respectively, in a final volume of 100 µL.  The reaction was incubated at 4 °C in the dark 
for 12-16 h, and the reaction progress was monitored by LC-MS/MS.  To label with 
aminooxy-biotin 7, the reactions were diluted 5-fold with saturated urea, 2.7 M NaOAc 
pH 3.9 (50 mM final concentration and pH 4.8), and 7 (5 mM final concentration, 
Dojindo) and incubated for 20–24 h at rt.  To label with ADIBO-biotin 6, 250 µM of 6 
(Click Chemistry Tools) was added, and the reaction was incubated for 3 h at rt.  
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Following the labeling steps, the azido-labeled samples were filtered through a 3,000 Da 
MWCO Vivaspin 500 spin filter (GE Lifesciences) and injected on a reverse-phase 
HPLC column (Phenomenex Gemini; 5 m, 2.0 x 100 mm), fitted with a C8 guard 
column, using a ThermoScientific Accela 600 HPLC pump interfaced with a 
ThermoScientific LTQ mass spectrometer.  A linear 3-90% gradient of B (A: 0.1% 
aqueous formic acid, B: 0.1% formic acid in MeCN) over 7 min was used to resolve 
peaks with a flow rate of 0.21 mL/min.  Mass analysis was performed in positive ion 
mode except in the case of sulfated compound 9, where the analysis was performed in 
negative ion mode.   
 
Kinetic Analysis of BgtA with UDP-GalNAz and UDP-GalNAc.  Reactions were 
performed in duplicate with 100 µM acceptor substrate (1), 0.7 µg BgtA, and varying 
concentrations of UDP-GalNAz or UDP-GalNAc (50 to 800 µM) in 20 mM Tris-HCl pH 
7.5, 50 mM NaCl, 10 mM MnCl2 at rt in a total volume of 20 µL.  Product formation was 
monitored at 280 nm by reverse phase-HPLC (Agilent 1100), and time points were taken 
over the course of 5 min using a linear, 3-95% gradient of B (A: 0.1% aqueous 
trifluoroacetic acid B: 0.1% trifluoroacetic acid in MeCN) over 8 min with a flow rate of 
1 mL/min.  The kinetic parameters, apparent Km, Vmax, and kcat, were obtained by 
linear regression analysis of initial velocity vs. donor substrate concentration using 
KaleidaGraph (version 4.1.2).   
 
Chemoenzymatic Labeling on the Glycan Array.  Glycan Array version 5.0 was 
provided by the Consortium for Functional Glycomics (CFG).  Pre-equilibrated arrays 
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were treated with BgtA enzyme (0.16 mg/mL) and 500 µM UDP-GalNAz 3 in 20 mM 
Tris•HCl pH 7.4, 50 mM NaCl, 2 mM MnCl2 containing 1% bovine serum albumin 
(BSA) for various times (0, 0.5, 2, and 12 h) at rt, washed four times with wash buffer 
(20 mM Tris•HCl pH 7.4, 50 mM NaCl, 0.1% Triton X-100) and then 4 times with rinse 
buffer (20 mM Tris•HCl pH 7.4, 50 mM NaCl).  The arrays were then incubated with 
ADIBO-biotin 6 (5 µM) in 20 mM Tris•HCl pH 7.4, 50 mM NaCl for 2 h at rt.  After 
washing as described above, the arrays were washed further with 20% aqueous MeOH 
and then incubated with streptavidin Cy-5 (0.5 µg/mL; eBioScience) in 20 mM Tris•HCl 
pH 7.4, 50 mM NaCl, 0.05% Tween-20, 1% BSA, for 1 h at rt.  The arrays were then 
washed four times with wash buffer (containing 0.05% Tween-20 instead of 0.1% Triton 
X-100), four times with rinse buffer, four times with water, dried under a low stream of 
filtered air, and scanned using a PerkinElmer ScanArray Express fluorescence scanner 
and ImaGene data analysis software (BioDiscovery).  Data were analyzed per the 
guidelines of the CFG.26,27,32  The background fluorescence for each spot was determined 
as the fluorescence signal outside of the area designated as a positive spot on the array.  
Because background fluorescence can be heterogeneous across the array, each array was 
divided into areas of 10 by 10 spots, or sub-arrays, and a background fluorescence value 
was calculated within each sub-array by the software.  This value was then subtracted 
from the fluorescence signal for each glycan spot within the sub-array by the software.  
Note that each glycan is printed six different times on the array.  To calculate the relative 
fluorescence intensity for a given glycan, the highest and lowest intensities for each 
glycan were discarded, and the mean and standard deviation of four fluorescence 
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intensities were calculated.  All microarray data will be uploaded on the Consortium of 
Functional Glycomics website (www.functionalglycomics.org) upon publication.  
 
Chemoenzymatic Labeling of Cell Lysates.  The olfactory bulbs of postnatal day 3 rat 
pups were dissected on ice and lysed in boiling 1% SDS (5 volumes/weight) with 
sonication until the mixture was homogeneous.  Protein was precipitated using 
methanol/chloroform/water.  Briefly, protein was diluted to 200 µL and precipitated by 
sequential mixing with 600 µL of MeOH, 200 µL of CHCl3 and 450 µL H2O, after 
which the mixture was centrifuged at 23,000 x g for 15 min. Precipitated protein was 
washed with 450 µL of MeOH and centrifuged at 23,000 x g for 10 min.  After the 
protein pellet was allowed to dry briefly, the pellet was re-dissolved at 5 mg/mL in 20 
mM HEPES pH 7.9 containing 1% SDS, and diluted 5-fold into a buffer with the 
following final concentrations: 20 mM HEPES pH 7.9, 50 mM NaCl, 2% NP-40, 5 mM 
MnCl2.  UDP-GalNAz 3 (25 µM; Invitrogen) and BgtA (0.16 mg/mL) were added, and 
the samples were incubated at 4 °C for 16-20 h.  The labeled proteins were precipitated as 
above and resuspended in 50 mM Tris pH 7.4 containing 1% SDS at 4 mg/mL.  
  The resuspended proteins were subsequently reacted with alkyne-TAMRA 10 
(Invitrogen) or alkyne-biotin 11 (Invitrogen) as per the Click-It™ TAMRA and Biotin 
Glycoprotein Detection Kit (Invitrogen) instructions, except that EDTA-free Complete™ 
protease inhibitors were added during the reaction.  For TAMRA labeling, negative 
controls were performed under identical conditions except that BgtA, UDP-GalNAz 3, or 
alkyne-TAMRA 10 was omitted from the labeling reaction.  For biotin labeling, negative 
controls were performed under identical conditions except that BgtA was omitted from 
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the labeling reaction. After the labeling reactions, protein was precipitated using 
chloroform/methanol/water as described above and re-dissolved in boiling 2% SDS.  This 
precipitation and resolubilization was then repeated once more to ensure removal of non-
specific interactions.  TAMRA-labeled proteins were resolved by SDS-PAGE and 
visualized in-gel using a Typhoon Scanner (GE Healthcare).  Interestingly, BgtA itself 
was labeled, and attempts to remove the signal by precipitation or heat and detergent 
denaturation were unsuccessful, suggesting covalent modification of the protein.  
 
Purification of Biotin-Labeled Fucα(1-2)Gal Proteins.  Chemoenzymatically labeled 
samples were precipitated using methanol/chloroform/water as described above and re-
dissolved in boiling 1% SDS plus Complete™ protease inhibitors at a concentration of 2 
mg/mL.  The SDS was quenched with 1 volume of NETFD buffer (100 mM NaCl, 50 
mM Tris•HCl pH 7.4, 5 mM EDTA, 6% NP-40) plus protease inhibitors.  The samples 
were incubated with pre-washed streptavidin resin (Pierce; 100 µL/1 mg protein) for 2 h 
at 4 °C.  The resin was washed twice with 10 column volumes each of low salt buffer 
(0.1 M Na2HPO4 pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS), twice with 10 
column volumes each of high salt buffer (0.1 M Na2HPO4 pH 7.5, 0.5 M NaCl, 0.2% 
Triton X-100), and once with 10 column volumes of 50 mM Tris•HCl pH 7.4.  Captured 
protein was eluted in boiling 2X sample buffer (100 mM Tris pH 6.8, 4% SDS, 200 mM 
DTT, 20% glycerol, 0.1% bromophenol blue; 50 µL /100 µL resin) for 5 min. 
 
Western Blotting for Parallel Identification of Fucα(1-2)Gal Glycoproteins.  The 
purified, labeled material from above was resolved on a NuPAGE 4-12% Bis-Tris gel 
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(Invitrogen) and transferred to a polyvinylidene difluoride (PVDF) membrane 
(Millipore).  The membrane was blocked in 5% milk (BioRad) in TBST (50 mM 
Tris•HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.4) for 1 h at rt.  Primary antibodies in 
5% milk in TBST were added overnight at 4 °C at the following concentrations: mouse 
anti-NCAM monoclonal antibody (Abcam) at 1 µg/mL, mouse anti-synapsin I ascites 
(Synaptic Systems) at 0.1 µg/ml, mouse anti-munc18-1 (Synaptic Systems) at 0.1 µg/mL, 
or mouse p44 MAPK monoclonal antibody (Cell Signaling) at 1:2000 dilution.  
Membranes were washed with TBST, incubated with the appropriate Alexa Fluor 680-
conjugated (Invitrogen) or IR800-conjugated (Rockland) secondary antibody, and 
visualized using a LiCOR Odyssey Imaging System. 
 
Lectin Affinity Chromatography with UEAI.  UEAI lectin conjugated to agarose 
(Vector Laboratories) or control protein A conjugated to agarose (Vector Laboratories) 
was packed into a minicolumn (50 µL bed volume; Bio-Rad), and the columns were run 
in parallel. The resin was equilibrated with 10 column volumes of lectin binding buffer 
(100 mM Tris pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 0.5% NP-40, and 0.2% 
sodium deoxycholate supplemented with EDTA-free Complete™ protease inhibitors).  
Olfactory bulb tissue from P3 rat pups was lysed in lectin binding buffer by sonication on 
ice.  The lysate was clarified by centrifugation at 12000 x g for 10 min, and the total 
protein concentration was determined using the BCA protein assay (Pierce).  Lysate (500 
µg) was bound batch-wise with gentle end-over-end mixing at rt for 4 h.  The agarose 
was then allowed to settle and the flow-through was passed over the column three 
additional times.  The columns were washed with 40 column volumes of lectin binding 
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buffer, followed by 10 column volumes of lectin binding buffer lacking detergent.  
Proteins were eluted in 10 column volumes of lectin binding buffer lacking detergent and 
supplemented with 200 mM L-fucose and Complete™ protease inhibitors.  Protein 
eluates were concentrated to a volume of 100 µL using a Vivaspin 500 spin filter (10,000 
Da MWCO).  Following concentration, samples were boiled in 1X sample buffer (35 µL 
of 200 mM Tris pH 6.8, 400 mM DTT, 8% SDS, 0.2% bromophenol blue, and 40% 
glycerol) and analyzed by SDS-PAGE and western blotting as described above.  
Synapsin I was detected using mouse anti-synapsin I ascites (Synaptic Systems) at 0.1 
µg/mL. 
 
Cell Culture.  HeLa, MCF-7, and MDA-mb-231 cells grown in DMEM medium 
supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 0.1 
mg/mL streptomycin (Gibco).  LNCaP and H1299 cells were grown in RPMI medium 
1640 supplemented with 10% FBS, 100 units/mL penicillin, and 0.1 mg/mL streptomycin 
(Gibco).  The PrEC line was maintained in PrEBM medium (Lonza).  All transfections 
were carried out in antibiotic-free media.  In all cases, cells were incubated in a 5% CO2 
humidified chamber at 37 °C.  The PrEC line was obtained from Lonza; all other cell 
lines were obtained from ATCC. 
 
Immunoprecipitation of TAMRA-Labeled Synapsin I from HeLa Cell Lysates.  
HeLa cells were transfected with pCMV-FLAG-synapsin Ia28 using Lipofectamine LTX 
reagent (Invitrogen). The cells were lysed and chemoenzymatically labeled and protein 
was precipitated as described above.  After the protein pellet was allowed to dry briefly, 
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the pellet was re-dissolved in boiling 1% SDS plus Complete™ protease inhibitors at a 
concentration of 2 mg/mL.  The SDS was quenched with 1 volume of NETFD buffer plus 
protease inhibitors, and the lysate was incubated with 40 µL of prewashed anti-Flag M2 
Affinity Gel (Sigma-Aldrich) for 90 min at 4 °C.  The resin was washed once with 4 
column volumes of NETFD buffer and three times with 4 column volumes of NETF 
buffer (100 mM NaCl, 50 mM Tris•HCl pH 7.4, 5 mM EDTA).  Captured protein was 
eluted in boiling 2X sample buffer (50 µL buffer/100 µL resin).  Purified, labeled 
material was resolved by SDS-PAGE and transferred to a polyvinylidene fluoride 
(PVDF) membrane (Millipore).  Western blotting was performed as above except the 
primary anti-TAMRA rabbit antibody (0.1 µg/µL; Invitrogen) was used.  
 
Detection of Cell-Surface Fucα(1-2)Gal Glycans on Live MCF-7 Cells by 
Fluorescence Microscopy.  MCF-7 cells (ATCC) were seeded at 2 x 105 cells/coverslip.  
Twelve hours after plating, the cells were washed twice with 1% FBS, 10 mM HEPES in 
calcium and magnesium free Hank’s Balanced Salt Solution (CMF HBSS, Gibco) and 
incubated in the chemoenzymatic labeling buffer (2% FBS, 10 mM HEPES pH 7.9 in 
HBSS) with UDP-GalNAz 3 (500 µM) and BgtA (0.17 mg/mL) in a total volume of 100 
µL for 2 h at 37 ºC.  Mock reactions were performed without the addition of BgtA.  After 
chemoenzymatic labeling, the cells were washed twice with 100% FBS and twice with 
the chemoenzymatic labeling buffer.  Enzymatic addition of GalNAz onto Fucα(1-2)Gal 
glycans was detected by incubating the cells with ADIBO-biotin (20 µM in the 
chemoenzymatic labeling buffer; 500 µL) for 1 h at rt, washing the coverslips as 
described, and then incubation with streptavidin-Alexa Fluor 488 (1 µg/mL in PBS 
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containing 3% BSA; Invitrogen) for 30 min at rt.  Cells were washed once with PBS, 
after which nuclei were stained with Hoechst-33342 (1 µg/µL; Invitrogen) in PBS for 15 
min at rt.  Coverslips were washed twice with 100% FBS and mounted in media (on ice), 
sealed with paraffin, and imaged immediately using a 40x Plan-Achromat objective on a 
Zeiss Meta510 inverted microscope. 
 
Detection of Fucα(1-2)-Gal Glycans on Synapsin I in Fixed HeLa Cells by 
Fluorescence Microscopy.  HeLa cells were plated onto 15 mm coverslips (Carolina 
Biological) at a density of 75 cells/mm2.  After 12 h, cells were transfected with pCMV-
Flag-synapsin Ia (0.5 µg DNA/coverslip) using Lipofectamine LTX (4 µL in 200 µL 
Optimem; Invitrogen).  After 24 h, the media was removed, and the cells were rinsed one 
time with PBS, fixed in 4% paraformaldehyde in PBS, pH 7.5 for 20 min at rt, washed 
twice with PBS, permeabilized in 0.3% Triton X-100 in PBS for 10 min at rt, and washed 
twice with the enzymatic labeling buffer (50 mM HEPES, 125 mM NaCl, pH 7.9).  
Reaction mixtures and negative controls (without BgtA) were prepared by adding 100 µL 
of 20 mM HEPES pH 7.9, 50 mM NaCl, 2% NP-40, 5 mM MnCl2, UDP-GalNAz 3 (25 
µM), and BgtA (0.17 mg/mL) at 4 °C for 24 h (100 µL/coverslip) in a humidified 
chamber.  After chemoenzymatic labeling, the cells were washed twice with the 
chemoenzymatic labeling buffer.  Enzymatic addition of GalNAz onto Fucα(1-2)Gal 
glycans was detected by treating the cells with 5 µM alkyne-functionalized Alexa Fluor 
488 (Invitrogen), 0.1 mM triazoleamine ligand (Invitrogen), 2 mM sodium ascorbate 
(Sigma-Aldrich), and 1 mM CuSO4 (Sigma-Aldrich) in 2% FBS (Gibco) in PBS at rt for 
1 h.  Synapsin I was detected by immunostaining with an anti-synapsin I antibody 
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(Millipore, 1:250 in 3% BSA) for 1 h at rt, followed by an anti-rabbit secondary antibody 
conjugated to Alexa Fluor 546 (Invitrogen; 1:1000 in 3% BSA) for 1 h at rt.  The 
coverslips were washed with PBS, mounted onto glass slides using Vectashield mounting 
medium with DAPI (4 µL; Vector Labs), and sealed with clear nail polish. Cells were 
imaged using a Nikon Eclipse TE2000-S inverted microscope, and images were captured 
with Metamorph software using a 20x Plan Fluor objective. 
 
Detection of Cell-Surface Fucα(1-2)Gal Glycans on Live Cancer Cells by Flow 
Cytometry.  All cells were seeded at 4 x 106 cells per 10-cm plate in 10 mL of the 
appropriate media.  On the day of analysis, cells were lifted off the plate with DNase (0.4 
mg/mL; Worthington) and 1 mM EDTA and washed with 1% FBS, 10 mM HEPES in 
CMF HBSS.  One million cells were chemoenzymatically labeled with UDP-GalNAz 
(500 µM) and BgtA (0.17 µg/µL) in 1% FBS, 10 mM HEPES in CMF HBSS (100 µL) 
for 2 h at 37 °C. Cells were spun twice through 100% FBS (1 mL) to remove excess 
reagent (500 x g, 5 min) and resupended in 1% FBS, 10 mM HEPES in CMF HBSS (100 
µL) containing ADIBO-biotin (20 µM) and incubated for 1 h at rt.  Cells were again spun 
twice through 100% FBS (1 mL), and washed with 3% BSA in PBS (1 mL).  Cells were 
then resuspended in 3% BSA in PBS (100 µL) containing streptavidin-Alexa Fluor 488 
(1 µg/mL) and incubated for 20 min at 4 °C.  Cells were subsequently spun twice through 
100% FBS (1 mL) and resuspended in 2% FBS, 10 mM HEPES in CMF HBSS (750 µL) 
for flow cytometry analysis.  Immediately before analysis, 7-amino-actinomycin D (7-
AAD, 5 µL; eBioscience) was added to measure cell viability.  Cells were analyzed for 
FITC intensity on a Beckman Dickenson FACSCalibur flow cytometer equipped with a 
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488-nm argon laser.  For each experiment, 10,000 live cells were analyzed, and data 
analysis was performed on FlowJo (Tristar Inc.).  Data points for LnCAP and PrEC cells 
were collected in triplicate, and for all other cells, in duplicate. 
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ABSTRACT  
 Core fucosylation is an abundant post-translational modification that regulates 
many important physiological functions, including cell signaling, long-term potentiation, 
and antibody-dependent cellular cytotoxicity, and is unregulated in various cancers. 
However, the tools currently used to detect core fucose suffer from poor specificity, 
exhibiting cross reactivity with all types of fucosylation. In this chapter, I report the 
development of a new chemoenzymatic strategy for the rapid and selective detection of 
core fucosylated glycoproteins. I demonstrate that the approach exhibits superior 
specificity towards core fucose on a variety of complex N-glycans.  Further, the approach 
is amenable to detection of core fucosylated glycans from complex cell lysates and the 
cell surface of live cells, and can be integrated into a diagnostic platform for the profiling 
of protein specific core fucosylation levels. This chemoenzymatic labeling approach 
offers a new strategy for the identification of disease biomarkers and enables researchers 
to further characterize the fundamental role that this carbohydrate plays in normal and 
disease physiology. 
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INTRODUCTION 
 Protein glycosylation is an abundant post-translational modification that regulates 
a variety of physiological functions such as development, cell signaling, mediating host-
pathogen interactions, and disease pathogenesis.1 With aberrant glycosylation being a 
hallmark of many human disease states, a major focus in the field has been elucidating 
the functional role that these carbohydrates play. Core fucose, a FUT8 catalyzed α-1,6-
fucose attached to the reducing end N-Acetylglucosamine (GlcNAc) of N-glycans, is an 
abundant post-translational modification that regulates many important physiological 
functions such as cell signaling,2,3 cell adhesion,4,5 long-term potentiation,6 and antibody-
dependent cellular cytotoxicity7 and is upregulated in various cancers.8-14 Specifically, 
increased core fucosylation of serum glycoproteins has been discovered in breast cancer,8 
prostate cancer,9 and pancreatic cancer,10 but perhaps has been best studied in the case of 
Hepatocellular Carcinoma (HCC), where increased core fucosylation of α-fetoprotein 
(AFP), among other proteins, has been shown to directly correlate with HCC 
pathogenesis.11-14 
 Currently, antibodies and/or lectins are commonly used to detect carbohydrate 
structures; however, these methods suffer from both weak binding and/or cross reactivity 
towards similar glycan structures.15-17 Alternatively, metabolic labeling of cells and 
model organisms with non-natural monosaccharaides has become a valued strategy 
towards the detection and study of glycoconjugates.18,19 However, by hijacking the cells 
salvage and biosynthetic pathways for metabolic incorporation of these non-natural 
monosaccharides, the sugar of choice is incorporated non-specifically anywhere the 
monosaccharide is endogenously found. Additionally, competition with the natural 
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substrate in the cell leads to low incorporation efficiency. Consequently, unique 
carbohydrate structures, such as of defined monosaccharide connectivity, α-1,2-fucose vs. 
α-1,6-fucose, and higher order glycans, such as unique disaccharide or trisaccharide 
motifs, cannot be specifically detected. Given these specificity constraints imposed by 
current glycan detection strategies and the diversity of cellular glycans, there is an urgent 
need for new technologies to be developed to enable the detailed study of specific glycan 
structures.  
 More recently, chemoenzymatic labeling approaches have been developed to 
detect specific and complex glycan structures such as O-linked-β-N-acetylglucosamine 
(O-GlcNAc),20,21 N-Acetyllactosamine (LacNAc),22 and fucose-α-1,2-galactose 
(Fucα(1,2)Gal).23 This approach exploits the acceptor substrate specificity of a 
glycosyltransferase to install a non-natural sugar analogue, bearing a chemical handle, 
onto the specific glycan structure of interest. Then, a reporter tag is installed using 
bioorthogonal chemistry, such as click chemistry, for detection. Because the enzymatic 
reaction proceeds in a quantitative yield and directs the specificity of labeling, the 
chemoenzymatic approach affords both superior specificity and sensitivity over antibody, 
lectin, and metabolic labeling approaches. Herein, I report the first strategy for the 
selective detection of core fucosylated glycans, enabling the investigation of a broad 
range of physiologically important glycoproteins and cancer biomarkers (Figure 3.1).   
 
Figure 3.1 The chemoenzymatic labeling approach for the detection of core fucosylated 
glycoproteins.  
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RESULTS AND DISCUSSION 
 To develop such an approach, I exploited the C. elegans β-1,4-
galatosyltransferase (GALT-1), which transfers galactose (Gal) from UDP-Gal onto the 4 
position of an α1,6-fucose (core fucose), generating a Gal-β-1,4-fucose structure.24 We 
reasoned that GALT-1 may tolerate substitution on the C-6 position of Gal,25 allowing for 
the selective tagging of core fucosylated glycans with azido functionality and enabling 
subsequent click chemistry detection of target glycoproteins (Figure 3.2A).  
 
Figure 3.2  (A) Chemoenzymatic labeling strategy for the detection of core fucosylated 
glycoproteins.  Glycoproteins are treated with 13 and GALT-1, followed by subsequent click 
chemistry reaction with alkyne containing, readout-specific reagents (immunohistochemistry, 
FACS, WB, affinity enrichment,…). 13, UDP-6-deoxy-6-azido-D-galactose (UDP-Gal-6-N3 )(B) 
Chemical reagents used for click chemistry (6, 10, and 11).; 6, Azadibenzocyclooctyne-sulfo-
biotin (ADIBO-biotin); 10, 5-Carboxytetramethylrhodamine-alkyne (TAMRA-alkyne); 11, 
biotin-alkyne.  
 
 To test the approach, GALT-1 was cloned into a pet28a vector containing an N-
terminal 6-his tag followed by a SUMO solubilization tag, yielding a His-SUMO-GALT-
1 pet28a construct. This construct was transformed into BL21 (DE3) cells and protein 
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expression was induced with IPTG. Cobalt-NTA resin purified GALT-1 was incubated 
with either UDP-galactose or the UDP-gal analogue, UDP-6-deoxy-6-azido-galactose 
(UDP-Gal-6-N3, 13) and a dabsylated-core fucosylated glycopeptide (14) for 2 hours at 
room temperature (Figure 3.3). Indeed, complete conversion of 14 to the desired products 
15 and 16, respectively, was witnessed, as determined by matrix-assisted laser 
desorption/ionization – time of flight mass spectrometry (MALDI-TOF MS; Figure 3.3).  
 
Figure 3.3 GALT-1 accepts the non-natural UDP-galactose analogue UDP-6-deoxy-6-azido-
galactose (13). MALDI-TOF-MS analysis of GALT-1 donor substrate specificity using a 
dabsylated glycopeptide acceptor substrate (14, m/z 2208 and 2076, upper).  GALT-1 utilizes the 
natural donor substrate UDP-galactose to give the predicted product (15, m/z 2370 and 2238, 
middle).  GALT-1 also utilizes the non-natural donor substrate 13 to give the azido-functionalized 
product (16, m/z 2095 and 2263). In each spectrum, the smaller peak (-136 Da) is due to loss of 
the dabsyl group from the N-terminus of the peptide.  
 
 Kinetic analysis for GALT-1 substrates revealed an apparent kcat/Km of 0.994 nM-
1 min-1 for UDP-Gal-6-N3, approximately 3 fold lower than the value of 3.195 nM-1 min-1 
for the natural substrate, UDP-Gal (Figures 3.4A and B). Furthermore, GALT-1 exhibited 
an apparent kcat/Km of 0.650 nM-1 min-1 for the core fucosylated acceptor substrate, 
N6000 (Figures 3.4A and C). Additional kinetic parameters for all substrates, such as Km, 
Vmax, and kcat, are noted in figure 3.4A. Taken together, the results from the glycopeptide 
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analysis above and the determination of these kinetic parameters demonstrate that GALT-
1 can efficiently utilize the non-natural UDP-Gal analogue, UDP-Gal-6-N3 (13), without 
engineering of the glycosyltransferase.  
 
Figure 3.4. Determination of the kinetic parameters of GALT-1 towards its substrates. (A) N6000 
was used as substrate to study the kinetic parameters towards donor substrates, and UDP-Gal was 
used as a substrate to study the kinetic parameters towards acceptor substrate N6000. (B) Kinetic 
comparison of the GALT-1-catalyzed reaction of N6000 with UDP-Gal (red) and UDP-Gal-6-N3 
(blue; 13) using a UDP-dependent turn-on fluorescent sensor specific for UDP (see chapter 5). 
Reactions were preformed in duplicate using 50 µM acceptor substrate, N6000, and varying 
concentrations of the donor substrates. (C) Determination of GALT-1’s kinetic parameters 
towards core fucosylated N-glycan structure N6000, inserted in graph. Reactions were preformed 
in duplicate using 50 µM donor substrate, UDP-Gal, and varying concentrations of the acceptor 
substrate N6000.  
 
 With GALT-1’s ability to efficiently utilize the non-natural UDP-Gal-6-N3, I next 
sought to investigate the acceptor substrate specificity of GALT-1 using a collection of 
synthetically prepared, homogenous N-glycans provided by the Peng George Wang lab 
(Figures 3.5 and 3.6).26 With biologically relevant core fucosylated N-glycans being 
heterogeneous in nature, it would be difficult to determine the acceptor substrate 
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specificity of GALT-1 without such purified compounds. To determine the preference of 
GALT-1 towards different acceptor substrates, I incubated GALT-1 and UDP-Gal-6-N3 
with N-glycans varying in antenna length (N6000, N6001, N6002), fucose connectivity 
(N224), and presence of core fucose (N000). These reactions were then analyzed by 
MALDI-TOF MS in positive mode (Figure 3.5). GALT-1 efficiently installed UDP-Gal-
6-N3 onto N6000, N6001, and N6002, suggesting that GALT-1 can label core fucosylated 
N-glycans whose antenna vary in length and terminate in GlcNAc, Gal, or sialic acid, 
respectively (Figures 3.5 A, C, and E). This suggests that these features still allowed 
GALT-1 to access the core fucose residue for modification. However, it is noted that the 
while these three N-glycans are all substrates for GALT-1, they are not all modified with 
the same efficiency (Figure 3.6).  In fact, progressive elongation of the N-glycan antenna, 
seem to perturb the addition of Gal-6-N3 on these different substrates. This phenomenon 
is important to keep in mind when using this method in cell or protein labeling 
experiments.  
 To address non-specific addition of UDP-Gal-6-N3 onto other fucose residues of 
N-glycans, I tested structure N224, containing no core fucose, but an outer-arm α1,3 
fucosylation on one antenna. No GALT-1 dependent addition of UDP-Gal-6-N3 was 
witnessed on N224 (Figure 3.5B).  As a final control, N-glycan structure N000, 
containing no fucose, was tested and did not result in addition of UDP-Gal-6-N3 (Figure 
3.5D).  These results demonstrate the strong specificity of GALT-1 for core fucose on 
various complex N-glycan structures (Figures 3.5 and 3.6).  
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Figure 3.5 GALT-1 acceptor substrate specificity. GALT-1 was incubated with UDP-Gal-6-N3 
(13) and different acceptor substrates (A-E) followed by MALDI-TOF MS analysis after two 
hours. A shift of 187 m/z resulted from the GALT-1 dependent addition of 13 onto the acceptor 
substrates (A) N6000, (C) N6001, and (E) N6002. No shift was witnessed for substrate (B) N224 
and control substrate (D) N000. (E) i.) Acceptor substrate N6002, due to various Na+ adducts and 
fragmentation. ii.) This table notes the peaks identified from i and the predicted molecular species 
are noted. All spectra were collected in positive mode.  
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Figure 3.6 GALT-1 acceptor substrate specificity continued. Approximate conversation 
percentages for the GALT-1 reaction with each acceptor substrate at the two hour time point 
(spectra from Figure 3.5). Percentages were calculated from the starting material and product 
peak intensity areas of the MALDI-TOF MS analysis.  
 
 To determine whether a chemoenzymatic approach could be used to detect core 
fucosylated glycoproteins, a known core fucosylated glycoprotein, bovine 
thyroglobulin,27 was incubated with GALT-1 and UDP-Gal-6-N3. Samples taken at 
various time points were subjected to the copper(I)-catalyzed alkyne-azide cycloaddition 
(CuAAC) with TAMRA-alkyne (Figure 3.2B; 10) for 1 hour at room temperature. Strong 
TAMRA specific signal was detected in a time dependent manner, illustrating the ability 
of the approach to label core fucosylated glycoproteins (Figure 3.7A). Core fucose was 
also robustly detected on secreted proteins secreted from liver cancer cells grown in 
culture, HepG2, with minimal non-specific signal witnessed when removing GALT-1, 
UDP-Gal-6-N3, or biotin-alkyne 11 (Figure 3.7B). To further investigate the specificity of 
our approach, protein lysates were chemoenzymatically labeled with biotin-alkyne 11, 
incubated with streptavidin resin to enrich biotinylated proteins, and immunoblotted for 
Acceptor Substrate % Conversion 
   N6000 > 98% 
   N6001 ~ 70% 
   N6002 ~ 35% 
   N000 0% 
   N224 0% 
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known core fucosylated glycoproteins. Core fucosylated epidermal growth factor receptor 
(EGFR) from MDA-MB-231 cells, α-fetoprotein (AFP) from HepG2 cells, and E-
Cadherin from MCF-7 cells, all established core fucosylated glycoproteins,2,28,29 were 
detected in a GALT-1 specific manner (Figure 3.7C). Taken together, these results 
highlight the ability of the approach to specifically detect core fucosylated glycoproteins 
in a complex protein sample. 
 
Figure 3.7 GALT-1 efficiently labels core fucosylated glycoproteins. (A) Time course of the 
GALT-1 reaction using purified bovine thyroglobulin as acceptor substrate. Labeling was 
detected by copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) with TAMRA-alkyne (10). 
(B) Chemoenzymatic detection of HepG2 secreted core fucose glycoproteins. Western blot 
detection was performed using streptavidin-conjugated Alexa Fluor 680 with subsequent 
detection of α-fetoprotein (AFP) for loading control.  (C) Chemoenzymatic labeling of cell 
lysates with TAMRA-alkyne (10) followed by a immunoprecipitation of TAMRA labeled 
material and western blot detection of known core fucosylated glycoproteins from human MDA-
MB-231 breast cancer cell lines (EGF receptor; EFGR), human HepG2 liver cancer cell lines 
(AFP), and  human MCF-7 breast cancer (E cadherin; E cad) cell lines. C performed by Lan Ban. 
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Figure 3.8 GALT-1 enzymatic efficiency comparing natural and non-natural donor substrates. 
(A) Chemoenzymatically labeled HepG2 proteins were treated with 500 µM UDP-Gal-6-N3 (13) 
and increasing amounts of the natural donor substrate UDP-Gal for 4 hours at room temperature. 
Samples were then subjected to CuAAC using TAMRA-alkyne (10) and western blot analysis for 
detection of TAMRA (top) and AFP (bottom).  (B)  Quantification of the percent labeling 
efficiency of 13 by GALT-1 with increasing the competing amounts of UDP-Gal.  The reaction 
without UDP-Gal was set to 100%.  
 
 Importantly, when performing the chemoenzymatic labeling approach, the 
naturally occurring UDP-Gal molecule could be present in the sample. The procedure 
generally calls for a protein precipitation step prior to the enzymatic labeling step in order 
to remove these types of metabolites from the sample. It has been witnessed in the lab 
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that subjecting a protein lysate directly to enzymatic labeling, with no prior precipitation 
step, does not enable efficient enzymatic labeling. It is suspected that metabolites, likely 
the natural UDP-Gal substrate, among others, cause competition of the reaction, reducing 
the sensitivity of detection. To determine the level of competition between the natural 
UDP-Gal and non-natural UDP-Gal-6-N3 (13), protein samples from HepG2 cells were 
subjected to the GALT-1 reaction with 500 µM UDP-Gal-6-N3 and increasing amounts of 
UDP-Gal, followed by the CuAAC reaction with TAMRA-alkyne 10 (Figure 3.8). Low 
levels of UDP-Gal, 1 µM, decreased the TAMRA signal by 25% and when these 
substrates were present at equal concentrations (500 µM) the signal decreased by over 
60%, suggesting that GALT-1 demonstrates a preference for the natural UDP-Gal 
substrate over the non-natural UDP-Gal-6-N3 (13). While these findings are not 
surprising, they highlight the importance of complete removal of endogenous metabolites 
to maximize the efficiency of enzymatic labeling.  
 To confirm the specificity for GALT-1 dependent chemoenzymatic labeling of 
core fucosylated glycoproteins, Fut8 knock-out (Fut8-/-) and wild type (Fut8+/+) brain 
lysates were treated with or without PNGaseF, followed by chemoenzymatic labeling and 
western blot detection (Figure 3.9). Only Fut8+/+ samples treated with GALT-1, and 
without PNGaseF (lane 2), show labeling over background, suggesting that α1-6 fucose 
of N-glycans is the only substrate modified by GALT-1. The Fut8-/- samples treated with 
GALT-1, without PNGaseF (lane 4), did not show labeling over background, 
demonstrating that the approach presents excellent specificity towards core fucose 
(Figure 3.9B).  L1CAM, a heavily N-glycosylated glycoprotein, was used as a positive 
control for the PNGaseF reaction.30  
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Figure 3.9 GALT-1 specifically labels core fucosylated glycoproteins.  (A) Cartoon 
representation of the N-glycans produced by Fut8 wild type (Fut8+/+), and knock-out (Fut8-/-) 
mice. FUT8 is the glycosyltransferase responsible for core fucosylation (red triangle). (B) Brain 
lysates from Fut8-/- and Fut8+/+ mice were chemoenzymatically labeled after PNGaseF digestion, 
or a mock control reaction without PNGaseF.  Western blot detection of biotinylated proteins 
using streptavidin-conjugated Alexa Fluor 680 demonstrates that GALT-1 is specific to core 
fucose.  Tubulin was detected as a loading control and L1CAM was detected to ensure 
completion of the PNGaseF reaction. (C) Click chemistry on mouse brain samples with biotin-
alkyne (11) causes non-specific background. These samples also contain proteins that are 
endogenously biotinylated.  
 
 Based on these findings, PNGaseF treatment eliminates the substrate for GALT-1 
and, most importantly, no Fut8-/- samples exhibit GALT-1 specific signal, further 
supporting the conclusion that GALT-1 is highly specific towards core fucose. We 
attribute the background labeling witnessed in all lanes (Figure 3.9B) to the CuAAC 
reaction with biotin-alkyne (11) and endogenously biotinylated proteins (Figures 3.9C 
and 3.10).  This high specificity towards core fucose is significant, given that many 
lectins commonly used to detect core fucose, such as Lens Culinaris Agglutinin (LCA), 
Fut8-/- Fut8+/+ 
A
B
Fuc 
Gal 
GlcNAc 
Man 
C
+      +     +     +      -      -      -      - 
+      -      +     -      +      -     +      -   
Fut8+/+ 
Tubulin 
L1CAM 
GALT-1            
PNGaseF
 250 
150 
100 
75 
50 
37 
20 
Fut8-/- Fut8+/+ Fut8-/- 
Click Chemistry (11) 
GALT-1            
PNGaseF 
  250 
150 
100 
75 
50 
37 
20 
Tubulin 
+ 
-       
+ 
+ 
-       
- 
+ 
-       
+ 
+ 
-       
- 
- 
-       
+ 
- 
-       
- 
- 
-       
+ 
- 
-       
- 
Fut8+/+ Fut8-/- Fut8+/+ Fut8-/- 
 1     2     3     4      5     6      7     8 
	   67 
Aleuria Aurantia Lectin (AAL), and Aspergillus Oryzae Lectin (AOL), exhibit cross 
reactivity with other fucosylated motifs.15-17  
 
Figure 3.10 Lectin blot analysis of Fut8-/- and Fut8+/+ mouse brain lysates treated with or without 
PNGaseF. Membranes were treated with the fucose specific biotinylated lectins Aspergillus 
Oryzae Lectin (AOL) , Aleuria Aurantia Lectin (AAL), and Culinaris Agglutinin Lectin (LCA) 
followed by streptavidin conjugated Alexa Fluor 680 (SAV).  A control western blot was 
performed to determine the background signal resulting from SAV, presumably due to 
endogenously biotinylated proteins.  Western blot analysis was performed against the known 
glycoprotein L1CAM, to ensure the complete digestion of N-glycans.  The fucose specific lectins 
AOL, AAL, and LCA detected non-core fucosylated N-glycan containing glycoproteins, 
highlighted by the red arrows.  
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 Additionally, the samples used above (Figure 3.9B) were subjected to lectin blot 
analysis, prior to chemoenzymatic labeling, to highlight the superior specificity of 
GALT-1 towards core fucose when compared to the biotinylated lectins LCA, AAL, and 
AOL (Figure 3.10; lane 4). These lectins all detected proteins in the Fut8-/- samples that 
were mock treated with PNGaseF treatment, further demonstrating their cross reactivity 
with other non-core fucose epitopes found on N-glycans.  
 
Figure 3.11 Chemoenzymatic labeling of cell surface core fucose. (A) Fluorescence detection of 
core fucosylated glycans (green) on fixed MDA-MB-231 cells (upper) and HepG2 cells (lower). 
No labeling was observed in the absence of either GALT-1 or UDP-Gal-6-N3. Nuclei were 
stained with DAPI, blue.  (B) Flow cytometry analysis detected the existence of core fucosylated 
glycans (green) on live breast cancer MDA-MB-231 cancer cell lines. No labeling was observed 
from untreated cells (red) or in the absence of GALT-1 (blue). Performed by Lan Ban. 
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 Having established the superior specificity of the approach for core fucose, we 
next investigated whether the chemoenzymatic strategy could image cell surface core 
fucosylated glycans. First, MDA-MB-231 and HepG2 cells were fixed, permeabilized, 
and chemoenzymatically labeled on coverslips with GALT-1 and UDP-Gal-6-N3. The 
CuAAC reaction was then performed using alkyne-biotin (11), followed by incubation 
with streptavidin-conjugated Alexa Fluor 488 to install a fluorescent reporter onto the 
core fucosylated glycans (green pseudo color; Figure 3.11A). Cell nuclei were detected 
with DAPI stain (blue pseudo color). In both cell lines, membrane-associated 
fluorescence was observed for cells treated with both GALT-1 and UDP-Gal-6-N3, 
whereas no labeling was detected for control cells labeled in the absence of GALT-1 or 
UDP-Gal-6-N3 (Figure 3.11A). Additionally, no nuclear labeling was observed, 
confirming the specificity of the chemoenzymatic strategy, as core fucose is only found 
on the cell surface (Figure 3.11A).  
 Next, we determined whether the approach could be used to track core fucose on 
live cells (Figure 3.11B). MDA-MB-231 cells were chemoenzymatically labeled, reacted 
with the strain-promoted alkyne-azide cycloaddition (SPAAC) reagent, ADIBO-biotin 
(6), and treated with a streptavidin-conjugated Alexa Fluor 488 dye. Flow cytometry 
analysis revealed strong fluorescence intensity of cells treated with GALT-1 and minimal 
background signal observed in both the absence of GALT-1 and untreated cells (Figure 
3.11B). These results highlight the flexibility of the chemoenzymatic approach, enabling 
the tracking of core fucose on both fixed and live cells. 
 With increasing reports suggesting that increased core fucosylation of serum 
glycoproteins is correlated with HCC pathogenesis,11-14 I sought to explore the diagnostic 
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potential for this method. To first determine if varying levels of core fucose could be 
detected from similar protein samples, HepG2 glycoproteins were subjected to PNGaseF 
treatment, and serially diluted into mock PNGaseF control samples, generating protein 
samples with decreasing core fucose levels with constant protein concentration levels. 
These samples were then chemoenzymatically labeled and subjected to western blot 
analysis (Figure 3.12).  
 
Figure 3.12 GALT-1 efficiently labels samples of comparable protein concentration with 
differing levels of core fucosylation. HepG2 proteins were treated with or without PNGaseF 
followed by serial dilution of the PNGaseF treated samples into the mock PNGaseF treated 
samples. These samples were then treated with or without GALT-1 and subjected to western blot 
analysis with streptavidin-conjugated Alexa Fluor 680 (green) and AFP (red). Intensity was 
quantified and plotted. The trendline of the GALT-1 treated samples has R2 values consistent 
with a linear response to levels of core fucose. 
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The signal witness from these samples exhibited a linear response in intensity when 
comparing the expected decreased levels of GALT-1 dependent signal and percentage of 
PNGaseF diluted sample (Figure 3.12). This suggests that the approach could be used to 
confidently compare core fucose levels across different protein samples.   
 
Figure 3.13 Chemoenzymatic labeling of serum from a healthy donor and an HCC patient. (A) 
Serum samples were depleted of either (i.) serum albumin and antibodies (red) or (ii.) only serum 
albumin (blue), chemoenzymatically labeled, and subjected to SDS-PAGE for western blot 
analysis with streptavidin-conjugated Alexa Fluor 680 (top) and coomassie stain for loading 
control (bottom). Red asterisks denote proteins with potentially increased core fucose levels. Red 
arrow denotes the suspected immunoglobulin heavy chain based on apparent molecular weight. 
(B) Core fucose signal was quantified and normalized over background from the minus GALT-1 
samples.  
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cases. As expected in the serum albumin depleted samples, due to the high levels of core 
fucosylation of antibodies, strong signal was witnessed at ~50kda, where the 
immunoglobulin heavy chain is expected to appear.  Additionally, stronger core fucose 
signal was witnessed on specific protein bands (~65 and 250 kda, red asterisk), and more 
generally overall, from HCC samples when compared to healthy controls (Figure 3.13). 
These findings agree with the reported increased levels of core fucose on serum 
glycoproteins from HCC patients when compared to healthy control.11-14 While I have 
only interrogated these two serum samples, I have demonstrated a proof-of-principle that 
serum glycoproteins can be detected with the approach. The efficient labeling of core 
fucosylated serum glycoproteins opens the door for researchers to exploit our approach 
for the identification of new diagnostic cancer biomarkers.  
 In order to identify new cancer biomarkers, a proteomic workflow was developed 
that leverages a cleavable tag that installs a mass tag onto the site of glycosylation, 
enabling simultaneous protein identification and glycosylation site mapping (Figure 
3.14A). Since core fucose is only found on N-glycans, PNGaseF can be used to 
selectivity cleave the core fucosylated proteins from the affinity resin. This PNGaseF 
reaction also converts the asparagine, N-glycans are exclusively found on asparagine 
residues in mammals, to an aspartate. This reaction installs a one Dalton mass tag onto 
the site of glycosylation. If the reaction is performed in 18O labeled H2O, a shift of three 
Daltons is witnessed. To test this approach, protein samples were subjected to 
chemoenzymatic labeling with biotin-alkyne 11 and enriched with streptavidin-
conjugated agarose resin. Following extensive washing, the resin was incubated with 
PNGaseF and the eluted proteins were subjected to SDS-PAGE followed by silver 
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staining (Figure 3.14B). Many proteins were eluted during this procedure with no visible 
proteins eluted in the control sample (Figure 3.14B). Here, I have developed and 
demonstrated a simple and efficient proteomic workflow with commercially available 
reagents that can be used to identify new cancer biomarkers.  
 
Figure 3.14 The chemoenzymatic approach can easily be incorporated into a proteomic work 
flow with the N-glycan acting as a cleavable linker. (A) Following chemoenzymatic labeling with 
biotin alkyne (11), biotinylated core fucose glycoproteins are enriched with streptavidin resin. 
The glycoproteins are then cleaved using PNGaseF, which normally cleaves N-glycans from the 
glycoprotein. Eluted proteins are then resolved by SDS-PAGE, silver stained, and bands can be 
excised for proteomic identification. (B) Silver stain (left) and western blot (streptavidin blot; 
right) demonstrate the feasibility of this work-flow.  
 
 To integrate this chemoenzymatic approach into a common diagnostic platform, 
an ELISA was developed for the detection of core fucosylated AFP, a known biomarker 
for HCC.31-33 Following chemoenzymatic labeling, capture of total AFP in an ELISA 
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well with subsequent detection of biotinylated core fucose, using a streptavidin-
conjugated HRP, would enable quantification of core fucosylated AFP (Figure 3.16A). 
Alternatively, biotinylated AFP could be captured in a streptavidin coated ELISA well 
and AFP could be detected with an anti-AFP-conjugated HRP antibody (Figure3.17A). 
While other methods used for detection of core fucosylated AFP rely on lectins and/or 
expensive machinery, this approach could be used as a more specific and cheaper 
alternative.34,35  
 
Figure 3.15 The chemoenzyamtic approach can label the Hepatocellular Carcinoma (HCC) 
biomarker, core fucosylated α-fetoprotein (AFP). AFP was purified chemoenzymatically labeled 
followed by western blot detection using streptavidin-conjugated Alexa Fluor 680 (core fucose, 
red) and anti-AFP (green). 
 
 To test this system, AFP was first purified from the media of HepG2 cells, using 
IMAC resin charged with Cu(II), and then enzymatically labeled to confirm that AFP 
from HepG2 media was indeed core fucosylated (Figure 3.15). Next, proteins secreted 
from HepG2 cells were labeled, serially diluted, and added to the ELISA plate. Each 
sample was added to additional wells for the quantification of total AFP using an anti-
AFP-conjugated HRP antibody and all samples were run in duplicate. Core fucosylated 
AFP could be robustly detected over a large dynamic range, from 1 ng/mL to 500 ng/mL, 
exhibiting sufficient sensitivity (Figure 3.16B). These experiments were repeated using 
the streptavidin coated ELISA plates and core fucosylated AFP was detected with the 
anti-AFP-conjugated HRP antibody (Figure 3.17B). Using the streptavidin-coated plates, 
core fucosylated AFP could be robustly detected in a linear dynamic range from 1 ng/mL 
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to 800 ng/mL, also exhibiting sufficient sensitivity. Together, these experiments highlight 
the ability of this approach to detect core fucosylated AFP in a complex protein sample. 
These results also constitute the first demonstration of a chemoenzymatic approach to be 
integrated into an ELISA format, enabling researchers to rapidly interrogate core fucose 
levels of specific proteins on a large sample population for biomarker verification tests.  
 
Figure 3.16 (A) Following chemoenzymatic labeling, AFP is captured in an ELISA well and 
biotinylated core fucose is detected with a streptavidin-conjugated horse radish peroxidase 
(HRP). (B) Proteins secreted from HepG2 cells were chemoenzymatically labeled, serially 
diluted, and applied to the ELISA wells for detection of core fucosylated AFP. Total AFP was 
also quantified and the total AFP levels were plotted against core fucose signal (Abs 450nm). The 
core fucosylated AFP ELISA demonstrated a linear detection range from 1-500 ng/mL of total 
AFP (insert) and was able to detect core fucose levels on samples containing AFP concentrations 
as low as 1 ng/mL.  
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Figure 3.17 Integration of chemoenzymatic labeling approach into an ELISA format for 
quantification of core fucosylated AFP. (A) Following chemoenzymatic labeling, biotin labeled 
material is captured in an ELISA well and biotinylated core fucosylated AFP is detected with an 
anti-AFP-conjugated horse radish peroxidase (HRP). (B) Proteins secreted from HepG2 cells 
were chemoenzymatically labeled, serially diluted, and applied to the ELISA wells for detection 
of core fucosylated AFP. Total AFP was also quantified using an AFP ELISA and the total AFP 
levels were plotted against core fucose signal (Abs 450nm). The core fucosylated AFP ELISA 
demonstrated a linear detection range from 1-800 ng/mL of total AFP (insert) and was able to 
detect core fucose levels on samples containing AFP concentrations as low as 1 ng/mL.  
 
 
CONCLUSION 
 In conclusion, I have developed a new chemoenzymatic labeling approach for the 
detection of core fucosylated glycans with superior specificity over existing methods. 
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lysates, human serum, and on both live and fixed cells. Additionally, this method can be 
integrated into an ELISA platform for tracking core fucose changes on specific proteins. I 
anticipate that this tool will be used to advance our understanding of the physiological 
functions of core fucose but also to identify new disease biomarkers. Future studies will 
apply this powerful strategy in systematic studies of core fucosylated proteins and will 
possibly identify a new set of effective glycoprotein biomarkers for the diagnosis of a 
variety of human diseases. 
 
EXPERIMENTAL METHODS  
General Reagents and Methods. Unless otherwise noted, reagents were purchased from 
the commercial suppliers Fisher (Fairlawn, NJ) or Sigma-Aldrich (St. Louis, MO). All 
the primers were purchased from Integrated DNA Technologies (IDT). Bovine 
thyroglobulin was purchased from Sigma-Aldrich. Protease inhibitor cocktails (PIC) were 
purchased from Roche Applied Sciences (Indianapolis, IN). HisPure Cobalt Resin and 
agarose-conjugated protein A/G was from Pierce (Rockford, IL) and Immobilon-FL 
PDVF membrane was from Millipore (Billerica, MA). Dulbecco's modified Eagle media 
(DMEM), fetal bovine serum (FBS), and penicillin/streptomycin were from Gibco 
(Carlsbad, CA). The mouse anti-AFP for western blot is from Abcam. Rabbit Anti- 
EGFR is from Santa Cruz Biotechnology. Rabbit anti-E cadherin is from Cell signaling 
technology. Click-It™ Biotin Glycoprotein Detection Kit, anti-TAMRA antibody, 4-12% 
NuPAGE® Bis-Tris Mini gels, streptavidin-IR680, streptavidin-Alexa488, anti-mouse 
IR680 and goat anti-rabbit IR680, goat anti-mouse Alexa488 conjugates, normal goat 
serum were from Invitrogen (Carlsbad, CA). The click chemistry ligand, Tris(3-
	   78 
hydroxypropyltriazolylmethyl)amine (THTPA), was purchased from Sigma-Aldrich (St. 
Louis, MO). TAMRA-alkyne and Biotin-alkyne were purchased from 
clickchemistrytools.com (Scottsdale, AZ).  (Peptide N-glycosidase F (PNGaseF) was 
purchased from New England Biolabs (Beverly, MA). Biotinylated Aleuria Aurantia 
Lectin (AAL) and Biotinylated Lens Culinaris Agglutinin Lectin (LCA) were purchased 
from Vector laboratories (Burlingame, CA). Aspergillus Oryzae Lectin (AOL) was 
purchased from TCI America (Boston, MA). The secondary goat anti-rabbit and goat 
anti-mouse antibody conjugated to IRDye800 was from Rockland Immunochemicals 
(Gilbertsville, PA). Western blots were visualized and quantified using an Odyssey 
infrared imaging system (LI-COR Biosciences).  
 
Cloning, Expression and Purification of GALT-1. The Galt-1 cDNA was amplified 
from sf9 cell harboring the bacmid pFastBac1-GALT-1, generously provided by Markus 
Aebi,24 by PCR using Expand High fidelity PCR system (Roche). After unsuccessful 
attempts at bacterial expression of active N- or C- terminal His tagged GALT-1, I 
designed a construct consisting of an N-terminal His tag, followed by a SUMO (small 
ubiquitin-related modifier) domain and GALT-1 for increased solubilization of 
recombinant GALT-1. The pet28a vector containing a N-terminal His tagged SUMO 
domain directly upstream of the multiple cloning site was provided by the Andre Holtz 
lab (California Institute of Technology, Pasadena CA). The construct of N-His-SUMO-
GALT-1 was generated by PCR amplification of cDNA using the forward and reverse 
primers overlapping the BamH1 and Not1 restriction sites, respectively (forward: 
GAGGCTCACAGAGAACAGATTGGTGGCCCGCGTATTACCGCTTCC; reverse: 
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GTGGTGCTCGAGTGCGGCCCCTTACAGGTCCAGCAGGCCGA). The resulting 
PCR fragments were cloned into the pet28a-N-term-His-SUMO vector, cut with BamH1 
and Not1, by Gibson Assembly. The resulting plasmids were transformed into DH5α 
(subcloning efficiency, Invitrogen) and grown at 37 °C overnight on Agar plates 
supplemented with kanamycin (50 µg/mL). Resulting colonies were used to inoculate 5 
mL 2xYT media and grown overnight at 37 °C and 225 rpm. Plasmids were extracted by 
miniprep kit (Qiagen) and the resulting clones, with the correct sequence and frame, were 
transformed into E. coli BL21 (DE3) cells. The colonies were inoculated into 5 mL 2xYT 
media supplemented with kanamycin (50 µg/mL) and grew for 18 hours at 37 oC. The 
resulting culture is supplemented with glycerol (15% final concentration) and stored in -
80 oC for long storage. 
 The proteins were expressed and purified as described in the following.  E. coli 
BL21 (DE3) harboring the pet28a-N-term-His-SUMO plasmid were grown in 2xTY 
medium (1L) at 37 °C and 250 rpm. Isopropyl-1-thio-β-D-galactospyranoside (IPTG, 0.5 
mM final concentration; Sigma) was added when the cells reached an OD600 of 0.6-0.8, 
and the cells were incubated for an additional 15 h at 18 °C. The pelleted cells were lysed 
in 2% Triton X-100 (vol%) in TBS buffer (50 mM Tris-HCl pH 8, 0.5 M NaCl) 
supplemented with EDTA-free Complete™ protease inhibitors (Roche). Lysozyme (1 mg 
per liter culture) and DNAse (50 µg per liter culture) were added to the lysis buffer and 
the cells were homogenized under sonication.  After centrifugation at 17,000 x g for 20 
minutes, the clarified lysate was added to prewashed Cobalt affinity beads (2 mL for 1 L 
culture, Pierce) and incubated at 4 °C for 1 h, end-over-end, in a batch format followed 
by washing with 20 volumes of wash buffer (50 mM Tris-HCl pH 8, 0.5 M NaCl, and 10 
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mM imidazole).  Resin was transferred to a column, washed with wash buffer until no 
protein was removed from the resin, checked by monitoring absorbance at 280 nm, and 
eluted with a gradient of increasing elution buffer (50 mM Tris-HCl pH 8, 0.5 M NaCl, 
and 150 mM imidazole) at 1 mL/minute.  After SDS–PAGE and WB analysis (anti-His 
antibody, GE Lifesciences), the purified protein was concentrated with 30,000 Da 
molecular weight cut-off (MWCO) spin filters (Millipore) and exchanged to the storage 
buffer (50mM Tris-HCl pH 8, 0.5 M NaCl, 5% glycerol), flash frozen, and stored at -80 
oC for longer term storage, up to 6 months, 4 oC up to 1 month.   
 
Synthesis of UDP-6-deoxy-6-azido-galactose (UDP-Gal-6-N3; 13). The synthesis of 
UDP-Gal-6-N3 was performed following literature report without modifications.25 The 
purification of the final product was done on a Biogel P2 column using water as the 
mobile phase instead of HPLC purification. ESI-MS and 1H, 31P NMR confirmed the 
identity of the final product.   
 
Chemoenzymatic Labeling of Core Fucosylated Glycopeptide. The core fucosylated 
glycopeptide was generously provided by Iain Wilson (Universität für Bodenkultur, 
Vienna, Austria).24  The reaction cocktail contained GALT-1 (0.4 mg/mL), 500 µM 
UDP-Gal-6-N3 (13) or UDP-Gal, 50 mM Tris-HCl pH 7.5, 5 mM MnCl2, 0.1% Triton X-
100. After 2 hours incubation at RT, 2 µL solution from each reaction was transferred 
into 5 µL α-Cyano-4-hydroxycinnamic acid (CHCA, 4 mg/mL) dissolved in 50% 
acetonitrile in water supplemented with 0.1% trifluoroacetic acid (TFA). 4 µL resulting 
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solution from each sample was transferred onto MALDI-TOF MS source and dried. The 
acquisition was done on reflector (2500) and positive mode.  
 
Kinetic Analysis of GALT-1 with UDP-Gal, UDP-Gal-6-N3 and N6000. Kinetic 
parameters were determined using the turn-on fluorescent sensor, 17-2Zn(II) (Chapter 5, 
Figure 5.1A), which detects UDP but not UDP-Gal.36  Reactions were set up in duplicate 
as follows: 50 mM HEPES pH 7.4, 10 mM NaCl, 0.1 mM MgCl2, 0.2 mM MnCl2, 0.3 
mM ZnCl2, 2.5 µM 17-2Zn(II) Sensor, 50 µM N6000, 1-500 µM UDP-Sugar, 0.2 mg/mL 
GALT-1. For determining GALT-1 kinetic parameters towards N6000, the reactions were 
set up identical to above except N6000 was varied from 25-500 µM and UDP-Gal was 
fixed to 50 µM.  Background was determined with the same reaction conditions without 
N6000. Fluorescence was detected with excitation and emission wavelengths of 500 nm 
and 534 nm respectively, with a 530 nm cutoff, using the Flexstation 3 (Molecular 
Devices). Initial rates were calculated and plotted as a function of UDP-Sugar 
concentration. Km’s were determined by fitting initial rates to a Michaelis-Menten model 
or Lineweaver-Burk plot using Kaleidagraph 4.0. 
 
GALT-1 Acceptor Substrate Specificity Characterization with Small Molecule N-
glycans and MALDI-TOF Analysis. Purified N-glycans, N6000, N6001, N6002, N000, 
and N224, provided by Peng George Wang (Georgia State University, Georgia),37 were 
dissolved into 5 mM HEPES pH 7.4, 1 mM MnCl2, 500 µM UDP-Gal-6-N3 (13), 0.2 
mg/mL GALT-1 at room temperature. 2 µL aliquots were taken at various time points 
and mixed 1:1 into 60 mg/mL Super DHB (Sigma-Aldrich) matrix in MeOH. 0.1 µL was 
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plated onto MALDI-TOF MS source, dried, and analyzed using the Voyager D-Pro MS 
using 1500 Reflector mode. 10 spectra were accumulated per spot, with two spots 
analyzed per sample. Spectra were baseline corrected and noise filtered by smoothing.  
The area of intensities was used to quantify the approximate reaction completion 
percentage.  
 
Chemoenzymatic Labeling of Bovine Thyroglobulin.  The bovine thyroglobulin was 
dissolved in water as 10 mg/mL stock solution. For a typical galactosylation reaction, the 
cocktail contained GALT-1 (0.2 mg/mL), 500 µM UDP-Gal-6-N3 (13) , 50 mM HEPES 
pH 7.5, 5mM MnCl2, 1% Triton X-100, 1x PIC at room temperature. Negative controls 
were performed under identical conditions, except GALT-1 or UDP-Gal-6-N3 were left 
out of the reactions. Aliquots of the reaction were quenched over 6 hours by adding 5 
volumes of ice cold acetone and storing at –20 oC overnight. Pellets were collected by 
centrifugation, resuspended in 1% SDS buffer in Tris-HCl 50 mM, pH 8.0, and brought 
to 0.05 mM TAMRA-alkyne, 0.1 mM THTPA ligand, 0.2 mM CuSO4, and 2 mM sodium 
ascorbate for 1 hour at room temperature.  Samples were then acetone precipitated for 2 
hours at -20 oC, and then resuspended into 2x protein loading buffer, minus a reducing 
reagent, to resolve discrete bands by western blot detection. Bovine thyroglobulin has 
many disulfide bonds connecting separate polypeptides, many of which are glycosylated.  
 
Western Blot Detection of Core Fucosylated Glycoproteins. Labeled protein samples 
were resolved on 1.5 mm, 10-well NuPAGE 4-12% Bis-Tris gels and transferred to 
PDVF. The membrane was blocked with 5% nonfat milk in 50 mM Tris-HCl pH 7.4, 150 
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mM NaCl containing 0.1% Tween-20 (TBST) for 1 h at RT. For TAMRA labeled 
proteins, the membrane was incubated with rabbit anti-TAMRA antibody in blocking 
buffer (1:1000) for 1 h at RT or 4 oC overnight, followed by incubation in anti-rabbit 
antibody conjugated to an IR680 dye (1:10,000). A fraction of the samples were analyzed 
separately by SDS-PAGE and coomassie staining (Bio-Rad) for total protein 
normalization.  
 
Chemoenzymatic Labeling of Cell Lysates and Serum Samples. All the cell lines were 
obtained from ATCC. HepG2, MCF-7, and MDA-MB-231 cells grown in DMEM 
medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 
0.1 mg/mL streptomycin (Gibco). Cells were incubated in a 5% CO2 humidified chamber 
at 37 °C. One 150 mm culture dish of MDA-MB-231 breast cancer cell line, MCF-7 
breast cancer cell line, HepG2 liver cancer cell line were lysed directly in dish by adding 
2 mL of hot 1% SDS in Tris-HCl 50 mM (pH 8.0).  HepG2 cells were grown to 80% 
confluency and washed in serum and phenol red free RPMI 1640 media twice then grown 
for three days in the same media. The secreted proteins were collected from this media by 
concentration in 30,000 MWCO spin filters and stored at -80 °C. The serum of a 
Hepatocellular Carcinoma (HCC) patient and a healthy donor were obtained from City of 
Hope (Duarte, CA). Serum was depleted using either Pierce™ Top 2 Abundant Protein 
Depletion Spin Columns (ThermoFisher Scientific) for removal of serum albumin and 
antibodies or Pierce™ Albumin Depletion Kit (ThermoFisher Scientific) to remove 
albumin only. Following cell lysis or depletion, protein samples were precipitated using 
methanol/chloroform/water. Briefly, protein was diluted to 200 µL and precipitated by 
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sequential mixing with 600 µL of MeOH, 150 µL of CHCl3 and 450 µL H2O, after which 
the mixture was centrifuged at 15,000 rpm for 15 minutes. The supernatant was removed, 
450 µL of MeOH was added to the protein pellet and CHCl3 that remained, and the 
sample was centrifuged at 15,000 x g for 10 minutes. After removal of the supernatant, 
the protein pellet was allowed to dry, ~10-15 minutes until translucent. The protein pellet 
was then resuspended into 1% SDS, 50mM Tris HCl pH 7.5 and BCA assayed for protein 
concentration. 
 The protein pellet was re-dissolved at 5 mg/mL by boiling in 1% SDS with 50 
mM HEPES pH 7.5 for 5 minutes. The sample was then brought to 1 mg/mL in 5 mM 
MnCl2, 1x protease inhibitor complex, 0.5 mM UDP-Gal-6-N3 (13), 0.2 mg/mL GALT-1 
and incubated at RT for 4 h. The labeled proteins were precipitated as above and 
resuspended in 50 mM Tris-HCl, pH 8 containing 1% SDS at 1 mg/mL. The resuspended 
proteins were subsequently reacted 0.1 mM biotin-alkyne (11), 3 mM THTPA (ligand), 1 
mM CuSO4, and 2 mM sodium ascorbate for 1 hour at room temperature. For TAMRA-
alkyne labeling, conditions were followed as above. Negative controls were performed 
under identical conditions except that GALT-1, UDP-Gal-6-N3 (13), or TAMRA-/biotin- 
alkyne were omitted from the labeling reaction. After the labeling reactions, protein was 
precipitated using chloroform/methanol/water as described above and re-dissolved in 1% 
SDS. This precipitation and resolubilization was then repeated once more to ensure 
removal of non-specific interactions. TAMRA-labeled proteins were resolved by SDS-
PAGE and visualized by western blot analysis as above. Biotin labeled proteins were 
resolved identically except that the blocking buffer used was 3% BSA (ThermoFisher 
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Scientific) in TBST and membranes were probed with streptavidin-conjugated IR680 
(Invitrogen) at 0.5 µg/mL for 30 minutes at RT in blocking buffer. 
 
Immunoprecipitation and Identification of TAMRA-Labeled Core Fucosylated 
Glycoproteins. The TAMRA labeled protein pellets of MDA-MB-231, MCF-7 and 
HepG2 cells from above were allowed to dry briefly. The pellets were re-dissolved in 
boiling 1% SDS plus Complete™ protease inhibitors at a concentration of 4 mg/mL. The 
SDS was then quenched with 1 volume of NETFD buffer (100 mM NaCl, 50 mM Tris-
HCl pH 7.4, 5 mM EDTA, 6% NP-40) plus protease inhibitors, and the lysate was pre-
cleared against washed protein A/G sepharose beads (1 mL/ 2 mg of protein) at 4 ºC for 1 
hour. After centrifugation, the supernatant was collected and incubated with an anti-
TAMRA antibody (100 µg/ 2 mg of protein) at 4 ºC for 4 hours. The samples were then 
added to pre-washed protein A/G sepharose beads (1 mL/ 2 mg of protein) at 4 ºC for 1.5 
hours. Following centrifugation, the beads were washed once with 4 column volumes of 
NETFD buffer and three times with 4 column volumes of NETF buffer (100 mM NaCl, 
50 mM Tris-HCl pH 7.4, 5 mM EDTA). After washing, the beads were boiled in elution 
buffer (200 mM Tris pH 6.8, 400 mM DTT, 8% SDS, 50 µL buffer/ 100 µL beads). The 
supernatant was collected after centrifugation and precipitated by adding 5 volumes of 
ice-cold acetone and incubating at -20 ºC overnight.  
 The protein pellet was then was dissolved in 2x SDS protein loading buffer and 
was resolved by western blotting as above except, primary antibodies in TBST were 
added overnight at 4 °C at the following concentrations: mouse anti-AFP monoclonal 
antibody (Cell Signaling Technologies) at 1 µg/mL, rabbit anti-E cadherin (Cell 
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Signaling Technologies) at 2 µg/mL, rabbit anti-EGF receptor (Santa Cruz 
Biotechnology) at 0.2 µg/mL. Membranes were washed with TBST, and incubated with 
the appropriate Alexa Fluor 680-conjugated secondary antibody (Invitrogen, 1:10,000 
dilution in blocking buffer) for detection. 
 
Comparing GALT-1 Donor Substrate Preference by Completion: UDP-Galactose 
vs. UDP-Gal-6-N3. Proteins secreted from HepG2 cells were chemoenzymatically 
labeled as above except that each reaction had increasing concentrations of UDP-Gal (0 – 
500 µM). A control sample did not include any UDP-Gal-6-N3 (13), but 500 µM UDP-
Gal. The samples were treated with TAMRA-alkyne (10) as above and subjected to 
western blot analysis as above.  
 
Determination of GALT-1 Specificity using Fut8 knock-out and wild type Mouse 
Brain Lysates with PNGaseF Treatment. The brains of Fut8-/- and Fut8+/+ mice, 
generously provided by Jianguo Gu (Tohoku Pharmaceutical University, Japan), were 
lysed in 1% SDS (5 volumes/weight) by sonication and boiled until the mixture was 
homogeneous. Protein was precipitated using methanol/chloroform/water as above. 
Samples were then subjected to PNGaseF treatment as recommended (NEB). Briefly, 
samples were resuspended into 1x Glycoprotein Denaturing Buffer at 2 mg/mL followed 
by boiling for 10 minutes. After allowing samples to cool to room temperature, samples 
were brought to 1 mg/ml, 1x Glycobuffer 2 and 1% NP-40. Samples were then split to 
prepare a PNGaseF treated and a mock treated sample. PNGaseF was added at 12.5 U/µg 
protein and samples were incubated at 37 oC for 1 hour followed by precipitation with 
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methanol/chloroform/water as above. Samples were then subjected to chemoenzymatic 
labeling as above, using biotin-alkyne 11, and visualized using SDS-PAGE and western 
blotting as above. To determine background labeling, Fut8-/- and Fut8+/+ brain lysates 
from above were subjected to only the CuAAC reaction with biotin-alkyne 11 and 
subjected to SDS-PAGE and western blot analysis. All samples were also subjected to 
western blot analysis for L1CAM, an internal control for the PNGaseF reaction 
containing 21 putative N-glycan sites.38,39 Western blot analysis was carried out as noted 
above except using anti-L1CAM antibody (ab24345) diluted 1:1000 into blocking buffer 
and incubated overnight at 4 oC. 
 
Lectin Blot Analysis of Fut8 knock-out and wild type Mouse Brain Lysates with 
PNGaseF Treatment.  PNGaseF brain lysate samples, generated above, were subjected 
to SDS-PAGE and lectin blot analysis prior to chemoenzymatic labeling. Protein samples 
were resolved on 1.5 mm, 10-well NuPAGE 4-12% Bis-Tris gels and transferred to 
PDVF. The membrane was blocked with 3% BSA in TBST for 1 hour at room 
temperature. Membranes were subsequently incubated with the biotinylated lectins AAL 
(2 µg/mL), LCA (5 µg/mL), AOL (5 µg/mL), and a mock incubation (a biotin negative 
control) in blocking buffer. After overnight incubated at 4 oC, membranes were incubated 
with a streptavidin-conjugated IR680 dye (0.5 µg/mL), washed, and imaged.   
 
Biotinylation of AOL Lectin. 1 mL AOL (5mg/mL in PBS from TCI America) was 
added with 15 µL EZ-Link™ NHS-PEG4-Biotin (ThermoFisher Scientific) in DMF and 
incubated for 2 hours at RT. The pH of the solution was adjusted to pH 5 by adding 1 M 
	   88 
HCl, and loaded to two 0.5 mL filter tubes (MWCO 10,000) at 4 oC and concentrated to 
around 100 µL. The solution was exchanged to 1X PBS using the same filter tubes. LC-
MS analysis of the flow through for each run was used to confirm that biotin-PEG4-NHS 
or its byproduct (biotin-PEG4-COOH) no longer exists in the lectin solution. The 
biotinylated AOL lectin was stored in a PBS solution 4 oC. 
 
Detection of Core Fucosylated Glycans in Fixed Cells by Fluorescence Microscopy. 
MDA-MB-231 and HepG2 cells were plated onto 15 mm coverslips (Carolina Biologics) 
at a density of 100 cells/mm2.  After 12 hours, the media was removed, and the cells were 
rinsed with PBS, fixed in 3.7% formaldehyde in PBS, pH 7.2 for 8 minutes at room 
temperature, washed twice with PBS, permeabilized in 0.3% Triton X-100 in PBS for 10 
minutes at room temperature, and washed twice with the enzymatic labeling buffer (50 
mM Tris-HCl, pH 7.5, 0.1% Triton X-100, 5 mM MnCl2, 150 mM NaCl). Reaction 
mixtures and negative controls (without GALT-1 or without UDP-Gal-6-N3) were 
prepared by adding GALT-1 (0.2 mg/mL) and UDP-Gal-6-N3 (13; 0.5 mM) to the 
enzymatic-labeling buffer. The reaction cocktail was added to the coverslip (100 
µL/coverslip) and incubated for 2 hours at room temperature in a humidified chamber. 
After chemoenzymatic labeling, the cells were washed twice with the chemoenzymatic-
labeling buffer. Enzymatic addition of Gal-6-N3 onto core fucose was detected by treating 
the cells with Click-It™ Biotin Glycoprotein Detection Kit, followed by incubating the 
slides with 0.1 µg/mL streptavidin-Alexa Fluor488 (Invitrogen) for 30 minutes at room 
temperature. The coverslips were washed with PBS, mounted onto glass slides using 
Vectashield mounting medium with DAPI stain (4 µL; Vector Labs), and sealed with 
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clear nail polish. Cells were imaged using a Nikon Eclipse TE2000-S inverted 
microscope, and images were captured with a Zeiss LSM 510 Meta NLO confocal 
microscope using 40x Plain Fluor objective and were processed in Image J. 
 
Detection of Cell-Surface Core Fucosylated Glycans on Live Cancer Cells by Flow 
Cytometry. MDA-MB-231 cells were seeded at 107 cells per 150 mm plate in 25 mL of 
DMEM with 10% FBS and 1% penicillin/streptomycin. On the day of analysis, cells 
were lifted off the plate with 2 mM EDTA and 1 mM EGTA, and washed with 1% FBS, 
10 mM HEPES in 1X HBSS. One million cells were chemoenzymatically labeled with 
UDP-Gal-6-N3 (13; 500 µM) and GALT-1 (0.2 µg/µL) in 1% BSA, 10 mM HEPES in 
HBSS (100 µL) for 1 hour at room temperature. Cells were spun twice through 100% 
FBS (1 mL) to remove excess reagent (500 x g, 5 minutes) and resuspended in 1% FBS, 
10 mM HEPES in CMF HBSS (100 µL) containing ADIBO-biotin, 6, (20 µM) and 
incubated for 1 hour at room temperature. Negative controls were performed with 
identical conditions, except for that GALT-1 or all reagents (untreated) were omitted. 
Cells were again spun twice through 100% FBS (1 mL), and washed with 3% BSA in 
PBS (1 mL). Cells were then resuspended in 3% BSA in PBS (100 µL) containing 
streptavidin-Alexa Fluor 488 (1 µg/mL) and incubated for 30 minutes at 4 °C. Cells were 
subsequently spun twice through 100% FBS (1 mL) and resuspended in BSA (1 mg/mL), 
20 mM MgCl2, 0.5 µg/mL DNAse, 10 mM HEPES in HBSS (600 µL) for flow cytometry 
analysis. Immediately before analysis, 7-amino-actinomycin D (7-AAD, 5 µL; 
eBioscience) was added to measure cell viability. Cells were analyzed for FITC intensity 
on a Beckman Dickenson FACSCalibur flow cytometer equipped with a 488-nm argon 
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laser. For each experiment, 10,000 live cells were analyzed, and data analysis was 
performed on FlowJo (Tristar Inc.).  
  
PNGaseF Treatment of HepG2 Secreted Proteins for Chemoenzymatic Detection of 
Protein Samples with Different Core Fucose Levels. Proteins secreted into the culture 
media from HepG2 cells were treated with PNGaseF as above, including a PNGaseF 
mock control. Mock control samples were serially diluted into PNGaseF treated samples, 
generating multiple samples with differing levels of core fucosylated glycoproteins. 
Samples were then chemoenzymatically labeled as above and imaged by western blotting 
for biotin as above. The exact percentage of PNGaseF treated sample was calculated from 
the signal of glycosylated AFP band (from mock PNGaseF treated sample, top band; 
Figure 3.12) and non-glycosylated AFP band (from PNGaseF treated sample, bottom 
band; Figure 3.12). Quantification of both AFP intensities and biotin (core fucose) 
intensities were calculated using Image Studio software (LI-COR).  
 
Proteomic Work Flow with PNGaseF Release for Cleavable Linker. 
Chemoenzymatically labeled protein, biotinylated, was incubated with magnetic 
streptavidin resin, (1mL per 100 µg protein; Peirce) for 1 hour at room temperature. 
Resin was washed 2x with PBS, 2x with PBS and 1% SDS, and then 2x with PBS again. 
Each wash was done rotating end-over-end for 5 minutes. Resin was resuspended into 
500 µL of PBS with 5000U PNGaseF and rotated end-over-end for 5 hours at room 
temperature. Supernatant was collected and acetone precipitated overnight at -20 °C. 
Sample was resuspended into 2x SDS protein loading buffer, boiled for 5 minutes, and 
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subjected to SDS-PAGE and silver stain (BioRad). A fraction of the sample was used for 
western blot analysis with streptavidin-conjugated Alexa Fluor 680 as above.  
 
Preparation of AFP. Literature report has been followed to prepare partially pure AFP 
from HepG2 cell lines.40 Briefly, HepG2 cells were cultured on a 150 mm culture dish 
with DMEM (10 % FBS) until there were 80% confluent. The cells were then washed 
with phenol free 1640 media three times (ThermoFisher Scientific). The same media (25 
mL), supplemented with 5% penicillin/streptomycin, was added to the dish and incubated 
for 72 hours. The media was transferred to a tube and insoluble precipitates were spun 
down at 2000 rpm for 2 minutes. The supernatant was concentrated with 10,000 Da 
molecular weight cut-off (MWCO) spin filters (Millipore) to a volume of about 1 mL 
from 100 mL media. The media was loaded to a 1 mL IMAC FF column (GE Healthcare) 
pre-charged with CuSO4. The column was washed with 10 column volumes of binding 
buffer (20 mM Na2HPO4, pH 7.2, 1 M NaCl). The protein was eluted by adding 5 column 
volumes of elution buffer (20 mM Na2HPO4, pH 7.2, 1M NH4Cl) with 0.5 mL for each 
fraction. After SDS–PAGE and coomassie staining analysis, the purified protein was 
concentrated with 30,000 Da molecular weight cut-off (MWCO) spin filters and 
dissolved into 50 mM Tris-HCl pH 7.5 containing 0.015 M NaCl and stored at -20 oC.  
 
ELISA for Detection of Core Fucosylated α-Fetoprotein (AFP). HepG2 protein 
samples were chemoenzymatically labeled with biotin as above.  Samples were then 
serially diluted into Calibrator Diluent RD5-24, applied to the ELISA wells, and the 
procedure was carried out following the protocol for the Quantikine® ELISA Human α-
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Fetoprotein Immunoassay (R&D systems) with exception to the detection of core fucose. 
Briefly, each sample was applied to four wells and incubated for two hours. Wells were 
then washed four times with wash buffer, and the anti-AFP conjugated HRP detection 
antibody was added to two duplicate wells and a streptavidin-conjugated HRP (R&D 
systems) was added to the other two duplicate wells. After two hours, wells were washed 
and incubated with substrate solution for 15-30 minutes to allow adequate reaction time. 
Samples were quenched with a stop solution and quantified on the Flexstation 3 
(Molecular Devices) by measuring absorbance at 450 nm. Both total AFP levels, 
determined against a standard curve of provided pure AFP, and core fucosylated AFP, 
after background subtracting the samples treated without GALT-1, were determined.   
 Detecting core fucosylated AFP using the Pierce™ Streptavidin Coated High 
Capacity Plates (ThermoFisher Scientific) was performed as above except that the 
biotinylated (core fucosylated) AFP was applied to the streptavidin coated plate and 
detected with the anti-AFP-conjugated HRP from the R&D kit above.  
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ABSTRACT  
 Antibody-drug conjugates (ADCs) have become a coveted method for targeted 
drug delivery. With only a few examples of ADCs passing FDA regulations, many 
companies are actively pursuing ADC leads. However, the conjugation methods currently 
used vary greatly, from exploiting reactive and non-natural amino acid chains to 
enzymatic manipulations and antibody engineering. More recently, newer conjugation 
methods have been focused on exploiting the single N-glycan site of the heavy chain at 
Asn-297. In this chapter, I describe the development of an antibody conjugation method 
that exploits the chemoenzymatic labeling approach used for the detection of core fucose 
glycoproteins (Chapter 3). Enzymatic installation of azide functionality followed by 
conjugation to biotin, through the strain-promoted azide alkyne cycloaddition (SPAAC), 
enables antibodies to be labeled with biotin. MS analysis confirms that the azide is indeed 
directly added to core fucose. The proof-of-principle experiments described in this 
chapter demonstrate that the chemoenzymatic approach can be utilized for antibody-
conjugation.  
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INTRODUCTION 
Antibody-drug conjugates (ADC) have become a popular method for targeted 
drug delivery. Many strategies have been used to install drugs onto antibodies. These 
include utilizing amino acid side chain reactivity (lysine and cysteine), primary sequence 
engineering, non-natural amino acid incorporation, and enzymatic transformations.1 
Additionally, many attempts have been made to glycoengineer the N-glycan present on 
antibodies, enabling the site-specific conjugation of 2-4 drugs per antibody (drug-
antibody ratio, DAR).1 Oxidation of core fucose, enzymatic remodeling of the glycans 
with non-natural sugars and bioorthogonal chemistry have all been employed for this 
approach, with only a handful of these ADCs currently in clinical trials.1 
 In this chapter, I will describe a workflow that repurposes the chemoenzymatic 
labeling approach described in chapter 3 (chemoenzymatic detection of core fucose) to 
selectively install chemical functionality onto two different antibodies (Figure 4.1). Core 
fucose is present on almost all antibodies and exists with over 90% stoichiometry.2-4 
Additionally, each antibody contains two N-glycans, one on each heavy chain Asn-297.  
Using the chemoenzymatic labeling method to install azide functionality onto the core 
fucose of antibodies, followed by the strain-promoted azide-alkyne cycloaddition 
(SPAAC) reaction, will enable site-specific conjugation of cyclooctyne derivatized drugs 
with a theoretical DAR of 1.8 (Figure 4.1). This workflow will enable a new strategy for 
antibody conjugation and highlight the versatility of the chemoenzymatic approach.  
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Figure 4.1 Schematic demonstrating proof-of-concept that the chemoenzymatic labeling strategy 
for core fucose detection can also be utilized as an antibody conjugation method.  Antibodies are 
treated with GALT-1 and UDP-Gal-6-N3 (13) followed by the SPAAC with ADIBO-biotin (6).  
 
 
RESULTS AND DISCUSSION 
 To determine if the chemoenzymatic approach developed in chapter 3 could be 
utilized as an antibody-conjugation method, the commercially available anti-TAMRA 
polyclonal antibody was used as an initial model antibody. The antibody was treated with 
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GALT-1 and UDP-Gal-6-N3 (13) and then split into four separate samples. Each of these 
samples were treated with either, increasing amounts of ADIBO-Biotin (6; 5, 50, 500 
µM), reacting with the azide through the SPAAC, or with biotin-alkyne (11) using the 
CuAAC as described in chapter 3 (Figure 4.2). These samples were subjected to western 
blot analysis for detection of both biotin and heavy chain IgG, as well as a coomassie 
stain for detection of total protein (Figure 4.2A).  
 As expected this approach could be used to label the antibody heavy chain. Each 
click chemistry reaction tested demonstrated significant signal over background (Figure 
4.2). Interestingly, the CuAAC provided the lowest signal-to-noise, about a seven-fold 
increase in signal over background (Figure 4.2B). The SPAAC reaction provided lower 
background when compared to the CuAAC. The 50 µM SPAAC condition exhibited the 
best signal-to-noise ratio of ~ 21 (Figure 4.2B). The 500 µM SPAAC condition exhibited 
a higher signal than the 50 µM condition; however, the background witnessed was also 
higher than desired. Background labeling exhibited by the SPAAC is suspected to be a 
result of the cysteine side chain thiol nucleophilic attack of the strained cyclooctyne,5 as 
antibodies contain many cysteine residues that participate in disulfide bonds.1 Based on 
this exploratory and optimization experiment, the chemoenzymatic labeling approach 
developed to detect core fucose can also be utilized to conjugate molecules to antibodies 
and 50 µM of ADIBO-molecule would be the ideal concentration moving forward. 
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Figure 4.2 (A) Optimization of ADIBO-biotin (6) concentration for antibody conjugation using 
the chemoenzymatic labeling approach. Anti-TAMRA antibody was treated with GALT-1 and 
UDP-Gal-6-N3 (13) followed by treatment with increasing concentrations of ADIBO-biotin 
(concentrations used were 5, 50, 500 µM). SDS-PAGE and western blot detection using 
streptavidin-conjugated Alexa Fluor 680 (top), anti-rabbit antibody (middle), and coomassie stain 
(bottom). (B) Quantification of signal over background for different concentrations of ADIBO-
biotin and comparison to the CuAAC with biotin-alkyne (11). 
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Figure 4.3 Antibody conjugation study using the core fucose chemoenzymatic approach with the 
anti-CSE antibody. (A) SDS-PAGE and western blot detection of chemoenzymatic labeling-
dependent biotin conjugation using streptavidin-conjugated Alexa Fluor 680 (left) and coomassie 
stain (right). (B) Heavy chain labeling is quantified over the background biotin signal. (C) 
Extracted ion chromatogram of the glycopeptide, EAQYN*STFR resulting from the tryptic digest 
of anti-CSE antibody treated with (top) and without (bottom) GALT-1 in the presence of UDP-
Gal-6-N3 (13). 
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conduct binding studies of pre- and post- conjugated antibodies, the Hsieh-Wilson lab is 
well equipped to conduct these studies in the future. To determine if the anti-CSE 
antibody could be conjugated to ADIBO-biotin using this method, the antibody was 
chemoenzymatically labeled as above with the optimized conditions (Figure 4.3).  The 
anti-CSE heavy chain was efficiently labeled, as determined by western blot analysis 
using streptavidin conjugated Alexa Fluor 680. This labeled demonstrated greater than an 
80-fold increase in signal over background (Figure 4.3B). When comparing the signal-to-
noise ratios of anti-TAMRA and anti-CSE labeling, anti-CSE appears to be labeled at 
over a four fold greater efficiency than anti-TAMRA (Figures 4.2B and 4.3B). Based on 
the specificity and preference for GALT-1 acceptor substrates determined in chapter 3 
(Figure 3.5), I suspect the difference in labeling efficiency witnessed is a result of the 
origin of these antibodies. They were produced in different species and, as a result, will 
have different N-glycan structures. This difference in glycan structure will require that 
the enzymatic labeling step will need to be optimized for each antibody used.  
 In order to further characterize this method, a mass spectrometry (MS) approach 
was utilized to better understand the labeling efficiency, identify the N-glycan structures 
modified by GALT-1, and to definitively demonstrate that Gal-6-N3 is directly added to 
core fucose. To achieve these goals, I set up a collaboration with a glycomics core facility 
run by Parastoo Azadi at the complex carbohydrate research center (CCRC) at the 
University of Georgia at Athens. The anti-CSE antibody was labeled with and without 
GALT-1, in the presence of UDP-Gal-6-N3 (13). The antibody was then reduced, 
alkylated, and digested with trypsin. Since antibodies contain only one N-glycan site at 
Asn-297 of the heavy chain, the glycopeptide EAQYN*STFR could easily be identified 
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using an extracted ion chromatogram. MS analysis demonstrated that, in the presence of 
GALT-1, this core fucosylated glycopeptide was indeed labeled with Gal-6-N3 (Figure 
4.3C).  
 
 
Figure 4.4 Antibody conjugation study using the core fucose chemoenzymatic approach with the 
anti-CSE antibody. Shown is the HCD MS2 spectra of the glycopeptide, EAQYN*STFR, 
resulting from the tryptic digest of anti-CSE treated with GALT-1 and UDP-Gal-6-N3 (13).  
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glycoproteins. Additionally, this method can be used to install a chemical handle onto 
antibodies for the development of ADCs.  
 
 
Figure 4.5 Antibody conjugation study using the core fucose chemoenzymatic approach with the 
anti-CSE antibody. Above is the full MS spectra of the glycopeptide, EAQYN*STFR, resulting 
from the tryptic digest of anti-CSE treated with GALT-1 and UDP-Gal-6-N3 (13). This 
glycopeptide is present a low abundances compared to the unmodified glycopeptide suggesting 
incomplete enzymatic labeling.  
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is supported by the MALDI-TOF analysis of GALT-1 specificity presented in chapter 3 
(Figure 3.5) However, it is possible that during the reduction and alkylation process, 
much of the azide is reduced to an amine, a difference of only one dalton from a hydroxyl 
group. When considering that the natural abundance of isotopes found in these 
glycopeptides produce multiple peaks during MS analysis, it is possible that when the 
Gal-6-N3 is reduced to Gal-6-NH2, Gal-6-N3 could ultimately be mistaken for galactose. 
Since is it established that N-glycan antenna are elongated by galactose, it is possible that 
the signal produced in the MS analysis could be misleading and perhaps the labeling 
efficacy is not as low as initially thought. Further studies will need to be conducted that 
do not utilize reduction and alkylation, use higher sensitivity instrumentation, and use 
more rounds of tandem MS to confirm this hypothesis. Additionally, reaction of the azide 
with a strained cyclooctyne, prior to reduction and alkylation, could provide a unique 
mass signature that could help elucidate this hypothesis.  
 
CONCLUSION 
 In this chapter, I have described an antibody-conjugation method that exploits the 
core fucose chemoenzymatic labeling approach developed in chapter 3. Two different 
antibodies were labeled, demonstrating the versatility of the approach; however, each 
were labeled with different efficiencies. This is likely due to different types of N-glycans 
present on each of the antibodies, resulting from the species in which the antibodies were 
produced. Using an MS analysis of the glycopeptides produced from the anti-CSE 
antibody, direct evidence was generated supporting previous findings that GALT-1 
directly adds Gal-6-N3 onto the core fucose of N-glycans.  Further optimization of this 
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antibody-conjugation method is required to make this process more efficient and if this 
technology will ever be commercialized. Additional studies are also needed that 
determine how ADCs produced using this technology effect the binding of this antibody 
to its target antigen and Fc receptors. Despite the requirement for further optimization 
and characterization of this strategy, I have provided proof-of-principle studies 
demonstrating that this approach presents a novel method for generating antibody-drug 
conjugates.  
 
EXPERIMENTAL METHODS  
General Reagents and Methods. Unless otherwise noted, reagents were purchased from 
the commercial suppliers Fisher (Fairlawn, NJ) or Sigma-Aldrich (St. Louis, MO). 
Protease inhibitor cocktails (PIC) were purchased from Roche Applied Sciences 
(Indianapolis, IN). Immobilon-FL PDVF membrane was from Millipore (Billerica, MA). 
The anti-TAMRA antibody, 4-12% NuPAGE® Bis-Tris Mini gels, streptavidin-
conjugated Alexa Flour 680 were from Invitrogen (Carlsbad, CA). The click chemistry 
ligand, Tris(3-hydroxypropyltriazolylmethyl)amine (THTPA) was purchased from 
Sigma-Aldrich (St. Louis, MO). Biotin-alkyne was purchased from 
clickchemistrytools.com (Scottsdale, AZ). Western blots were visualized and quantified 
using an Odyssey infrared imaging system (LI-COR Biosciences). The anti-CSE 
antibody was purified in house.  
 
Chemoenzymatic Labeling of anti-TAMRA and anti-CSE Antibodies. Antibodies 
were precipitated using chloroform/methanol/water as described in the experimental 
procedures section in chapters 2 and 3. The antibody pellet was re-dissolved at 5 mg/mL 
	  108 
by boiling in 1% SDS with 50 mM HEPES pH 7.5 for 5 minutes. The sample was then 
brought to 1 mg/mL in 5 mM MnCl2, 1x protease inhibitor complex, 0.5 mM UDP-Gal-6-
N3 (13), 0.2 mg/mL GALT-1 and incubated at RT for 4 h. The labeled antibody was 
precipitated as above and resuspended in 50 mM Tris-HCl, pH 8 containing 1% SDS at 1 
mg/mL. The resuspended antibody was subsequently reacted 0.1 mM biotin-alkyne (11), 
3 mM THTPA (ligand), 1 mM CuSO4, and 2 mM sodium ascorbate for 1 hour at room 
temperature or incubated with 5, 50, or 500 µM ADIBO-biotin (6) for 2 hours. Negative 
controls were performed under identical conditions except that GALT-1 was omitted 
from the labeling reaction. After the labeling reactions, antibody was precipitated using 
chloroform/methanol/water as described and re-dissolved in 1% SDS. This precipitation 
and resolubilization was then repeated once more to ensure removal of non-specific 
interactions.  
 
Western Blot Detection of Core Fucosylated Glycoproteins. Labeled antibodies were 
resolved on 1.5 mm, 10-well NuPAGE 4-12% Bis-Tris gels and transferred to PDVF. 
The membrane was blocked with 3% BSA (ThermoFisher Scientific) in 50 mM Tris-HCl 
pH 7.4, 150 mM NaCl containing 0.1% Tween-20 (TBST) for 1 h at RT and then the 
membranes were probed with streptavidin-conjugated IR680 (Invitrogen) at 0.5 µg/mL 
for 30 minutes at RT in blocking buffer. A fraction of the samples were analyzed 
separately by SDS-PAGE and coomassie staining (Bio-Rad) for total protein 
normalization.  
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Detection of Antibody N-glycans by MS Analysis. Anti-CSE antibody was 
enzymatically labeled as above and precipitated as described. The protein pellet was 
washed two times in 80% MeOH. The antibody pellet was then frozen and shipped to the 
CCRC as noted. The protein was resuspended, reduced with TCEP and alkylated with 
iodoacetamide, and digested with trypsin. Samples were desalted and subjected to LC-
MS analysis. Tandem MS was conducted using higher-energy collisional disassociation 
(HCD). Additional details can be found by contacting Parastoo Azadi at the complex 
carbohydrate research center (CCRC) at the University of Georgia at Athens. 
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ABSTRACT  
 During the development of chemoenzymatic labeling approaches, multiple tools 
are relied upon to monitor glycosyltransferase activity. In this chapter, I describe the 
development of LC-MS, HPLC, and fluorescence-based assays that were used to monitor 
glycosyltransferase reactions. These assays were developed for GalT, the enzyme used 
for chemoenzymatic labeling of O-GlcNAc. GalT was also used as a model enzyme to 
optimize a fluorescence-based assay that utilizes a xanthene-based Zn (II) complex 
chemosensor 17-2Zn(II), which exhibits turn-on fluorescence in the presence of 
nucleotide diphosphate (NDP).  This fluorescence-based assay was also used to describe 
the kinetic parameters of GALT-1, used for chemoenzymatic labeling of core fucose 
(Chapter 3), towards its substrates. Finally, the 17-2Zn(II) sensor was used to monitor 
GalT labeling of the O-GlcNAcylated protein, alpha-crystallin. The ability of the 17-
2Zn(II) sensor to monitor glycosyltransferase reactions with protein acceptor substrates is 
a novel finding and provides the groundwork for new methods of O-GlcNAc detection.  
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INTRODUCTION 
 When characterizing glycosyltransferase activity during the development of 
chemoenzymatic labeling methods, tools to monitor glycosyltransferase reactions are 
imperative. Traditionally, the field has used radiolabeled nucleotide sugars and a 
scintillation counter.1 Additionally, acceptor substrate derivatization has been utilized for 
capillary electrophoresis (CE), high performance liquid chromatography (HPLC), or 
mass spectrometry (MS) analysis.2 More recently, reactions have been monitored using 
glycan array technologies with MS or fluorescent readouts.3,4 Finally, in solution 
fluorescent based assays have proven to be effective and simple readouts for 
glycosyltransferase activity.  
 Due to the nature of glycosyltransferase donor substrates being almost exclusively 
nucleotide diphosphate-sugars (NDP-sugar), colorimetric assays rely on the enzymatic 
release of the NDP for detection of the reaction progress. A commercially available kit 
from R&D Systems relies on a phosphatase-coupled assay which converts the NDP to a 
monophosphate, which can be detected by malachite green.5 Recently, a turn-on 
fluorescence sensor was developed that directly detects free NDPs but not NDP-sugars.6,7 
This xanthene-based Zn (II) complex chemosensor 17-2Zn(II) fluoresces in the presence 
of NDPs but not NDP-sugars (Figure 5.1A).  
 This type of sensor is extremely valuable when characterizing 
glycosyltransferases that have complex acceptor substrates, as in the case of GALT-1 
discussed in chapter 3. This type of chemosensor is also a valuable tool for development 
of a high-thoughput assay that should enable the discovery of candidate 
glycosyltransferases amenable to chemoenzymatic labeling (Figure 5.2). This could lead 
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to the development of a suite of chemoenzymatic labeling approach in a high-thoughput 
fashion.  
 
Figure 5.1 Turn-on fluorescence xanthene-based Zn (II) complex chemosensor (17-2Zn(II)) for 
the monitoring of glycosyltransferase reactions. (A) Scheme of fluorescent glycosyltransferase 
assay used to compared the kinetic parameters of GALT-1 towards UDP-Gal and UDP-Gal-6-N3. 
(Full kinetic data noted in Figure 3.4). The sensor (17) is non-fluorescent in the presence of Zn. 
Following Zn binding, the sensor (17-2Zn(II)) binds UDP, generated during the 
glycosyltransferase reaction, and turns on the fluorescence of the sensor. (B) Representative time 
course data of kinetic assay with increasing concentration of UDP-Gal. Initial rates were 
determined using the first five minutes of this time course assay.  
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glycosyltransferase activity of GALT-1 (labeling of core fucose) and GalT (labeling of 
O-GlcNAc). I will also explore the ability of this sensor to be utilized for detecting O-
GlcNAc on purified glycoproteins. 
 
Figure 5.2 Use of the fluorescent sensor (17-2Zn(II)) for development a high throughput 
discovery platform that will enable the identification of novel chemoenzymatic labeling enzymes 
and rapid characterization of donor substrate specificities. This platform can also be utilized for 
the high-throughput engineering of mutant glycosyltransferases with enhanced specificity and 
activity.  
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 Briefly mentioned in chapter 3, was the use of the xanthene-based Zn (II) 
complex chemosensor 17-2Zn(II) for the kinetic characterization of GALT-1. The ability 
to characterize GALT-1’s kinetic parameters towards its various substrates was 
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chapter 3, I was able to obtain the small molecule acceptor substrate, N6000, which could 
Glycosyltransferase 
Library 
N
NH
O
O O
O
OHHO
OPOPO
O O-O O-
HO
R
New Candidate Enzymes for the Development of 
a  Suite of  Chemoenzymatic Methods 
Sensor (17) 
O OHHO
NN
N N N N
Non-natural Donor 
Substrates 
	  115 
be used to compare kinetic parameters with the natural and non-natural donor substrates 
of GALT-1 (Figure 3.4).  
 To describe the function of this sensor 17-2Zn(II) I have highlighted the time 
course data resulting from GALT-1 was incubation with N6000, 17-2Zn(II), and 
increasing concentrations of UDP-Gal (Figure 5.1B). During the reaction, GALT-1 
transferred Gal from UDP-Gal to N6000, liberating UDP. With Zn present in the 
reaction, 17-2Zn(II) was then able to bind UDP and fluorescence was turned on (Figure 
5.1A). It is important to note that 17-2Zn(II) does bind UDP-sugars to a small degree so 
background fluorescence control reactions are run in the absence of acceptor substrate. 
After background subtraction and normalizing the first time point to zero, a time course 
analysis plot was generated (Figure 5.1B).  
 
Figure 5.3 Emission profile optimization for the sensor (17-2Zn(II)) in presence of UDP. 
Excitation wavelength set to 490 nm and filter cut-off set to 530 nm. UDP was serially diluted ten 
times from 1 mM (orange) to 0 mM (dark blue). 534 nm determined to be the λmax. 
 
 However, before these kinetic assays could be performed, much optimization was 
required. While the excitation and emission profiles of the sensor were previously 
characterized in different groups, I validated these numbers in our system. By setting up 
mock reactions with increasing concentrations of UDP, I was able to determine that the 
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optimal excitation wavelength was 500 nm, previously determined to be 488 nm, and the 
optimal emission wavelength was 534 nm, previously determined to be 523 nm (Figure 
5.3). With a 530 nm filter cutoff, I was able to generate robust signals over background 
(Figure 5.3).  
 
Figure 5.4 Investigating the effects of sensor (17-2Zn(II)) concentration and efficacy in the 
presence of 5 mM MnCl2 and 1% Triton X-100. These additives are used for glycosyltransferase 
reactions of interest. Sensor concentrations tested were 1 and 2.5 µM. UDP standards were added 
in increasing concentrations to determine linear range of detection.  
 
 With these parameters in hand, I next set out to determine the effects different 
reagents, required for GALT-1 activity, would have on sensor performance. GALT-1 had 
been optimized with 5 mM MnCl2. In previous reports, 17-2Zn(II) was utilized in the 
presence of 0.2 mM MnCl2; however, it was not determined if higher MnCl2 
concentrations would affect the sensor’s performance.6 To determine if 17-2Zn(II) would 
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maintain its turn-on fluorescent properties in the presence of 5 mM MnCl2, I incubated 
17-2Zn(II) in mock reaction buffer with and without 5 mM MnCl2 and increasing 
concentrations of UDP (Figure 5.4). The addition of 5 mM MnCl2 was detrimental to the 
performance of the sensor 17-2Zn(II), indicating that this amount of MnCl2 could be not 
be tolerated for proper sensor function.  
 Next, I tested the performance of the sensor 17-2Zn(II) in the presence of 1% 
Triton X-100. Before obtaining 17, GALT-1 activity assays were performed on purified 
protein acceptor substrates in the presence of 1% Triton X-100 (Figure 3.7A). If these 
initial activity assay conditions were going to be used in the fluorescence assay, 17-
2Zn(II) would need to perform in the presence of this detergent. To test this, mock 
reactions were set up with and without 1% Triton X-100 and showed that the presence of 
this detergent killed the fluorescent properties of 17-2Zn(II) (Figure 5.4). Thus, 
modifications to the initial GALT-1 activity assay were required when using 17-2Zn(II) 
to monitor the GALT-1 reaction. It was later determined that 1% Triton X-100 was not 
required for the activity of GALT-1, data not shown.  
 Finally, I set out to determine if the effects of MnCl2 and 1% Triton X-100 could 
be mitigated by increasing the concentration of 17-2Zn(II). The studies mentioned above 
were conducted following the previous reports of using 1 µM 17-2Zn(II). I repeated the 
above experiments in 2.5 µM 17-2Zn(II) and determined that, (i) the linear dynamic 
range and sensitivity were both increased at this concentration for the UDP 
concentrations desired, and (ii) MnCl2 and 1% Triton X-100 still killed the activity of the 
17-2Zn(II) despite the higher concentrations (Figure 5.4). Taken together, these key 
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optimization steps shaped the assays used to determine the kinetic parameters for GALT-
1 (Figure 3.4).  
 
Figure 5.5 Development of MS based glycosyltransferase assay for GalT, the enzyme used for 
the chemoenzymatic labeling of O-GlcNAc. (A) Reaction scheme for the MS analysis confirming 
that p-nitrophenol-GlcNAc (18) acts as a substrate for GalT. UDP-ketoGal (2; Figure 2.2) was 
used as a donor substrate and p-nitrophenol-GlcNAc (18) was used as an acceptor substrate. LC-
MS analysis revealed the product 19, suggesting that GalT does utilize p-nitrophenol-GlcNAc 
(18) as an acceptor substrate. (B) Starting material and product peaks identified during the LC-
MS analysis. (C) Fragmentation products identified during MS/MS analysis.  
 
 With this fluorescent glycosyltransferase assay in hand, I wanted to see if other 
this chemoenzymatic labeling methods developed in the lab could utilize this assay. The 
Hsieh-Wilson lab has developed a chemoenzymatic approach for the detection of O-
GlcNAc; however, the activity assay currently used for GalT, the enzyme for this 
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GlcNAc glycopeptide with a MALDI-TOF readout after overnight incubation.8,9 For 
these reasons I developed several additional activity assays for GalT that are cheaper, 
faster, and technically simple.  
 First, I utilized a cheap and commercially available acceptor substrate, p-
nitrophenol-GlcNAc (18, pnp-GlcNAc). The nitrobenzyl group acts as a UV tag for 
HPLC and allows the molecule have a significant retention time using any reverse phase 
column, compared to free GlcNAc. Additionally, this p-nitrophenol group helps with 
ionization for MS analysis. However, p-nitrophenol groups have also been shown to 
inhibit some glycosyltransferases.10 To address this concern, pnp-GlcNAc 18 was 
incubated with GalT and UDP-ketoGal (2) overnight (Figure 5.5A). LC-MS analysis 
discovered the expected ketoGal-GlcNAc-pnp product 19, demonstrating that pnp-
GlcNAc 18 could act as an acceptor substrate for GalT (Figure 5.5). Both Na+ and H+ 
forms of pnp-GlcNAc, in the control and the product, were discovered (Figure 5.5B). 
Tandem MS analysis of the product confirmed its identity by identifying the expected 
fragmentation ions (Figures 5.5 B and C). This data demonstrates that pnp-GlaNAc 18 
acts as a suitable substrate for GalT and that this LC-MS method could be used to 
monitor GalT activity.  
 Next, an HPLC based assay was developed to establish a quick and easy way to 
determine the activity of new GalT preparations. The UV active p-nitrophenol group 
enables both a visualization tag and adds hydrophobic character to the GlcNAc substrate 
for adequate retention on a reverse phase column. To test this assay, GalT was incubated 
with pnp-GlcNAc 18 and UDP-ketoGal 2, as above (Figure 5.6A). The reaction was 
started, by addition of GalT, directly before the autosampler needle could draw the first 
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time point. Time points were taken every 14 minutes and the reaction was monitored at 
280 nm. Within the first time point (14 minutes), the reaction was over 60% complete 
and the reaction reached completion between 84 and 98 minutes (Figures 5.6 B and C).  
 
Figure 5.6 Development of HPLC based glycosyltransferase assay for GalT. (A) Reaction 
scheme using p-nitrophenol-GlcNAc (18) as acceptor substrate and UDP-KetoGal (2) as the 
donor substrate. (B) HPLC spectra of selected time points demonstrating the reaction progress 
over time. The detection of the p-nitrophenol group was achieved by monitoring at 280 nm. (C) 
Quantification of starting material (18) and product (19) percentages using the area under the 
curve for the respective chromatogram peaks.  
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concentration used (500 µM UDP-ketoGal 2, 100 µM pnp-GlcNAc 18). This information 
on reaction rate was considered during the development of the fluorescence-based assay.  
 
Figure 5.7 Development of fluorescence based glycosyltransferase assay for GalT, the enzyme 
used for the chemoenzymatic labeling of O-GlcNAc.  Fluorescent sensor 17-2Zn(II) monitoring 
of the glycosyltransferase reaction over 1000 seconds (top) was conducted using 20 µM UDP-
KetoGal and increasing concentrations of p-nitrophenol-GlcNAc (18). The first 200 seconds of 
the reaction are highlighted (bottom).  
 
 With the LC-MS assay confirming that pnp-GlcNAc could act as a substrate for 
GalT and the HPLC based assay informing the speed of the reaction, I tested if this 
reaction could be monitored with the fluorescence-based assay described above. GalT 
was incubated with UDP-ketoGal 2 and increasing concentrations of pnp-GlcNAc 18 in 
the presence of the fluorescent sensor 17-2Zn(II) (Figure 5.7). A time dependent increase 
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concentrations of pnp-GlcNAc correlated to increased reaction rates (Figure 5.7). This 
data shows that GalT activity can also be monitored using this fluorescence-based assay. 
Further engineering of GalT or optimization of its reaction conditions could now be 
conducted in a high-throughput format with the new assay developed above.  
 Given the versatility of the chemoenzymatic approach, I hypothesized that the 
fluorescent sensor 17-2Zn(II) might be able to act as a readout for changes in levels of 
protein O-GlcNAcylation. To test this hypothesis, I repeated the above fluorescent assay 
with alpha-crystallin as an acceptor substrate because this protein is an established O-
GlcNAcylated protein detected by this chemoenzymatic approach.8 A time dependent 
increase in signal was witnessed; however, increasing alpha-crystallin concentrations 
seemed to perturb the fluorescence change (Figure 5.8). When alpha-crystallin was 
present at 0.5 mg/mL, a robust time depend increase in fluorescence was clear (Figure 
5.8). Increasing the protein concentration seemed to be negatively correlated with 
reaction progress. When alpha-crystallin was present at 2 mg/mL, very low levels of 
fluorescence change was witnessed over 30 minutes (Figure 5.8). Present at 1 mg/mL, 
alpha-crystallin showed an intermediate signal over background over this time scale 
(Figure 5.8). It is not clear whether the decrease in protein concentration allows the GalT 
reaction to proceed faster or if the increased protein concentration inhibits the capacity or 
fluorescent properties of the sensor. It is possible that the protein itself chelates metal 
away from 17-2Zn(II) or binds the sensor directly, inhibiting the accessibility for UDP to 
bind 17-2Zn(II). More studies are needed to elucidate these issues; however, this data 
suggests that it is possible to utilize this sensor to detect O-GlcNAc on glycoproteins and 
utilize glycoproteins as acceptor substrates.  
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Figure 5.8 Using fluorescent glycosyltransferase assay sensor 17-2Zn(II) to monitor reaction 
progress during chemoenzymatic labeling of alpha-crystallin. Readings were taken over one hour 
(top) and the first five minutes of the reaction are highlighted (bottom). Increasing the protein 
acceptor substrate concentration causes a decreased response in fluorescence.  
 
 This assay could be used to determine kinetic parameters that describe how a 
glycosyltransferase adds sugars onto specific glycoprotein substrates. One could envision 
an ELISA-type assay where proteins are immunoprecipitated in a well and changes in O-
GlcNAcylation on these proteins can be detected using 17-2Zn(II) based on rates of 
reaction. Taken together, this data demonstrates that this fluorescent assay can be used to 
monitor glycosyltransferase activity when utilizing glycoprotein acceptor substrates, 
opening the door for multiple possible applications for the glycobiology field.  
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CONCLUSION 
 In this chapter I have described the development of multiple glycosyltransferase 
assays that can be utilized in house to decrease cost and time used for monitoring 
glycosyltransferase activity of our chemoenzymatic labeling enzymes, GalT (O-GlcNAc) 
and GALT-1 (core fucose). These assays rely on LC-MS, HPLC, and fluorescence-based 
readouts. Optimization of the fluorescent sensor 17-2Zn(II), used to determine the kinetic 
parameters of GALT-1 towards its substrates, was also discussed. The 17-2Zn(II) sensor 
was finally used to monitor the GalT reaction to detect O-GlcNAc on a protein acceptor 
substrate, alpha-crystallin. This sensor also affords the ability to monitor 
glycosyltransferase reactions in a high-throughput fashion, enabling studies to identify a 
suite of glycosyltransferases amenable to chemoenzymatic labeling.  
 
EXPERIMENTAL METHODS  
General Reagents and Methods. Unless otherwise noted, reagents were purchased from 
the commercial suppliers Fisher (Fairlawn, NJ) or Sigma-Aldrich (St. Louis, MO). 
Alpha-crystallin, UDP and p-nitrophenol-GlcNAc were from ThermoFisher Scientific 
(Carlsbad, CA). Fluorescent assay were detected using the Flexstation 3 (Molecular 
Devices).  HPLC analysis was performed on an Agilent 1100 HPLC with C-18 reverse 
phase column (150 mm x 4.6 mm with 3.5 µm pore size).  
 
GALT-1 Activity Assay Monitoring with Fluorescent Sensor. The turn-on fluorescent 
sensor, 17-2Zn(II), detects UDP but not UDP-Gal.6,7  50 µL reactions were set up in 
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duplicate in a 96 well plate format as follows: 50 mM HEPES pH 7.4, 10 mM NaCl, 0.1 
mM MgCl2, 0.2 mM MnCl2, 0.3 mM ZnCl2, 2.5 µM 17-2Zn(II) sensor, 50 µM N6000, 1-
500 µM UDP-Gal, 0.2 mg/mL GALT-1. Background was determined with the same 
reaction conditions without N6000. Fluorescence was detected with excitation and 
emission wavelengths of 500 nm and 534 nm, respectively, with a 530 nm cutoff.  
 
Sensor Emission Profile Optimization. Mock Reactions were set up as above except 
UDP-Gal, N6000, and GALT-1 were omitted and a starting UDP concentration was set to 
1 mM. Serial dilutions were made into the same mock reaction buffer without UDP. One 
condition contained no UDP. Fluorescence was detected with an excitation wavelength 
set to 500 nm, previously determined, and emission profiles were determined by 
sweeping an emission range of 515 – 549 nm with a 530 nm cutoff. The λmax was 
determined to be 534nm. Raw data was worked up and plotted in excel.  
 
Determining the Effects of MnCl2 and 1% Triton X-100 on Sensor Performance. 
Mock reactions were set up as above, in the optimization experiments, except that either 
5 mm MnCl2 or 1% Triton X-100 were added to the solution. Increasing concentrations of 
UDP were added and fluorescence was determined as above. Raw data was plotted in 
EXCEL.  
 
LC-MS Analysis of GalT Reaction with p-nitrophenol-GlcNAc (18) and UDP-
ketoGal (2). The O-GlcNAc substrate 18 (100 µM) was dissolved in 10 mM HEPES pH 
7.5 and 5 mM MnCl2.  GalT enzyme and UDP-ketoGal (2) were added to final 
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concentrations of 0.1 mg/mL and 500 µM, respectively.  The reaction was incubated at 
room temperature in the dark for 12-16 h, and the reaction progress was monitored by 
LC-MS.  The samples were injected on a reverse-phase HPLC column (Phenomenex 
Gemini; 5 m, 2.0 x 100 mm), fitted with a C8 guard column, using a ThermoScientific 
Accela 600 HPLC pump interfaced with a ThermoScientific LTQ mass spectrometer.  A 
linear 3-90% gradient of B (A: 0.1% aqueous formic acid, B: 0.1% formic acid in MeCN) 
over 7 min was used to resolve peaks with a flow rate of 0.21 mL/min.  Mass analysis 
was performed in positive ion mode.   
 
HPLC Monitoring of GalT Reaction with p-nitrophenol-GlcNAc (18) and UDP-
ketoGal (2).    The reactions were set up as described above except that the total volume 
was 200 µL and reactions were added to LC/MS vials. Product formation was monitored 
at 280 nm by reverse phase-HPLC (Agilent 1100), and 10 µL time points were taken 
every 14 minutes over the course of 126 min using a linear, 3-95% gradient of B (A: 
0.1% aqueous trifluoroacetic acid B: 0.1% trifluoroacetic acid in MeCN) over 8 min with 
a flow rate of 1 mL/min.  Starting material and product formation percentages were 
quantified using area under the curve from the corresponding chromatograms.  
 
Fluorescent Sensor Monitoring of GalT Reaction with p-nitrophenol-GlcNAc and 
UDP-ketogal. Reactions were set up as for GALT-1 and UDP-Gal above, except that 
GalT (0.1 mg/mL) and UDP-ketoGal (20 µM) were used and p-nitrophenol-GlcNAc (X) 
was used at 0.05, 0.1, 0.2, and 0.5 mM. All reactions were performed in duplicate. 
Fluorescence was monitored as above.  
	  127 
 
Fluorescent Sensor Monitoring of GalT Reaction with alpha-crystallin Acceptor 
Substrate. Reactions were set up as above except that alpha-crystallin was substituted for 
p-nitrophenol-GlcNAc at 0, 0.5, 1, and 2 mg/mL. The 0 mg/mL acted as the negative 
control.   
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This data is organized with the highest signal for the 0.5 hr time point. All the data 
numbers, RFU, below for 0 – 12 hour time points are divided by 1000 from the raw data 
to simplify the viewing of this data. The chart # is in reference to the glycan number on 
the CFG glycan array, version 5.0. The fuc-gal # represents on of the Fucα(1-2)-Gal 
structures on the array. When reading the structure, a = alpha, b = beta, and sp = spacer 
number.  
 
Chart 
# 
Fuc-
gal 
# 
Structure 0  
hr 
0.5 
hr 
2  
hr 
12 
hr 
 - 12 
hr 
545 55 
Fuca1-2Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 5.2 43.6 44.8 46.4 3.0 
501 52 Fuca1-2Galb1-3(6S)GlcNAcb-Sp0 4.0 29.2 36.5 35.1 6.1 
75 17 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 1.4 27.3 41.7 38.3 5.3 
450 44 Fuca1-2Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)GalNAc-Sp14 4.8 26.5 31.7 43.7 6.6 
77 19 Fuca1-2Galb1-4GlcNAcb-Sp8 4.4 25.6 31.6 17.1 4.7 
430 41 Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 5.3 24.0 23.9 13.9 3.8 
67 9 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 3.7 23.9 25.2 15.3 2.5 
74 16 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4.8 23.1 29.4 34.7 3.0 
362 28 
Fuca1-2Galb1-4GlcNAcb1-2Mana1-
6(Fuca1-2Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 3.4 22.2 29.8 39.9 1.3 
423 39 Fuca1-2Galb1-3GlcNAcb1-3GalNAc-Sp14 0.7 22.0 20.9 26.7 6.6 
222 23 Fuca1-2Galb1-4(6S)GlcNAcb-Sp8 1.5 21.2 24.2 30.2 9.2 
60 2 Fuca1-2Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp9 4.8 20.1 31.9 11.2 2.2 
66 8 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp8 1.9 19.7 26.3 37.7 6.3 
361 27 
Fuca1-2Galb1-3GlcNAcb1-2Mana1-
6(Fuca1-2Galb1-3GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 1.4 17.4 25.3 30.8 1.1 
457 45 Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 1.8 17.4 28.1 37.3 7.0 
401 36 Fuca1-2Galb1-4GlcNAcb1-3GalNAca-Sp14 2.2 15.3 11.5 10.8 3.9 
78 20 Fuca1-2Galb1-4Glcb-Sp0 2.2 15.1 23.0 32.2 4.1 
65 7 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp9 2.4 14.5 21.2 33.8 4.9 
223 24 Fuca1-2(6S)Galb1-4(6S)Glcb-Sp0 5.0 14.2 21.1 37.0 15.1 
79 21 Fuca1-2Galb-Sp8 1.6 14.2 11.9 7.0 0.3 
369 30 Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)Galb1-4Glc-Sp21 3.7 13.5 20.4 37.8 3.4 
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263 26 Fuca1-2Galb1-4(6S)Glcb-Sp0 4.0 12.9 17.9 7.3 2.9 
63 5 Fuca1-2Galb1-3GalNAca-Sp14 0.8 12.6 15.6 26.2 4.8 
68 10 Fuca1-2Galb1-3GlcNAcb-Sp0 1.4 12.5 12.9 6.2 5.9 
69 11 Fuca1-2Galb1-3GlcNAcb-Sp8 3.1 12.1 10.0 7.0 1.8 
446 42 
Fuca1-2Galb1-4 GlcNAcb1-2Mana1-
6(Fuca1-2Galb1-4GlcNAcb1-2(Fuca1-
2Galb1-4GlcNAcb1-4)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 3.5 11.0 13.6 32.5 2.8 
27   (3S)Galb1-4(6S)Glcb-Sp8 2.8 11.0 14.2 23.1 19.3 
515   GalNAcb1-4(6S)GlcNAc-Sp8  4.7 10.8 16.4 13.3 5.3 
62 4 Fuca1-2Galb1-3GalNAca-Sp8 1.3 10.8 25.8 31.6 8.5 
76 18 Fuca1-2Galb1-4GlcNAcb-Sp0 2.4 10.7 11.9 25.5 3.0 
502 53 Fuca1-2(6S)Galb1-3(6S)GlcNAcb-Sp0 6.5 10.6 16.5 30.0 7.6 
542   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 5.4 10.5 14.6 16.3 14.4 
486   
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-
2)Mana1-6(Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 4.8 9.3 9.9 22.9 4.6 
390 34 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 2.3 9.2 12.4 18.9 5.1 
39   (6S)(4S)Galb1-4GlcNAcb-Sp0 2.7 9.1 14.1 22.2 12.0 
304   GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0 6.7 9.0 11.2 8.0 5.2 
427 40 
Fuca1-2Galb1-3GlcNAcb1-2Mana1-
6(Fuca1-2Galb1-3GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22 1.8 9.0 8.3 11.3 1.6 
268   Neu5Aca2-6Galb1-4(6S)GlcNAcb-Sp8 4.6 8.7 12.6 25.7 18.6 
445   (6S)Galb1-3(6S)GlcNAc-Sp0 3.7 8.4 17.7 27.7 16.7 
452   
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-
6(GalNAca1-3(Fuca1-2)Galb1-
4GlcNAcb1-3)GalNAc-Sp14 4.7 8.2 11.1 20.4 3.9 
159   Galb1-4GalNAcb1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 2.3 7.9 14.4 10.8 8.0 
391 35 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 0.8 7.8 8.8 14.8 2.5 
448   Galb1-4(Fuca1-3)GlcNAcb1-6GalNAc-Sp14 5.7 7.5 10.1 21.8 10.2 
64 6 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 0.5 7.5 15.1 20.1 4.4 
158   Galb1-4GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 4.2 7.4 8.8 9.0 3.3 
409   GalNAcb1-3Gala1-6Galb1-4Glcb-Sp8 3.4 7.1 10.6 10.9 4.7 
468   Gala1-3(Fuca1-2)Galb1-3GalNAca-Sp8 7.5 7.0 9.8 18.8 12.0 
429   
Galb1-3GlcNAcb1-6(Galb1-3GlcNAcb1-
2)Mana1-6(Galb1-3GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 4.6 7.0 7.0 9.9 2.6 
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433   
GlcNAcb1-2Mana1-6(GlcNAcb1-
4)(GlcNAcb1-4(GlcNAcb1-2)Mana1-
3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 2.8 6.9 10.5 10.0 4.5 
297   4S(3S)Galb1-4GlcNAcb-Sp0 3.4 6.9 9.1 11.9 7.2 
532   
Galb1-4GlcNAcb1-2 Mana1-6(GlcNAcb1-
4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 4.0 6.8 7.9 11.1 7.9 
306   Galb1-4GlcNAcb1-6Galb1-4GlcNAcb-Sp0 7.3 6.8 7.4 7.3 3.7 
499   Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAca-Sp14 2.0 6.8 12.1 33.9 13.0 
221 22 Fuca1-2(6S)Galb1-4GlcNAcb-Sp0 3.8 6.7 10.0 20.0 4.6 
103   Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp8 5.0 6.6 12.3 14.0 11.1 
387   
Galb1-3GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb1-6(Galb1-3GlcNAcb1-
3)Galb1-4Glc-Sp21  4.0 6.5 6.2 14.5 4.9 
303   Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0 2.6 6.5 8.2 14.1 3.6 
22   6S(3S)Galb1-4(6S)GlcNAcb-Sp0 4.7 6.4 6.3 12.2 8.9 
180   GlcNAcb1-3GalNAca-Sp8 3.5 6.4 7.6 16.7 7.6 
477   
Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-
4)(Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 4.9 6.4 9.2 12.0 4.9 
114   Gala1-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 3.9 6.4 5.8 7.4 9.1 
105   Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp8 7.1 6.4 12.4 8.5 6.1 
94   GalNAca1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 4.8 6.3 6.9 4.4 6.9 
529   GalNAcb1-4GlcNAcb1-2Mana-Sp0 1.5 6.3 8.4 16.9 4.1 
421 38 
Fuca1-2Galb1-4GlcNAcb1-2Mana1-
6(Fuca1-2Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22 0.7 6.3 12.9 15.6 3.1 
476   
GlcNAcb1-6(GlcNAcb1-2)Mana1-
6(GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 6.2 6.2 5.6 9.8 5.3 
543   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp24 4.6 6.2 12.0 16.2 3.1 
524   GalNAca1-3(Fuca1-2)Galb1-4 GlcNAcb1-2Mana-Sp0 7.9 6.2 6.7 10.9 2.9 
110   Gala1-4(Gala1-3)Galb1-4GlcNAcb-Sp8 4.7 6.2 9.4 19.4 6.9 
495 49 Fuca1-2Galb1-4GlcNAcb1-6GalNAca-Sp14 0.3 6.2 12.7 19.3 2.6 
212   
Mana1-2Mana1-6(Mana1-3)Mana1-
6(Mana1-2Mana1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 4.5 6.2 6.5 10.4 4.3 
179   GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAcb-Sp8 5.3 6.2 8.1 12.4 6.2 
61 3 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb-Sp8 2.5 6.2 12.5 16.9 8.1 
385 32 Galb1-4GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-3)Galb1-4Glc-Sp21 2.3 6.2 8.3 9.4 2.3 
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435   
GlcNAcb1-6(GlcNAcb1-2)Mana1-
6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-
2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp21 4.5 6.2 8.5 12.4 7.8 
73 15 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp8 2.0 6.1 9.2 6.3 3.7 
500 51 Fuca1-2Galb1-4GlcNAcb1-2Mana-Sp0 2.3 6.1 8.7 19.1 6.6 
560   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Mana1-
4GlcNAcb1-4GlcNAc-Sp24 3.7 6.1 5.8 12.2 2.4 
454   GalNAcb1-4Galb1-4Glcb-Sp0 2.2 6.1 7.5 13.0 5.1 
564   GalNAcb1-4GlcNAcb1-3GalNAcb1-4GlcNAcb-Sp0  4.6 6.1 10.6 10.5 4.0 
160   Galb1-4GlcNAcb1-3GalNAca-Sp8 4.6 6.0 6.6 13.1 7.2 
552   
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-6(Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp25 1.7 6.0 10.6 19.8 2.0 
317   
Mana1-2Mana1-6(Mana1-2Mana1-
3)Mana1-6(Mana1-2Mana1-2Mana1-
3)Mana-Sp9 3.4 5.9 4.5 5.8 10.3 
531   
GlcNAcb1-2 Mana1-6(GlcNAcb1-
4)(GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 6.4 5.9 5.5 10.3 5.4 
146   Galb1-3GalNAcb1-4Galb1-4Glcb-Sp8 3.4 5.8 8.1 11.3 6.2 
106   Gala1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 7.4 5.7 7.9 14.3 5.3 
24   (3S)Galb1-4(Fuca1-3)(6S)Glc-Sp0 5.0 5.7 8.9 11.5 8.8 
53   GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 3.7 5.6 7.8 6.5 6.9 
498 50 Fuca1-2(6S)Galb1-3GlcNAcb-Sp0 4.7 5.6 8.8 16.2 10.4 
503   Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 3.4 5.6 9.9 20.1 4.3 
104   Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 5.0 5.6 6.4 14.0 4.3 
35   (3S)Galb1-4(6S)GlcNAcb-Sp8 3.1 5.6 8.0 9.3 4.9 
208   Mana1-2Mana1-2Mana1-3Mana-Sp9 2.5 5.6 9.3 8.4 4.1 
96   GalNAcb1-3(Fuca1-2)Galb-Sp8 3.6 5.6 7.3 12.3 6.4 
19   Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAca-Sp8 7.6 5.6 8.1 11.9 2.7 
451   
Gala1-3Fuca1-2Galb1-4GlcNAcb1-
6(Gala1-3Fuca1-2Galb1-4GlcNAcb1-
3)GalNAc-Sp14 4.6 5.5 7.5 12.9 4.3 
170   Galb1-4GlcNAcb-Sp8 1.0 5.5 7.5 5.9 5.5 
447 43 
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-
2Mana1-6(Fuca1-2Galb1-4(Fuca1-
3)GlcNAcb1-4(Fuca1-2Galb1-4(Fuca1-
3)GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 1.5 5.5 6.0 5.9 5.5 
213   
Mana1-2Mana1-6(Mana1-2Mana1-
3)Mana1-6(Mana1-2Mana1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 4.6 5.5 8.5 12.5 2.9 
	   133	  
164   Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4.5 5.4 7.3 10.5 1.2 
459   
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-
2)Mana1-6(Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 3.2 5.4 6.9 14.9 4.4 
248   Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4.3 5.3 3.8 6.6 2.9 
72 14 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp0 3.6 5.3 7.3 10.4 6.5 
370   
Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-4(Galb1-4GlcNAcb1-
2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp21 4.2 5.3 8.9 10.4 2.2 
41   (6P)Mana-Sp8 2.2 5.2 11.1 31.9 6.6 
434   
GlcNAcb1-6(GlcNAcb1-2)Mana1-
6(GlcNAcb1-4)(GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 1.0 5.2 7.4 7.3 4.9 
510   Galb1-3GlcNAca1-3Galb1-4GlcNAcb-Sp8  2.1 5.2 15.2 14.9 7.4 
563   GalNAcb1-3GlcNAcb-Sp0  4.2 5.2 8.5 8.2 1.4 
195   GlcNAcb1-6Galb1-4GlcNAcb-Sp8 3.8 5.1 5.7 7.8 5.6 
124   Gala1-4GlcNAcb-Sp8 3.5 5.1 7.5 9.7 4.7 
250   Neu5Aca2-3Galb1-3GlcNAcb-Sp0 4.3 5.1 5.3 3.9 3.4 
90   GalNAca1-3(Fuca1-2)Galb-Sp8 3.0 5.1 3.9 8.3 8.8 
378   Neu5Aca2-6Galb1-4GlcNAcb1-3GalNAc-Sp14 3.6 5.1 7.4 8.3 2.8 
188   GlcNAcb1-6(GlcNAcb1-4)GalNAca-Sp8 3.9 5.1 2.2 0.0 5.2 
530   Neu5Aca2-3Galb1-3GlcNAcb1-4Galb1-4Glcb-Sp0 1.2 5.0 10.5 25.4 11.7 
34   (3S)Galb1-4(6S)GlcNAcb-Sp0 3.0 5.0 8.0 11.0 3.9 
224   Neu5Aca2-3Galb1-3GalNAca-Sp8 1.6 5.0 5.4 10.3 4.1 
479   Neu5Aca2-3Galb1-4GlcNAcb1-2Mana-Sp0 4.0 5.0 9.6 17.9 5.4 
253   Neu5Aca2-3Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 3.3 4.9 7.6 19.1 6.7 
426   Gala1-3Galb1-3GlcNAcb1-3GalNAc-Sp14 4.1 4.9 6.6 13.8 6.0 
174   GlcNAca1-3Galb1-4GlcNAcb-Sp8 2.4 4.9 5.5 3.8 4.4 
377   Neu5Aca2-3Galb1-4GlcNAcb1-3GalNAc-Sp14 1.9 4.9 5.5 7.6 3.7 
386 33 
Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-
4(Fuca1-2Galb1-3)GlcNAcb1-3)Galb1-
4Glc-Sp21 1.1 4.9 8.4 8.0 4.4 
417 37 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 7.6 4.9 7.3 8.1 3.5 
453   
Neu5Aca2-8Neu5Aca2-3Galb1-
3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-
3)Galb1-4Glcb-Sp0 6.0 4.8 5.6 9.8 3.0 
219   Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 1.9 4.8 5.5 5.0 2.7 
126   Galb1-2Galb-Sp8 3.0 4.8 9.5 16.4 10.5 
344   GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 3.6 4.8 5.6 4.6 5.0 
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20   Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAc-Sp14 2.9 4.8 6.9 8.4 3.4 
167   Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp8 6.8 4.8 7.8 9.3 6.4 
388   
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-
2)Mana1-6(Galb1-4GlcNAcb1-4(Galb1-
4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 2.5 4.8 8.2 8.6 5.3 
220   (3S)Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8  3.3 4.8 14.3 26.4 13.9 
342   GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 3.3 4.7 3.2 3.6 4.0 
536   GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAc-Sp0 2.9 4.7 4.8 6.4 3.4 
231   Neu5Aca2-3(6S)Galb1-4(Fuca1-3)GlcNAcb-Sp8 1.7 4.7 10.6 20.5 10.9 
573   
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-
6(Galb1-3GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 4.6 4.7 9.5 30.0 3.1 
478   Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glcb-Sp21 3.3 4.7 7.5 14.7 3.6 
449   Galb1-4GlcNAcb1-2Mana-Sp0 2.3 4.7 5.9 10.0 6.8 
210   Mana1-2Mana1-3Mana-Sp9 2.9 4.7 4.7 4.7 3.8 
328   
Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-
6(Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 4.0 4.7 8.4 19.9 5.2 
209   Mana1-2Mana1-6(Mana1-2Mana1-3)Mana-Sp9 1.2 4.7 9.1 7.7 7.4 
392   Galb1-3GlcNAcb1-3GalNAca-Sp14 4.2 4.7 5.3 9.1 2.8 
407   Galb1-3GlcNAcb1-6Galb1-4GlcNAcb-Sp0 11.7 4.7 4.5 6.8 1.7 
337   
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-
Sp0 3.5 4.6 6.4 9.2 4.5 
376 31 
Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-
2Mana1-3(Fuca1-4(Fuca1-2Galb1-
3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp19 5.3 4.6 6.4 10.3 5.9 
128   Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 5.5 4.6 8.4 10.4 7.1 
403   GalNAca1-3GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 3.0 4.6 6.8 7.6 3.1 
149   Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 0.8 4.6 5.6 7.9 5.2 
95   GalNAcb1-3GalNAca-Sp8 2.0 4.6 5.2 2.5 3.8 
87   GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 3.0 4.6 4.8 8.1 3.9 
431   Fuca1-3GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4Glc-Sp21 7.5 4.6 6.7 8.5 2.7 
416   GalNAca1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 3.0 4.6 5.0 6.6 3.9 
252   Neu5Aca2-3Galb1-4(6S)GlcNAcb-Sp8 3.3 4.5 10.7 23.9 7.8 
85   (3S)Galb1-4(Fuca1-3)Glcb-Sp0 1.9 4.5 8.3 13.9 9.4 
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45   (6S)Galb1-4(6S)Glcb-Sp8 2.7 4.5 8.9 9.8 3.9 
139   Neu5Aca2-6(Galb1-3)GlcNAcb1-4Galb1-4Glcb-Sp10 2.5 4.5 6.1 11.3 5.0 
513   (6S)GalNAcb1-4GlcNAc-Sp8  3.7 4.5 9.0 15.7 4.3 
29   (3S)Galb1-3GalNAca-Sp8 1.5 4.5 5.7 5.7 5.8 
381   Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glc-Sp0 4.2 4.5 3.8 6.9 1.9 
322   Neu5Aca2-8Neu5Acb-Sp17 4.2 4.4 11.8 13.3 6.2 
165   Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 3.4 4.4 6.3 8.6 3.4 
567   GlcNAb1-3Galb1-3GalNAc-Sp14 0.3 4.4 2.7 6.1 2.5 
402   Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 5.3 4.4 6.1 12.4 2.8 
528   Gala1-3Galb1-3GlcNAcb1-2Mana-Sp0 3.6 4.4 7.5 14.4 5.8 
177   GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp8 6.8 4.4 4.8 7.2 2.6 
546   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 7.4 4.4 6.5 8.2 2.7 
51   Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 1.1 4.4 7.3 5.7 6.0 
70 12 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 2.9 4.4 4.8 4.3 3.5 
308   GlcAb1-3GlcNAcb-Sp8 4.5 4.4 5.3 7.1 1.4 
331   Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 3.5 4.4 5.5 8.1 2.3 
394   GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 3.8 4.4 4.9 9.5 4.4 
523   Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana-Sp0 3.7 4.3 3.9 6.6 4.4 
518   Galb1-4(6P)GlcNAcb-Sp0  1.4 4.3 5.4 25.4 6.5 
425   GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 4.1 4.3 6.3 7.7 6.4 
469   Gala1-3(Fuca1-2)Galb1-3GalNAcb-Sp8 8.6 4.3 5.4 3.9 3.5 
86   GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 1.1 4.3 8.5 6.7 6.0 
295   Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0        4.0 4.3 6.2 6.6 3.1 
438   
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-4)(Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 2.5 4.3 3.6 4.2 4.7 
305   Galb1-4GlcNAca1-6Galb1-4GlcNAcb-Sp0 7.0 4.3 7.6 12.7 3.6 
291   Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp0  3.5 4.3 7.3 10.3 5.9 
508   
GlcNAcb1-6(GlcNAcb1-2)Mana1-
6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-
2)Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAc-Sp21 1.2 4.3 9.7 8.7 5.9 
279   Neu5Acb2-6GalNAca-Sp8 2.2 4.3 7.5 14.4 9.9 
30   (3S)Galb1-3GlcNAcb-Sp0 2.9 4.3 7.0 7.5 6.0 
111   Gala1-3GalNAca-Sp8 1.0 4.2 6.5 9.7 6.8 
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379   Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 5.3 4.2 5.9 6.9 2.1 
28   (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp8 3.7 4.2 6.3 8.1 6.4 
147   Galb1-3Galb-Sp8 0.8 4.2 4.9 5.0 3.4 
408   Galb1-3GlcNAca1-6Galb1-4GlcNAcb-Sp0 11.0 4.2 5.5 4.4 3.0 
32   (3S)Galb1-4(Fuca1-3)GlcNAc-Sp0  3.1 4.1 7.6 10.2 4.6 
102   Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 3.4 4.1 8.3 12.2 7.0 
21   GlcNAcb1-6(GlcNAcb1-4)(GlcNAcb1-3)GlcNAc-Sp8 4.9 4.1 5.3 8.7 2.1 
533   
Galb1-4GlcNAcb1-2 Mana1-6(Galb1-
4GlcNAcb1-4)(Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAc-Sp21 6.5 4.1 6.0 8.7 2.7 
356   (6S)GlcNAcb1-3Galb1-4GlcNAcb-Sp0 5.1 4.1 6.2 7.7 2.6 
42   (6S)Galb1-4Glcb-Sp0 1.0 4.1 7.7 28.0 13.4 
506 54 Fuca1-2Galb1-3GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)GalNAca-Sp14 0.1 4.1 8.1 14.0 2.1 
154   Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 4.6 4.1 4.4 7.7 0.8 
397   
Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-
6(Neu5Aca2-3Galb1-3GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp19 1.4 4.1 9.7 15.8 14.2 
410   Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)Glcb-Sp21 1.0 4.1 7.9 10.2 6.4 
547   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp25 6.3 4.1 5.1 9.5 2.0 
522   Gala1-3Galb1-4GlcNAcb1-2Mana-Sp0 5.5 4.0 6.4 10.3 6.5 
233   GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp8 1.9 4.0 5.8 10.4 6.8 
559   
GlcNAcb1-3Galb1-4GlcNAcb1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-2Man a1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp24 4.1 4.0 1.0 -0.9 3.4 
173   Galb1-4Glcb-Sp8 2.1 4.0 9.7 19.9 11.8 
269   Neu5Aca2-6Galb1-4GlcNAcb-Sp0 3.7 4.0 5.2 8.9 4.9 
330   Neu5,9Ac2a2-3Galb1-3GlcNAcb-Sp0 2.5 4.0 6.6 11.3 2.9 
399   
Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp12 1.0 4.0 5.1 6.4 4.9 
419   GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 6.3 4.0 7.1 11.7 2.4 
267   Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 3.0 4.0 6.5 9.1 2.0 
473 46 
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-
2Mana1-6(Fuca1-2Galb1-4(Fuca1-
3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 4.8 4.0 8.5 10.7 4.7 
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155   
Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb-Sp0 4.8 4.0 6.7 6.4 2.6 
166   Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp8 5.0 4.0 6.1 5.8 2.3 
300   Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3)GalNAca-Sp14 2.9 3.9 4.7 6.5 2.6 
108   Gala1-3(Fuca1-2)Galb-Sp8 4.8 3.9 5.3 10.1 1.0 
316   Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Mana-Sp9 4.6 3.9 6.3 12.4 3.8 
119   Gala1-3Galb-Sp8 1.1 3.9 4.1 5.9 4.6 
134   GlcNAcb1-6(Galb1-3)GalNAca-Sp8  1.8 3.9 6.3 9.4 4.7 
535   Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 1.9 3.9 4.6 10.7 2.3 
57   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-2Man-
a1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 1.6 3.9 5.1 7.1 2.4 
411   Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 2.4 3.9 4.0 8.5 3.0 
541   
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp25 0.9 3.8 4.1 6.6 2.5 
132   Galb1-4GlcNAcb1-6GalNAca-Sp8 4.4 3.8 6.3 5.4 3.3 
236   Neu5Aca2-6(Neu5Aca2-3)GalNAca-Sp8 1.8 3.8 5.8 10.2 2.7 
538   Gala1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 5.6 3.8 5.9 10.0 3.2 
189   GlcNAcb1-4Galb1-4GlcNAcb-Sp8 4.5 3.8 3.7 6.4 0.8 
293   Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 4.1 3.8 6.7 10.8 3.7 
131   Fuca1-4(Galb1-3)GlcNAcb-Sp8 4.9 3.8 5.6 11.4 0.9 
83   GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 3.0 3.8 5.9 3.1 2.1 
343   
GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb-Sp0 1.7 3.8 5.4 6.5 6.9 
71 13 
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb-Sp0 2.7 3.8 5.7 2.5 2.3 
23   6S(3S)Galb1-4GlcNAcb-Sp0 3.6 3.8 9.8 13.6 3.6 
184   GlcNAcb1-3Galb1-4GlcNAcb-Sp8 1.2 3.8 5.7 1.7 6.5 
238   Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0 3.4 3.8 6.4 7.7 3.8 
389   
GlcNAcb1-2Mana1-6(GlcNAcb1-
4(GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 5.9 3.8 6.3 8.9 3.1 
584   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 4.5 3.7 3.3 1.5 2.0 
368   Neu5Aca2-6GlcNAcb1-4GlcNAcb1-4GlcNAc-Sp21 3.8 3.7 5.6 4.2 3.1 
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418   Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 3.0 3.7 5.0 5.4 3.7 
127   Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 4.1 3.7 5.9 9.6 5.3 
183   GlcNAcb1-3Galb1-4GlcNAcb-Sp0 2.1 3.7 4.4 7.9 4.8 
43   (6S)Galb1-4Glcb-Sp8 1.1 3.7 6.5 10.8 3.4 
384   Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21  6.6 3.7 3.7 4.8 1.2 
382   Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 5.4 3.7 5.0 9.2 2.0 
186   GlcNAcb1-3Galb1-4Glcb-Sp0 2.2 3.7 4.4 9.9 9.8 
182   GlcNAcb1-3Galb-Sp8 0.7 3.7 8.6 12.5 10.2 
18   GlcN(Gc)b-Sp8 3.1 3.7 4.5 20.4 7.3 
335   GalNAcb1-3Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 5.7 3.7 8.1 4.9 3.0 
511   Galb1-3(6S)GlcNAcb-Sp8  3.2 3.6 7.4 19.7 4.8 
436   
Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-
4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 1.4 3.6 5.5 11.3 7.0 
175   GlcNAca1-6Galb1-4GlcNAcb-Sp8 5.8 3.6 7.5 8.1 4.1 
3   Mana-Sp8 1.4 3.6 8.4 13.5 14.8 
153   Galb1-4(Fuca1-3)GlcNAcb-Sp8 3.5 3.6 4.7 2.0 2.0 
54   
Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 2.9 3.6 4.3 9.0 5.7 
441   Galb1-6Galb-Sp10 1.1 3.6 7.4 11.3 4.2 
161   Galb1-4GlcNAcb1-3GalNAc-Sp14 0.3 3.6 4.4 14.4 5.3 
483   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 1.3 3.6 2.5 4.0 1.7 
44   (6S)Galb1-4GlcNAcb-Sp8 1.8 3.6 6.2 7.7 5.7 
266   Neu5Aca2-6GalNAca-Sp8 2.9 3.5 5.3 7.5 2.9 
140   Galb1-3GalNAca-Sp8 2.2 3.5 4.9 6.7 8.4 
150   Galb1-3GlcNAcb-Sp0 3.2 3.5 6.3 9.5 6.0 
215   Mana1-2Mana1-2Mana1-6(Mana1-3)Mana-Sp9 6.8 3.5 7.6 10.1 2.4 
383   Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glcb-Sp0 5.0 3.5 4.7 5.6 1.4 
251   Neu5Aca2-3Galb1-3GlcNAcb-Sp8 4.3 3.5 6.6 6.1 4.3 
130   Galb1-3(Fuca1-4)GlcNAc-Sp8  6.6 3.5 5.2 5.9 3.9 
26   (3S)Galb1-4(6S)Glcb-Sp0 3.4 3.5 15.5 26.1 10.8 
200   Glcb1-6Glcb-Sp8 2.1 3.5 5.9 16.9 10.5 
256   Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 2.5 3.4 4.8 6.5 4.8 
549   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp24 4.8 3.4 4.1 7.2 0.2 
491   Galb1-3(Fuca1-4)GlcNAcb1-6GalNAca-Sp14 3.0 3.4 3.9 9.6 1.5 
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340   GlcNAca1-4Galb1-4GlcNAcb-Sp0 2.2 3.4 5.0 9.6 8.9 
504   GalNAcb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 3.0 3.4 7.6 9.5 3.5 
120   Gala1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 8.3 3.4 4.4 4.3 1.9 
605   GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 3.5 3.4 1.7 5.7 2.4 
242   Neu5Aca2-3Galb1-4(Neu5Aca2-3Galb1-3)GlcNAcb-Sp8 2.4 3.4 6.7 8.6 4.0 
204   GlcAb1-3Galb-Sp8 1.4 3.4 4.1 14.4 6.0 
338   Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAc-Sp14 2.1 3.4 4.7 7.0 1.2 
525    Galb1-3GlcNAcb1-2Mana-Sp0 4.5 3.4 4.9 4.6 0.9 
244   Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp8 2.5 3.4 6.9 14.7 3.1 
521   Neu5Aca2-6Galb1-4GlcNAcb1-2Man-Sp0 1.0 3.4 6.2 11.1 11.5 
101   Gala1-2Galb-Sp8 1.9 3.4 5.8 11.6 3.8 
424   Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 3.2 3.4 6.5 12.6 7.8 
534   Fuca1-4(Galb1-3)GlcNAcb1-2 Mana-Sp0 2.3 3.3 5.4 13.4 5.6 
190   GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-Sp8 2.2 3.3 6.0 10.5 2.4 
49   Neu5,9Ac2a2-6Galb1-4GlcNAcb-Sp8 1.3 3.3 6.5 3.6 2.5 
92   GalNAca1-3GalNAcb-Sp8 2.3 3.3 3.6 2.1 4.1 
590   Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 4.9 3.3 2.0 6.3 1.7 
444   (6S)Galb1-3GlcNAcb-Sp0 1.7 3.3 5.4 12.6 8.5 
324   Neu5Gcb2-6Galb1-4GlcNAc-Sp8 4.8 3.3 6.2 5.5 3.0 
405   
Gala1-4Galb1-4GlcNAcb1-2Mana1-
6(Gala1-4Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 6.3 3.3 0.9 1.7 0.1 
599   GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 3.2 3.3 4.2 9.6 3.5 
55   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 2.2 3.3 5.7 7.3 1.6 
249 25 Fuca1-2(6S)Galb1-4Glcb-Sp0 0.9 3.2 6.8 10.2 2.3 
25   (3S)Galb1-4Glcb-Sp8 0.7 3.2 6.9 8.3 7.0 
292   Galb1-4(Fuca1-3)(6S)Glcb-Sp0 1.5 3.2 4.9 8.3 2.9 
107   Gala1-3(Fuca1-2)Galb1-4Glcb-Sp0 4.0 3.2 5.5 8.1 4.4 
432   
GlcNAcb1-2Mana1-6(GlcNAcb1-
4)(GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 6.9 3.2 5.5 9.0 2.5 
554   Neu5Aca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 1.3 3.2 6.4 8.6 5.4 
88   GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 0.9 3.2 5.0 6.4 7.9 
59 1 Fuca1-2Galb1-3GalNAcb1-3Gala-Sp9 1.2 3.2 6.2 4.6 2.2 
36   (3S)Galb1-4GlcNAcb-Sp0 3.3 3.2 6.6 5.5 2.9 
575   
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 5.1 3.2 3.8 5.3 0.9 
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205   GlcAb1-6Galb-Sp8 2.9 3.2 13.7 21.4 7.8 
192   GlcNAcb1-4GlcNAcb1-4GlcNAcb-Sp8 4.4 3.2 5.6 8.2 1.9 
84   GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 3.2 3.2 5.6 6.3 2.1 
493   (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp0 4.3 3.2 5.3 6.9 3.2 
593   Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 4.3 3.2 6.1 9.7 3.9 
115   Gala1-3Galb1-3GlcNAcb-Sp0 0.8 3.2 6.2 7.8 9.3 
270   Neu5Aca2-6Galb1-4GlcNAcb-Sp8 3.4 3.2 3.3 3.7 2.0 
243   Neu5Aca2-3Galb1-3(6S)GalNAca-Sp8 2.7 3.2 9.6 21.3 8.5 
282   Neu5Gca2-3Galb1-3GlcNAcb-Sp0 3.4 3.2 6.2 9.1 3.7 
480   Neu5Aca2-3Galb1-4GlcNAcb1-6GalNAca-Sp14 1.8 3.1 8.6 18.5 3.6 
202   GlcAa-Sp8 0.9 3.1 7.2 8.1 5.6 
375   
Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-
2Mana1-6(Gala1-3(Fuca1-2)Galb1-
3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 1.0 3.1 3.8 1.9 3.4 
539   Galb1-3GalNAcb1-3Gal-Sp21 0.9 3.1 5.7 11.1 4.1 
91   GalNAca1-3(Fuca1-2)Galb-Sp18 2.9 3.1 4.8 5.6 2.7 
172   Galb1-4Glcb-Sp0 0.7 3.1 4.9 8.4 8.9 
284   Neu5Gca2-3Galb1-4GlcNAcb-Sp0 2.8 3.1 6.0 9.9 1.9 
46   Neu5Aca2-3(6S)Galb1-4GlcNAcb-Sp8 1.8 3.1 5.6 10.0 6.1 
404   
Gala1-4Galb1-3GlcNAcb1-2Mana1-
6(Gala1-4Galb1-3GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 5.1 3.1 2.6 5.7 1.2 
156   Galb1-4(6S)Glcb-Sp0 1.6 3.1 5.4 18.0 5.9 
603   Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 0.9 3.1 2.1 5.8 1.9 
257   Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 1.1 3.1 5.3 5.7 5.9 
474 47 
Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-
2Mana1-6(Fuca1-2Galb1-3(Fuca1-
4)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb1-
4(Fuca1-6)GlcNAcb-Sp19 1.9 3.1 5.2 15.6 3.8 
481   Neu5Aca2-6Galb1-4GlcNAcb1-6GalNAca-Sp14 4.2 3.1 8.4 18.5 6.5 
336   GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 6.3 3.0 4.2 6.1 2.7 
97   GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 4.6 3.0 6.3 5.6 2.1 
280   Neu5Acb2-6Galb1-4GlcNAcb-Sp8 0.9 3.0 8.1 5.0 5.5 
519   (6P)Galb1-4GlcNAcb-SP0  1.1 3.0 7.1 10.8 15.8 
281   Neu5Gca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 3.0 3.0 5.8 3.7 4.6 
152   Galb1-4(Fuca1-3)GlcNAcb-Sp0 4.8 3.0 6.6 7.8 3.7 
380   
GalNAcb1-4GlcNAcb1-2Mana1-
6(GalNAcb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 1.0 3.0 0.4 5.7 0.0 
113   Gala1-3GalNAcb-Sp8 0.7 3.0 10.4 12.7 7.9 
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406   Gala1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 4.0 3.0 4.0 4.8 2.2 
442   Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 2.8 3.0 3.4 8.3 4.5 
47   (6S)GlcNAcb-Sp8 4.0 3.0 7.5 10.5 4.1 
298   (6S)Galb1-4(6S)GlcNAcb-Sp0 2.7 3.0 9.2 9.4 12.0 
37   (3S)Galb1-4GlcNAcb-Sp8 1.3 2.9 4.6 8.2 3.3 
439   
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-4)(Galb1-
4GlcNAcb1-4(Galb1-4GlcNAcb1-
2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp21 5.3 2.9 6.0 10.4 1.5 
245   Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 2.4 2.9 3.5 4.1 5.6 
117   Gala1-3Galb1-4Glcb-Sp0 2.4 2.9 11.8 10.2 9.7 
482   
Neu5Aca2-6Galb1-4 GlcNAcb1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-
3)GalNAca-Sp14 2.0 2.9 2.2 7.6 2.8 
191   GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-Sp8 3.8 2.9 7.0 4.1 2.1 
246   Neu5Aca2-3Galb-Sp8 2.4 2.9 4.3 9.5 5.1 
122   Gala1-4Galb1-4GlcNAcb-Sp8 4.3 2.9 5.0 7.3 3.9 
400   Neu5Aca2-3Galb1-3GlcNAcb1-3GalNAca-Sp14 2.3 2.9 4.0 5.6 5.0 
4   GalNAca-Sp8 1.5 2.9 4.9 10.7 8.1 
163   Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 2.7 2.9 5.4 8.2 4.7 
185   GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 3.5 2.9 5.6 9.2 3.8 
38   (3S)Galb-Sp8 0.5 2.9 8.9 18.3 14.1 
287   Neu5Gca2-6Galb1-4GlcNAcb-Sp0 4.7 2.9 1.2 2.0 1.7 
496   Gala1-3Galb1-4GlcNAcb1-6GalNAca-Sp14 2.9 2.9 5.7 6.9 2.6 
145   Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 3.1 2.9 5.4 7.0 4.1 
11   Neu5Acb-Sp8 1.3 2.9 5.2 7.6 2.1 
586   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 3.6 2.9 3.1 2.6 1.4 
290   Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 2.0 2.8 6.4 7.1 3.0 
334   Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 5.4 2.8 4.2 3.9 1.6 
365   Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 1.9 2.8 1.9 5.1 1.2 
116   Gala1-3Galb1-4GlcNAcb-Sp8 3.9 2.8 5.1 12.6 4.2 
13   Glcb-Sp8 1.4 2.8 10.0 22.6 9.6 
199   Glcb1-4Glcb-Sp8 0.4 2.8 6.5 10.5 11.5 
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207   KDNa2-3Galb1-4GlcNAcb-Sp0 2.0 2.8 4.9 6.4 0.8 
157   Galb1-4(6S)Glcb-Sp8 2.3 2.8 5.2 16.1 4.8 
516   (3S)GalNAcb1-4GlcNAc-Sp8  3.2 2.8 6.7 7.5 4.2 
93   GalNAca1-3Galb-Sp8 2.4 2.8 2.5 3.3 3.3 
537   GalNAca1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 5.9 2.8 8.5 7.1 4.6 
176   GlcNAcb1-2Galb1-3GalNAca-Sp8 3.3 2.8 4.5 2.9 2.4 
351   Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 3.0 2.7 5.4 9.0 5.1 
358   KDNa2-6Galb1-4GlcNAc-Sp0 5.1 2.7 4.4 6.9 2.3 
143   Galb1-3GalNAcb-Sp8 7.2 2.7 3.5 5.3 2.1 
315   Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb-Sp10 0.9 2.7 5.6 7.5 3.8 
367   Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21 2.9 2.7 3.4 3.2 2.5 
255   Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 0.6 2.7 7.5 6.8 3.7 
211   
Mana1-6(Mana1-2Mana1-3)Mana1-
6(Mana1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12 0.6 2.7 4.1 7.6 6.1 
329   Neu5,9Ac2a2-3Galb1-4GlcNAcb-Sp0 1.9 2.7 5.0 7.5 3.0 
144   Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 2.8 2.7 5.9 6.0 2.4 
33   (3S)Galb1-4(Fuca1-3)GlcNAc-Sp8 3.0 2.7 4.5 4.9 0.8 
8   Rhaa-Sp8 1.5 2.7 3.0 5.0 0.1 
228   Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 2.0 2.6 4.2 4.6 1.2 
414   Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 2.4 2.6 4.2 5.9 3.9 
234   GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 0.9 2.6 4.9 8.7 9.5 
133   Galb1-4GlcNAcb1-6GalNAc-Sp14 1.9 2.6 11.6 24.8 7.3 
339   GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 3.3 2.6 4.6 8.3 2.8 
283   Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 2.9 2.6 5.5 6.4 2.1 
514   (3S)GalNAcb1-4(3S)GlcNAc-Sp8 2.6 2.6 3.9 9.0 4.2 
129   Galb1-3(Fuca1-4)GlcNAc-Sp0  4.2 2.6 5.8 7.1 3.7 
232   GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp0 0.8 2.6 6.3 4.4 4.4 
52   GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 2.4 2.6 3.3 5.0 3.5 
555   Neu5Gca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 1.4 2.6 4.1 7.9 5.0 
121   Gala1-4Galb1-4GlcNAcb-Sp0 2.8 2.5 5.4 5.0 1.9 
301   Galb1-3Galb1-4GlcNAcb-Sp8 2.3 2.5 5.3 5.7 2.9 
310   GlcNAcb1-3Man-Sp10 2.1 2.5 3.4 1.2 1.7 
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572   
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 0.5 2.5 8.9 15.2 3.6 
40   (4S)Galb1-4GlcNAcb-Sp8 1.0 2.5 5.1 16.1 13.7 
31   (3S)Galb1-3GlcNAcb-Sp8 2.6 2.5 5.9 5.6 2.8 
118   Gala1-3Galb1-4Glc-Sp10 3.1 2.5 6.0 6.2 2.1 
171   Galb1-4GlcNAcb-Sp23 1.3 2.5 6.1 7.6 3.3 
151   Galb1-3GlcNAcb-Sp8 1.9 2.5 6.8 2.6 3.4 
10   Neu5Aca-Sp11 1.5 2.5 6.5 10.7 3.8 
278   Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 0.5 2.5 6.7 6.2 2.9 
520   GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAc-Sp14 2.2 2.5 4.7 7.3 2.1 
363 29 
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-
2Mana1-6(Fuca1-2Galb1-4(Fuca1-
3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAb-Sp20 2.0 2.5 1.1 1.7 1.4 
325   
Galb1-3GlcNAcb1-2Mana1-6(Galb1-
3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp19 1.9 2.5 5.2 14.6 0.7 
254   
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb-Sp0 1.0 2.5 3.6 3.2 2.3 
138   Neu5Acb2-6(Galb1-3)GalNAca-Sp8 0.6 2.4 7.8 6.3 5.6 
265   Neu5Aca2-3Galb1-4Glcb-Sp8 1.8 2.4 4.6 5.1 3.3 
455   
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-
2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 5.2 2.4 6.3 7.2 4.4 
81   Fuca1-4GlcNAcb-Sp8 0.5 2.4 4.0 4.0 1.3 
544   
Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(Neu5Gca2-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp24 2.6 2.4 2.3 2.9 2.7 
277   Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 0.5 2.4 5.6 15.8 5.7 
484   
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 1.3 2.4 3.4 6.8 3.3 
162   
Galb1-4GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-
Sp0 4.1 2.4 5.8 11.9 2.4 
16   GlcNAcb-Sp0 0.1 2.4 3.4 11.7 8.4 
136   Neu5Aca2-6(Galb1-3)GalNAca-Sp8 0.6 2.4 7.6 7.8 4.3 
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373   
Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-
2Mana1-6(Gala1-3Galb1-4(Fuca1-
3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 1.1 2.4 4.1 3.0 1.5 
350   Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 3.0 2.4 5.1 6.9 2.6 
169   Galb1-4GlcNAcb-Sp0 1.6 2.3 3.8 4.5 3.5 
553   Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 0.2 2.3 3.9 12.2 4.2 
307   GalNAcb1-3Galb-Sp8 3.2 2.3 5.3 7.9 0.1 
571   (3S)GlcAb1-3Galb1-4GlcNAcb1-2Mana-Sp0 2.8 2.3 2.8 15.7 6.7 
437   
Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-
4)(Galb1-4GlcNAcb1-4(Galb1-
4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 4.2 2.3 6.0 11.6 2.9 
100   GalNAcb1-4GlcNAcb-Sp8 2.1 2.3 6.6 9.1 4.1 
398   
GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp12 1.9 2.3 5.0 8.4 2.1 
1   Gala-Sp8 1.0 2.3 7.5 8.5 9.4 
259   Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4.1 2.3 3.1 1.8 1.0 
123   Gala1-4Galb1-4Glcb-Sp0 1.1 2.3 5.1 5.9 3.2 
602   Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 1.4 2.3 3.1 10.2 2.6 
352   Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 3.6 2.3 4.8 6.4 1.1 
235   Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 2.7 2.3 3.6 4.4 1.2 
600   Galb1-4GlcNAcb1-3Galb1-3GalNAca-Sp14 0.3 2.3 7.6 11.0 2.1 
258   Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4GlcNAcb-Sp8 4.7 2.2 1.7 2.5 -0.8 
2   Glca-Sp8 2.9 2.2 12.4 23.8 9.7 
512   (6S)(4S)GalNAcb1-4GlcNAc-Sp8 2.6 2.2 5.3 6.0 5.2 
526   Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAc-Sp14 4.2 2.2 1.8 9.9 1.8 
218   Manb1-4GlcNAcb-Sp0 1.6 2.2 4.0 4.0 2.0 
488 48 
Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-
2Galb1-4(Fuca1-3)GlcNAcb1-3)Galb1-
4Glc-Sp21 2.4 2.2 5.6 15.5 2.5 
591   Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 3.3 2.2 2.5 11.0 1.1 
566   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp25 0.5 2.2 3.7 4.1 1.8 
345   GlcNAca1-4Galb1-3GalNAc-Sp14 -1.5 2.2 4.3 4.0 5.9 
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5   GalNAca-Sp15 0.9 2.2 4.8 6.4 5.6 
125   Gala1-6Glcb-Sp8 1.3 2.1 7.2 20.0 6.1 
557   Neu5Gca2-8Neu5Gca2-6Galb1-4GlcNAc-Sp0 0.9 2.1 4.4 7.1 3.8 
589   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4G 0.3 2.1 4.1 9.4 1.3 
556   Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAc-Sp0 3.2 2.1 3.9 3.2 0.7 
98   GalNAcb1-4(Fuca1-3)GlcNAcb-Sp0 1.9 2.1 5.0 5.8 2.1 
296   Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 1.7 2.1 4.4 6.8 3.4 
422   
GlcNAcb1-2(GlcNAcb1-6)Mana1-
6(GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp19 2.3 2.1 3.4 5.3 1.2 
197   Glca1-4Glca-Sp8 0.2 2.1 4.6 6.6 3.1 
359   KDNa2-3Galb1-4Glc-Sp0 0.8 2.1 4.8 8.2 2.6 
360   KDNa2-3Galb1-3GalNAca-Sp14 1.6 2.1 3.7 6.7 3.0 
82   Fucb1-3GlcNAcb-Sp8 1.1 2.0 4.3 5.5 1.7 
428   
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-
2Mana1-6(Gala1-3(Fuca1-2)Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 3.9 2.0 6.8 10.4 2.3 
569   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp25 1.7 2.0 2.7 6.4 1.7 
273   Neu5Aca2-6Galb1-4Glcb-Sp0 1.9 2.0 3.6 3.3 3.6 
364   
Gala1-3Galb1-4GlcNAcb1-2Mana1-
6(Gala1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 4.3 2.0 2.2 2.6 2.1 
550   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 2.6 2.0 3.2 4.2 1.8 
262   Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 6.1 2.0 5.3 2.3 1.9 
505   (3S)GalNAcb1-4(Fuca1-3)GlcNAcb-Sp8 0.9 2.0 4.0 9.0 3.4 
598   Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 1.1 2.0 3.5 11.0 2.1 
299   (6P)Glcb-Sp10 1.0 2.0 7.5 9.3 6.7 
168   Galb1-4GlcNAcb1-6(Galb1-3)GalNAc-Sp14 1.6 2.0 4.0 6.1 2.0 
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135   GlcNAcb1-6(Galb1-3)GalNAca-Sp14 0.3 2.0 3.0 4.8 2.8 
14   Manb-Sp8 0.4 2.0 12.9 26.7 14.2 
214   Mana1-6(Mana1-3)Mana-Sp9 7.2 2.0 3.1 3.2 0.5 
472   
Neu5Aca2-3Galb1-4GlcNAcb1-
6(Neu5Aca2-3Galb1-4GlcNAcb1-
3)GalNAca-Sp14 0.5 1.9 2.8 3.6 1.7 
372   
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-
2Mana1-6(Gala1-3(Fuca1-2)Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 1.1 1.9 3.2 4.5 0.5 
374   
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-
2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-
3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 0.9 1.9 3.8 3.2 1.5 
458   
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-
2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-
3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 0.2 1.9 3.3 5.8 2.1 
203   GlcAb-Sp8 3.3 1.9 6.4 7.2 6.8 
275   Neu5Aca2-6Galb-Sp8 1.6 1.9 4.7 6.7 3.8 
206   KDNa2-3Galb1-3GlcNAcb-Sp0 2.0 1.9 3.2 7.8 2.1 
198   Glca1-6Glca1-6Glcb-Sp8 1.3 1.9 7.6 13.8 7.0 
181   GlcNAcb1-3GalNAca-Sp14 0.7 1.9 4.2 11.1 4.3 
327   
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 2.1 1.9 1.6 1.4 0.9 
148   Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 0.8 1.9 4.3 7.7 1.4 
99   GalNAcb1-4GlcNAcb-Sp0 1.9 1.9 5.2 8.3 2.2 
271   
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb-Sp0 2.2 1.8 2.5 -0.5 1.8 
239   Neu5Aca2-3Galb1-3(6S)GlcNAc-Sp8 1.7 1.8 6.5 6.8 2.3 
264   Neu5Aca2-3Galb1-4Glcb-Sp0 2.2 1.8 4.6 5.9 3.2 
261   Neu5Aca2-3Galb1-4GlcNAcb-Sp8 3.9 1.8 4.1 6.5 1.4 
247   Neu5Aca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 1.2 1.8 1.3 2.3 0.4 
470   Glca1-6Glca1-6Glca1-6Glcb-Sp10 2.0 1.8 6.0 8.1 2.7 
606   
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-6(Neu5Aca2-6Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-
3)GalNAca-Sp14 4.5 1.8 -0.1 1.9 1.0 
56   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp13 3.1 1.8 4.6 4.9 1.3 
509   
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-4)Galb1-
4GlcNAcb1-4(Gal b1-4GlcNAcb1-
2)Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAc-Sp21 1.6 1.7 3.9 10.0 4.0 
17   GlcNAcb-Sp8 0.1 1.7 7.1 15.7 5.0 
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551   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp25 0.1 1.7 3.5 5.4 1.5 
314   Mana1-6Manb-Sp10 1.6 1.7 5.0 7.2 4.1 
588   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb 3.8 1.7 2.0 3.3 1.1 
187   GlcNAcb1-4-MDPLys -0.1 1.7 3.2 4.7 1.8 
80   Fuca1-3GlcNAcb-Sp8 0.6 1.7 4.3 5.8 1.4 
597   
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-6(Neu5Aca2-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-
3)GalNAca-Sp14 0.4 1.6 2.5 3.1 0.9 
109   Gala1-3(Fuca1-2)Galb-Sp18 2.6 1.6 6.9 5.1 4.0 
318   Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 2.9 1.6 6.0 9.4 2.8 
50   Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 1.6 1.6 3.5 4.3 1.0 
240   Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp8 3.7 1.6 6.3 5.8 3.3 
492   Neu5Aca2-3Galb1-3GlcNAcb1-6GalNAca-Sp14 3.0 1.6 4.8 4.3 2.4 
272   Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 1.0 1.5 3.9 2.3 2.0 
497   Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 0.8 1.5 6.4 20.1 9.2 
570   (3S)GlcAb1-3Galb1-4GlcNAcb1-3Galb1-4Glc-Sp0 2.2 1.5 7.6 13.3 7.3 
517   (4S)GalNAcb-Sp10 0.4 1.5 4.8 9.8 5.1 
286   Neu5Gca2-6GalNAca-Sp0 1.7 1.5 6.2 2.0 2.1 
142   Galb1-3GalNAca-Sp16 0.9 1.5 3.4 4.8 2.4 
574   
Neu5Aca2-8Neu5Aca2-3Galb1-
3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glc-
Sp21 0.4 1.5 3.1 5.9 1.7 
333   Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4.9 1.5 4.0 0.0 0.7 
464   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-4)(Neu5Aca2-6Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 2.0 1.5 3.3 7.1 0.9 
323   Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8 1.3 1.5 1.9 3.2 1.9 
540   
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 0.4 1.5 2.2 1.7 1.7 
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241   Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 2.1 1.5 4.4 4.1 2.2 
294   Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 0.5 1.5 3.2 5.5 4.4 
583   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 -0.7 1.4 1.0 1.0 1.6 
321   
GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 1.7 1.4 2.1 3.9 0.8 
611   
Galb1-3GalNAcb1-4(Neu5Aca2-
8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-
Sp21 0.2 1.4 3.1 3.9 1.7 
201   G-ol-Sp8 0.8 1.4 3.7 5.9 3.8 
475   
Neu5Aca2-3Galb1-3GlcNAcb1-
6(Neu5Aca2-3Galb1-4GlcNAcb1-
2)Mana1-6(Neu5Aca2-3Galb1-
3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp19 2.4 1.3 1.1 1.1 2.5 
456   
Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-
2Mana1-6(Gala1-3(Fuca1-2)Galb1-
3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 4.7 1.3 5.5 6.8 1.7 
420   
Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-
6(Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22 -0.4 1.3 3.0 5.3 1.6 
562   GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-3)GalNAca-Sp14 3.2 1.3 1.2 7.3 1.3 
276   Neu5Aca2-8Neu5Aca-Sp8 0.0 1.3 3.1 3.7 1.6 
193   GlcNAcb1-6GalNAca-Sp8 5.8 1.3 4.0 -0.9 0.7 
225   Neu5Aca2-3Galb1-3GalNAca-Sp14 1.3 1.2 3.3 4.5 1.1 
357   KDNa2-3Galb1-4(Fuca1-3)GlcNAc-Sp0 1.4 1.2 5.2 8.2 1.3 
371   
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-
2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 2.1 1.2 1.9 4.0 0.9 
48   Neu5,9Ac2a-Sp8 2.0 1.2 3.4 4.0 2.6 
592   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3)GalNAca-Sp14 4.1 1.2 3.0 3.6 1.6 
604   
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(Neu5Aca2-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 2.9 1.2 1.4 3.3 0.0 
460   
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-4)(Neu5Aca2-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 1.1 1.2 1.8 6.4 2.5 
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507   GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAca-Sp14 0.2 1.2 4.5 9.9 4.3 
178   GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp14 1.0 1.1 4.1 4.1 1.9 
302   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 1.6 1.1 1.7 2.6 0.3 
12   Galb-Sp8 1.7 1.0 3.8 7.3 2.1 
577   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 6.0 1.0 -0.5 2.2 0.8 
229   GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 1.9 1.0 1.9 3.9 0.9 
349   Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 0.6 1.0 2.1 2.4 0.5 
576   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 4.2 1.0 5.1 12.8 2.6 
216   
Mana1-6(Mana1-3)Mana1-6(Mana1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 5.1 1.0 3.5 7.4 3.7 
217   Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 2.0 1.0 6.4 6.8 1.1 
285   Neu5Gca2-3Galb1-4Glcb-Sp0 2.2 0.9 4.4 2.5 0.9 
274   Neu5Aca2-6Galb1-4Glcb-Sp8 2.0 0.9 5.2 4.1 2.3 
15   GalNAcb-Sp8 0.1 0.9 3.1 7.2 3.1 
312   GlcNAcb1-4GlcNAcb-Sp12 1.6 0.9 5.6 5.0 3.4 
594   GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 3.6 0.9 3.8 4.7 2.2 
260   Neu5Aca2-3Galb1-4GlcNAcb-Sp0 3.2 0.9 3.3 4.0 1.0 
608   
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 5.7 0.9 5.1 8.5 3.6 
548   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 0.0 0.8 9.0 17.0 4.8 
494   
Galb1-4(Fuca1-3)GlcNAcb1-
6(Neu5Aca2-6(Neu5Aca2-3Galb1-
3)GlcNAcb1-3)Galb1-4Glc-Sp21 0.7 0.8 3.5 4.9 1.7 
558   Neu5Aca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 -1.0 0.8 2.3 8.8 1.6 
196   Glca1-4Glcb-Sp8 0.6 0.8 3.7 5.0 3.2 
610   GlcNAcb1-3Fuca-Sp21 0.7 0.8 4.1 6.5 2.3 
227   GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 1.0 0.8 1.1 3.1 1.1 
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466   
Neu5Aca2-6Galb1-4GlcNAcb1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-
6Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 1.7 0.8 2.1 5.2 1.3 
332   Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 3.0 0.8 4.6 7.7 1.4 
440   Galb1-4Galb-Sp10 0.4 0.8 4.9 9.2 4.4 
596   
GlcNAcb1-3Galb1-4GlcNAcb1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-
3)GalNAca-Sp14 0.6 0.8 3.7 5.6 1.9 
112   Gala1-3GalNAca-Sp16 0.0 0.7 1.8 6.2 3.1 
485   Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 0.1 0.7 4.8 4.0 1.7 
137   Neu5Aca2-6(Galb1-3)GalNAca-Sp14 -0.1 0.7 5.2 8.3 5.0 
89   GlcNAcb1-3Galb1-3GalNAca-Sp8 1.8 0.7 3.8 8.8 1.4 
471   Glca1-4Glca1-4Glca1-4Glcb-Sp10 0.9 0.7 4.2 9.7 3.5 
461   
Neu5Aca2-3Galb1-4GlcNAcb1-4Mana1-
6(GlcNAcb1-4)(Neu5Aca2-3Galb1-
4GlcNAcb1-4(Neu5Aca2-3Galb1-
4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 0.0 0.7 6.4 10.4 2.3 
415   GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 1.7 0.6 4.1 9.9 2.1 
527   Neu5Aca2-3Galb1-3GlcNAcb1-2Mana-Sp0 0.9 0.6 7.4 14.0 5.1 
319   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 0.8 0.6 3.9 2.7 0.5 
346   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp12 1.8 0.6 1.4 1.7 0.4 
412   Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 0.1 0.5 3.9 9.6 6.7 
582   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 0.1 0.5 1.4 3.7 1.1 
443   GalNAcb1-6GalNAcb-Sp8 0.6 0.5 6.8 9.4 1.4 
578   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 -0.6 0.5 0.9 0.9 -1.0 
320   
Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-
6Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 -0.8 0.4 3.4 1.6 1.4 
230   Neu5Aca2-8Neu5Aca2-8Neu5Aca-Sp8 1.4 0.4 2.1 3.7 0.9 
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487   
Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-
6(GlcNAcb1-4)(Neu5Aca2-3Galb1-
3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 -0.1 0.4 6.0 9.0 1.7 
348   Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 1.3 0.4 1.8 2.1 0.2 
347   
Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp12 1.2 0.4 2.0 1.5 0.6 
237   Neu5Aca2-3GalNAca-Sp8 1.9 0.4 2.3 3.2 1.1 
354   
Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 2.4 0.4 -0.2 -0.2 -0.3 
587   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb- -1.0 0.4 3.9 5.5 0.7 
311   GlcNAcb1-4GlcNAcb-Sp10 0.6 0.3 5.6 2.3 1.2 
326   
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 0.3 0.3 1.1 -0.7 0.2 
579   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 5.0 0.3 0.0 -0.2 1.0 
413   
Neu5Aca2-3Galb1-3GalNAcb1-
4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-
Sp0 -0.5 0.3 4.1 8.4 3.7 
601   Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 0.6 0.3 7.2 7.2 3.2 
595   GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 2.4 0.3 4.5 7.5 2.2 
313   MurNAcb1-4GlcNAcb-Sp10 0.8 0.2 3.2 5.1 1.9 
289   Neu5Aca2-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 2.5 0.2 5.0 3.3 0.9 
6   Fuca-Sp8 0.3 0.2 3.8 0.2 2.0 
467   
Neu5Aca2-6Galb1-4GlcNAcb1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-
6Galb1-4GlcNAcb1-4(Neu5Aca2-6Galb1-
4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 0.0 0.2 2.2 10.5 1.5 
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581   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp19 0.3 0.1 1.1 -0.3 0.8 
561   
Gala1-3Galb1-4GlcNAcb1-2Mana1-
6(Gala1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAc-Sp24 5.6 0.0 0.7 3.5 3.6 
490   Gala1-3Galb1-3GlcNAcb1-6GalNAca-Sp14 1.8 0.0 5.8 13.0 3.3 
568   Galb1-3GlcNAcb1-6(Galb1-3)GalNAc-Sp14 0.0 0.0 1.0 10.0 2.1 
366   
Fuca1-4(Galb1-3)GlcNAcb1-2Mana1-
6(Fuca1-4(Galb1-3)GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22 -0.3 -0.1 1.2 -1.1 0.9 
580   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 0.2 -0.1 -0.8 0.5 -0.5 
309   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 1.6 -0.1 5.9 5.9 0.7 
194   GlcNAcb1-6GalNAca-Sp14 0.6 -0.1 3.5 6.3 1.4 
462   
Neu5Aca2-3Galb1-4GlcNAcb1-
6(Neu5Aca2-3Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 1.4 -0.1 2.2 1.6 1.5 
141   Galb1-3GalNAca-Sp14 0.6 -0.2 5.2 8.1 4.1 
288   Neu5Gca-Sp8 1.1 -0.2 5.8 3.7 1.8 
341   GlcNAca1-4Galb1-3GlcNAcb-Sp0 -0.1 -0.2 5.6 2.4 2.0 
9   Neu5Aca-Sp8 1.0 -0.3 4.2 4.0 1.7 
489   Galb1-3GlcNAcb1-6GalNAca-Sp14 0.3 -0.3 4.3 4.5 1.8 
226   
GalNAcb1-4(Neu5Aca2-8Neu5Aca2-
8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-
Sp0 3.6 -0.3 5.4 6.9 3.6 
353   
GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22 -0.7 -0.4 -0.3 -0.1 -0.4 
463   
Neu5Aca2-3Galb1-4GlcNAcb1-
6(Neu5Aca2-3Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-
3Galb1-4GlcNAcb1-4(Neu5Aca2-3Galb1-
4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 -0.5 -0.4 5.5 7.5 0.7 
393   GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb1-3GalNAca-Sp14 2.4 -0.6 3.0 6.7 1.1 
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396   
Gala1-3Galb1-3(Fuca1-4)GlcNAcb1-
2Mana1-6(Gala1-3Galb1-3(Fuca1-
4)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp19 -1.0 -0.6 2.4 4.6 1.1 
585   
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 -0.1 -0.6 3.1 7.3 2.3 
609   
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(Neu5Aca2-
6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 0.8 -0.6 0.0 2.3 -0.4 
465   
Neu5Aca2-6Galb1-4GlcNAcb1-4Mana1-
6(GlcNAcb1-4)(Neu5Aca2-6Galb1-
4GlcNAcb1-4(Neu5Aca2-6Galb1-
4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 -0.5 -0.8 0.3 5.2 2.1 
395   
Gala1-3Galb1-3GlcNAcb1-2Mana1-
6(Gala1-3Galb1-3GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAc-Sp19 0.1 -0.9 1.1 2.4 -0.1 
7   Fuca-Sp9 0.3 -1.0 1.3 0.5 -0.1 
607   
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 3.4 -1.0 -0.1 0.8 0.2 
565   
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp25 0.0 -1.1 -0.8 -1.5 -0.3 
355   
Galb1-3GlcNAcb1-2Mana1-6(Galb1-
3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 -0.9 -1.2 -0.5 -0.3 -0.5 
58   
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp24 1.9 -2.0 1.2 2.2 0.2 	  
